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Abstract 
Viral infections account for 25.4% of all human illnesses. Current anti-viral 
nucleosides are able to prevent viral replication; however, viruses evolve resistance 
to available treatments. Ribose nucleosides are ubiquitous; however due to the 
discriminatory nature of kinases, low intracellular concentrations of the active 
triphosphate is a significant factor in inactivity. In contrast, oxetane nucleosides have 
been shown to be phosphorylated by these kinases with high levels of the required 
active nucleotide triphosphate (NTP) resulting. Oxetane nucleosides, however, have 
been found to be inactivated by pyrimidine nucleoside phosphorylases (PNPs). 
Previous studies have illustrated that sulfur containing nucleosides are not 
hydrolysed by PNPs. Therefore in this programme a library of 9 novel 3,3-
bis(hydroxymethyl)-thietan-2-yl nucleosides was synthesised using Vorbrüggen 
conditions starting from a fluorothietane precursor, over 8 steps. Cell viability studies 
using an XTT assay on the thymine (103% ± 4.9%), uracil (95% ± 2.3%), 5-
fluorouracil (98% ± 7.5%) and 5,6-dimethyl uracil (82% ± 4.1%) derivatives showed 
no significant loss in cell viability at up to 100 μM concentration, suggesting they 
were suitable for further study in anti-viral screens.  Steps towards the synthesis of a 
complementary library of 4,4-bis(hydroxymethyl)-thietan-2-yl nucleosides have been 
optimised with successful synthesis of a novel key intermediate, thietane-2-one, in a 
yield of 37% over 6 steps.  4’-Thiohamamelose nucleosides show promise as 
potential anti-viral compounds as previous studies have shown that 4’-thioribose 
nucleosides are stable to PNPs and have longer half-lives than ribose nucleosides. 
Increasing the stability of the 4’-thiohamamelose nucleosides could improve the 
potential for development of the anti-viral profiles of this class of compounds. 
Therefore the chemistry of 4’-thiohamamelose nucleosides has been explored, with 
an intermediate hamamelolactone being prepared in a yield of 44% over 5 steps. 
Small molecule nucleosides offer the greatest benefits as anti-viral compounds 
versus other small molecule anti-viral agents as nucleosides are able to directly halt 
viral replication. The sulfur containing nucleosides are potentially more stable than 
their ribose counterparts, leading to better pharmacological and pharmacodynamics 
outcomes.  
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Chapter 1: Introduction 
The emergence of severe viral infections coupled with the limited availability of anti-
viral agents is a common cause of human illness and death.1 Of these viral 
infections, the most severe infections are due to the human immunodeficiency virus 
(HIV) which infects 28.1-31.7 million people worldwide with 1.3-1.5 million deaths and 
1.7-2.1 million new infections per year; and the hepatitis C virus (HCV) which infects 
180 million people with 3 – 4 million new cases a year of which 80% of the patients 
develop a chronic infection that leads to death.2-5 Although these are the most severe 
viral infections, there are many other viruses that can cause illness in humans such 
the influenza virus, the common cold virus, herpes simplex virus (HSV), HIV, varicella 
zoster virus (VZV), hepatitis B (HBV), HCV and cytomegalovirus (CMV) and the 
Eppstein-Barr virus (EBV) to name a few. New anti-viral agents are needed because 
viruses are able to replicate quickly and evolve resistance to any anti-viral agents 
that are used as treatments. The problems of long term toxicity and poor 
bioavailability of these drugs is also a major concern that requires further 
investigation into new anti-viral agents.1,6 
1.1 Lifecycle of Viruses 
The first identified virus was the tobacco mosaic virus (TMV), discovered in 1898 by 
Martinus Beijerinck. Since then over 5000 types of viruses have been found in almost 
every ecosystem on Earth and are the smallest known infectious agents.1,7-10 There 
are two broad classifications of viruses: those that contain deoxyribonucleic acid 
(DNA) in their core and those that contain ribonucleic acid (RNA) in their core. These 
are termed DNA-viruses and RNA-viruses respectively. These entities are unable to 
reproduce on their own, and hence require a host cell process to propagate.1,7-10 A 
typical viral lifecycle is shown in figure 1.1.  
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Figure 1.1: Viral genome (DNA or RNA) 1, capsid 2, viral envelope 3, viral glycoproteins 4, host cell 
receptors 5, host cell membrane 6, virus binds 7, endocytosis 8, virus released from endosome in pH 
dependent manner 9, virus uncoats 10, genome replicated 11, viral protein synthesis at ribosomes 12, 
viral assembly 13, exocytosis of mature virions 14.  
Viral infections typically eventually kill the host cell. This is due to alterations to host 
cell metabolism, alterations to the host cell membrane (that usually contain a viral 
proteins that upon exocytosis, become the new viral envelope) and cell lysis.1,11 
By understanding the viral lifecycle there are several potential drug targets that can 
be exploited to stop infection. Historically, drug targets of interest have been fusion 
inhibitors, co-receptor antagonists, integrase inhibitors, protease inhibitors, and 
transcriptase and replicase inhibitors. Each class has shown activity to varying 
degrees of success.11,12 The most important classes of anti-viral drugs are protease 
inhibitors which prevent the formation of mature viral proteins from the polyprotein 
precursors; and directly acting anti-viral agents (DAA) nucleosides which act as anti-
metabolites to prevent elongation of the viral genome during replication.6 These 
nucleosides are mutagenic, causing error catastrophe at such a rate that they are 
able to obliterate an entire viral population by preventing genome replication, and 
hence are the most important class of anti-viral agent available.13 However, due to 
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the speed at which viruses are able to evolve, even when combination therapies of 
protease inhibitors and DAAs are used, there is an urgent and on-going need for new 
DAAs.  
1.2 Types of Antiviral Agents 
There are several classes of antiviral agents available to treat viral infections. Each 
class acts on a specific part of the viral lifecycle, from preventing binding and fusion 
(see 7 in figure 1.1), to preventing viral replication (see section 11 in figure 1.1). Each 
class of antiviral agent will be critically evaluated in the proceeding sections with key 
developments discussed. Research over the past 30 years has shown that the best 
methods to treat viral infections use combination therapy of a replicase/transcriptase 
inhibitor and a protease inhibitor. These drugs act early in the viral lifecycle to 
prevent an increase in viral load, and in the case of HCV infection, a complete cure. 
Combination therapy has also been shown to significantly reduce the chance of viral 
resistance from evolving. This is because the chance of evolving more than one 
resistance trait to multiple targets is unlikely. 
1.2.1 Interferons 
Interferons (IFNs) are a class of proteins known as cytokines that are excreted from 
cells that protects against viral infections.14 IFNs activate the host immune system via 
signal transduction by binding to immune receptors, though the mechanism of action 
is not fully understood.11,14 IFNs have broad activity against many cancers and viral 
infections, including HIV, HCV and HBV.11,14,15   
IFN is used in combination with other anti-viral drugs, and is administered via 
injection. Monotherapy of interferon is associated with a high rate of relapse that 
necessitates retreatment, which is invariably unsuccessful for patients with HCV 
infection.15 Recent advances in anti-viral therapies have occurred because IFN has 
serious side effects, especially when used in combination with other drugs. Interferon 
free therapies offer the best patient outcomes as the side effects of these new 
regimens are not as serious. IFN has been associated with side effects such as 
influenza like symptoms, depression, fatigue and fever.14,15 
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IFN activates the immune system but does not prevent the viral infection from 
spreading. Targeting the virus directly, whether it be by preventing viral replication, 
preventing binding, or preventing the maturation of the viral polyproteins, are far 
better methods to combat infection.14,17 
1.2.2 Inhibitors 
Inhibitors are chemical compounds that block receptors, proteins or enzyme function, 
and therefore prevent a biological function from occurring. Inhibitors as anti-viral 
agents are the broadest class of drug as there are several important targets. 
Inhibitors can target every stage in the life-cycle of the virus, from preventing the 
virus from binding to a receptor prior to viral attachment, to preventing viral 
replication (see figure 1.1). In the proceeding sections, the main classes of inhibitors 
and the key challenges and discoveries are discussed. 
1.2.2.1 Integrase Strand Inhibitors 
Integrase inhibitors (IIs) are a class of anti-viral agent targeting HIV-1 infection. They 
prevent the integration of viral DNA into the host cell chromosomes which is achieved 
by integrase enzymes, thereby preventing viral replication.16-18 Integrases are 
essential for viral replication and the absence of a host cell equivalent means that 
there are potentially less off target side effects.16 The most common class of IIs are 
diketo aryl and diketo aryl like inhibitors (DKAs).16,18 Shown in figure 1.2 are two of 
the first generation IIs discovered.16,19 
 
Figure 1.2: First generation IIs DKAs tetrazole 1 and acid 2 
Divalent metal cofactors such as Mg2+ and Mn2+ are important for DKA activity. The 
tetrazole moiety in figure 1.2 was found to have poor binding affinity to Mg2+ ions and 
hence exhibited lower than expected activity.16,18,19 Extensive analysis of structure-
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activity relationships (SAR) led to the discovery that replacement of the tetrazole 
moiety with a carboxylate derivative increased binding affinity to Mg2+ and hence, 
increased activity of the DKAs.16,17,19,20 
SAR found that although the carboxylate was important for activity, it was not 
important for binding to the enzyme. However, the aromatic groups were found to be 
essential for potency, and the binding site tolerated a wide range of functionalisations 
on the aromatic rings.16,19 Since the carboxylate was not essential for binding, 
research carried on until the discovery of Raltagevir 3 (figure 1.3).19 
 
Figure 1.3: Raltagevir 3 
Although integrase strand inhibitors are excellent inhibitors of genome replication, 
resistance to DKA IIs has arisen quickly. Mutations coding for the integrase enzymes 
show that 6 amino acids have changed at the binding site to prevent DKAs from 
binding.20,21 Some of the amino acid mutations reduce the affinity of the integrase 
enzyme for Mg2+.20,21 Since the metal cofactor is essential for DKA binding, this 
reduced affinity for the cofactor reduces the activity of DKA based drugs. Also, 
changes to the binding site amino acids changes the binding interactions and also 
reduce the binding interactions between the DKAs and the enzyme active site.16,19-21 
Though resistance of the integrase enzyme towards DKA based drugs is an issue, IIs 
also inhibit recombinases, RNAses, and other integrases. Therefore they are not 
selective for HIV-1 integrases. Since integration of the viral genome into the host 
genome is a multistep process, viral resistance can evolve to bypass IIs. A key 
problem with IIs is that they are required to act early in the viral lifecycle to prevent 
the viral genome being incorporated into the host genome. This means that late 
stage infections cannot be treated with IIs alone and require the use of other drugs in 
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combination with them. Therefore, IIs cannot prevent replication of the viral genome 
directly, and so, act indirectly, limiting their utility.  
1.2.2.2 Fusion Inhibitors/Co-receptor antagonists 
Fusion inhibitors and co-receptor antagonists prevent viruses from binding to host 
cell membranes. Either the compound blocks receptors on the host cell, or the 
compound blocks receptors on the viral envelope. In figure 1.4, three compounds are 
shown: Arbidol 4 a fusion inhibitor for influenza A and B, and Neu5Ac2en 5 and 
Zanamivir 6, the co-receptor antagonists for the same indication.22-24 
 
Figure 1.4: Fusion inhibitors and co-receptor antagonists Arbidol, Neu5Ac2en and Zanamivir 
Arbidol 4 is a fusion inhibitor that intercalates the host cell and prevents the virus 
from binding. It also occupies the viral receptors on the viral envelope disrupting the 
ability of the virus to bind to the host cell.22  Neu5Ac2en 5 and Zanamivir 6 are both 
co-receptor antagonists that mimic neuranimic acid. In influenza, the neuraminidase 
enzyme cleaves neuraminic acid residues in the mucin to allow the virus to bind to 
the host cells. Neuranimic acid inhibitors such as Zanamivir act as a competitive 
substrate for the viral enzyme and thus prevent viral binding by mimicking the host 
cell neuranimic acid residues.23,24 A major issue with both classes of these drugs is a 
result of their high specificity, which allows viral resistance to evolve rapidly.22 
In the case of the neuraminidase inhibitors, although they prevent the virus binding to 
the host cell, they cannot prevent initial infection unless given prophylactically. The 
initial stages of influenza are asymptomatic, therefore drugs administered after the 
initial infection will only reduce the duration of infection by 1-4 days.24 Prophylactic 
administration of the drugs has been shown to reduce infections between people in 
close quarters by 70 – 90%. However, these drugs are unable to halt viral replication 
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directly which means the initial infection persists. Also, due to the high specificity of 
these drugs, resistance evolves very quickly.23,24  
1.2.2.3 Protease Inhibitors 
Protease inhibitors (PIs) are an important class of anti-viral agent that inhibit the 
cleavage of viral polyproteins into mature viral proteins before the virion is 
assembled. Typically when the viral genome is replicated, the genome is translated 
into a viral polyprotein which is cleaved by host cell or viral proteases. The cleavage 
of the viral polyprotein into mature proteins happens before viral assembly. Inhibition 
of viral proteases therefore prevents assembly of the mature virion.7-11,25 In figure 1.5 
boceprevir 8 and telaprevir 7 are shown, and both of these drugs are HCV protease 
inhibitors. PIs were first developed to counter HIV-1 infection.26 
 
Figure 1.5: Telaprevir 7 and Boceprevir 8 
Telaprevir 7 and Boceprevir 8 are both NS3 PIs termed linear peptidomimetic 
ketoamide serine protease inhibitors and their mechanism of action is shown in figure 
1.6.27-29 
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Figure 1.6: In the HCV protease active site, histadine and serine make up the catalytic core of the 
enzyme and cleaves the C-N bond. 
In the NS3 active site, the incoming peptide is attacked by the serine residue at the 
carbonyl end which forms a tetrahedral intermediate. The histidine residue binds to 
the proton on the amine end which withdraws electron density from the C-N bond so 
that when the C=O bond is reformed, the C-N bond breaks. Water then enters the 
active site which reacts with the serine residue which forms another tetrahedral 
intermediate that acts as a leaving group to reform the catalytic core. Boceprevir 
uses a ketoamide to trap the catalytic serine residue, binding to it covalently (figure 
1.7). The tetrahedral intermediate of boceprevir is stable however the reaction is 
reversible.29 
 
Figure 1.7: Mechanism of action of boceprevir ketoamide in NS3 HCV protease. 
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X ray diffraction data of boceprevir in the active site of the NS3 protease shows that it 
is covalently bound to the serine residue (figure 1.8).29 This is consistent with the 
mechanism of action expected for the drug. In all PIs, the mechanism of action is 
similar.29 
 
Figure 1.8: Binding interactions of boceprevir 
 
In HCV, the protease is a serine protease and thus, boceprevir and telaprevir are 
serine protease inhibitors. In retroviruses such as HIV-1, the protease is an aspartyl 
protease.30The mechanism of action is similar serine and aspartyl proteases, with the 
nucleophilic attack occurring via the carboxylate in aspartic acid and the alcohol in 
serine. In figure 1.9, saqinavir, an aspartyl protease inhibitor for HIV-1 is shown.30 
 
Figure 1.9: Saquinavir, an aspartly protease inhibitor for HIV-1 
In both serine and aspartly proteases, the bound drug blocks the active site of the 
protease preventing cleavage of the viral polyprotein into the active mature proteins, 
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and thus prevents viral assembly in both HIV and HCV. However, because protease 
inhibitors are highly specific, they must be used in combination with other drugs as 
viral resistance to proteases evolves quickly.28,29 Protease inhibitors act indirectly to 
prevent viral replication, and as such, do not inhibit viral polymerases that allow for 
viral genome replication. Therefore, monotherapy with PIs is avoided.  
1.2.2.4 Non-nucleoside Inhibitors 
Non-nucleoside inhibitors bind to allosteric sites on viral polymerases.4,31 Two 
classes of these drugs exist: non-nucleoside reverse transcriptase inhibitors 
(NNRTI’s) and non-nucleoside replicase inhibitors (NNRIs). The NNRTIs are active 
against HIV and the NNRIs are active against HCV.11 
1.2.2.4.1 Non-nucleoside Reverse Transcriptase Inhibitors 
NNRTIs interact with allosteric sites on HIV reverse transcriptase that change the 
morphology of the binding site.11 This change in morphology inhibits genome 
replication, therefore NNRTI’s are an important class of drug. However, rapid 
resistance evolves against this class of drug and therefore they are used in 
combination therapy with DAAs. The use of combination therapy reduces the 
incidence of resistance from evolving.11 Figure 1.10 shows a typical NNRTI used to 
treat HIV infection.11 
 
Figure 1.10: NNRTIs used to treat HIV infections: Etravirine 10 
These drugs bind to allosteric binding sites that affect the shape of the active site, 
preventing the natural substrate from binding. This then prevents the enzyme from 
functioning. Etavirine 10 (figure 1.10) has also been shown to block RNAse H 
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function, preventing the reverse transciptase enzyme from implanting viral DNA into 
the host DNA. This means that the viral genome cannot be replicated.11 
1.2.2.4.2 Non-nucleoside Replicase Inhibitors 
NNRIs target the HCV NS5B polymerase, which has several allosteric binding sites. 
This has led to a significant number of different classes of NNRIs being developed.11 
However, despite the increased number of allosteric binding sites, cross mutations 
and resistance are still a major problem with this class of drug.32 
 
Figure 1.11: HCV-796 11 non-nucleoside replicase inhibitor 
Figure 1.11 shows the non-nucleoside replicase inhibitor of HCV NS5B polymerase. 
HCV-796 11 was shown to bind to the palm site subdomain of the enzyme (the 
others being the finger subdomain and the thumb subdomain).31 It was shown that 
the major binding interactions occurred between arginine and cysteine residues of 
the palm subdomain. This interaction changes the shape of the active site, reducing 
the enzymes ability to replicate the viral genome. Rapid viral resistance evolved to 
this, and other candidate compounds.11,31 (Reference 33 gives an overview of the 
palm, finger and thumb domains. See references 34 - 40 for an overview of the 
biology of HCV polymerases, and some other papers dealing with NNRIs).  
1.2.2.5 Nucleoside Inhibitors 
Nucleoside inhibitors are a class of drug that act on the viral genome and prevent 
viral genome replication. They are the most important class of anti-viral drugs.7,14,19-22 
These drugs mimic endogenous nucleotides but are chemically modified to prevent 
binding. These classes of drugs are called directly acting antiviral agents as they bind 
directly to the active site of a virus’s replicase complex.7,14,19-22 Nucleoside drugs can 
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be phosphate modified, sugar modified or based modified in order to increase their 
activity.33 These drugs act via two mechanisms: as obligate chain terminators and 
non-obligate chain terminators (figure 1.12).7,14,19-22 
 
Figure 1.12: Top: obligate chain terminator. 1 the 3’-hydroxy group of the DNA or RNA bound 
nucleotide attacks the triphosphate of an incoming nucleotide, in this case, the drug molecule. 2 the 
phosphodiester bond is formed between the DNA or RNA chain and the drug molecule. 3 with no 3’-
hydroxy group on the drug molecule, the incoming nucleotide cannot bind and chain elongation is 
halted. Botton: non-obligate chain terminator. 4 and 5 are similar to steps 1 and 2. In step 6 though the 
3’-hydroxy group is present in the drug molecule, steric hindrance and conformational changes caused 
by the methyl group prevents binding of the incoming nucleotide 
Obligate chain terminators (see example in figure 1.13) do not contain the 3’-OH 
group that is essential for the formation of the phosphodiester bonds. As such, the 
next in coming nucleotide is unable to react with the bound obligate chain terminatior. 
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In non-obligate chain terminators the 3’-OH group is present, but steric and electronic 
effects prevent the formation of new phosphodiester bonds. The elongation of the 
viral genome is terminated and therefore viral replication is halted.6,11,34-37 
 
 
Figure 1.13: Example of an obligate and non-obligate chain terminating DAA. Elvucitabine an anti-HIV 
obligate chain terminator and 2’-C-methylcytidine an anti-HCV non-obligate chain terminator. 
It can be seen therefore, that both types of prodrugs are used to exploit the metabolic 
pathways of endogenous nucleosides and nucleotides by acting as anti-metabolites. 
These drugs enter the cells through specific nucleoside transporter mechanisms and 
are phosphorylated by three kinases, the first step to the monophosphate by 
nucleoside phosphate kinase is rate limiting as this kinase is very discriminatory.6,31 
This is a major cause of observed inactivity in DAAs. The next two kinases: 
nucleoside diphosphate kinase and either creatine kinase or 3-phosphoglycerate 
kinase make the di- and tri-phosphate of the DAA.6 Only the triphosphate is active, 
therefore, all unmodified DAAs are prodrugs since they require phosphorylation 
before activity is observed.4,6,11,31,35,38,39 As will be discussed, methods to mask the 
monophosphate groups have been successful in overcoming the rate limiting step of 
the first kinase.  
1.2.2.5.1 Nucleoside Reverse Transcriptase Inhibitors 
Nucleoside reverse transcriptase inhibitors are all obligate chain terminators. They 
lack the 3’-OH group necessary (figure 1.14) for the formation of the phosphodiester 
bond that must form for genome replication to occur.40 These drugs are used to treat 
HIV patients, and throughout their clinical development, significant challenges had to 
be overcome. 
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Figure 1.14: Current reverse transcriptase inhibitors in clinical use. All lack the 3’-OH group necessary 
for genome replication. Without this group, chain extension is not possible.  14: Zidovudine (AZT) 15: 
Didanosine 16: Zalcitabine 17: Stavudine 18: Lamivudine 19: Abacavir 20: Tenofovir diisoproxil 
fumarate 
In figure 1.14, seven nucleoside reverse transcriptase inhibitors are shown. All of 
these compounds are assumed to have the same mechanism of action as zidovudine 
14, in that they act as competitive metabolites.40,41 These compounds are converted 
to their active triphosphates at the 5’-OH end by endogenous kinases. Then, these 
compounds bind to the catalytic binding site of reverse transcriptase and are 
incorporated into the growing viral genome. Once these compounds are 
incorporated, chain elongation is terminated as the next nucleotide is unable to 
bind.11,35,40,42-46  
1.2.2.5.2 Nucleoside Polymerase Inhibitors 
With the success of anti-HIV nucleosides, focus shifted towards HCV viral infection 
with research into nucleoside replicase inhibitors, known as DAAs coming to the 
forefront.  
The 2’-β-C-methyl and 2’-α-OH compounds were the first class of inhibitors to be 
developed and has subsequently grown into a broad class which are potent and 
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devoid of cytotoxicity. The first compound discovered was NM107 21 (table 1.1) and 
studies indicated that the 3’-OH in the alpha orientation was essential for activity 
without cytotoxicity.  
Table 1.1: Biological data for 2’-α-flouro compounds 
Compound IC50 
(µM) 
EC50( 
µM) 
Viral Load 
Reduction (–log10) 
 
21 
NM107 
- 1.23 - 
 
22 
NM283 
- 7.6 -1.2 
monotherapy 
 
23 
- 4.5 - 
 
24 
PSI6130 
1.19 - - 
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25 
PSI6206 
- - -2.7 
monotherapy 
-5 combination 
therapy 
 
26 
RG7128 
Mericitabine 
- 7.3 - 
 
27 
TMC647078 
- - - 
 
28 
- 42.8 - 
 
29 
 20.3  
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NM107 21 had moderate potency (EC50 = 1.23 µM), though its triphosphate, acting 
as a non-obligate chain terminator, was much more active (IC50 = 0.09 – 0.18 µM) 
however studies revealed that resistance developed quickly.11,31,37,47-50 This led to the 
development of the 3-O-valinyl ester prodrug, NM283 22 (figure 1.14, table 1.1) 
known as valopicitabine had an EC50 = 7.6 µM with bioavailability in rats of 
34%.31,37,47 NM283 22 entered human clinical trials and showed modest reduction in 
viral load by -1.2 log10, however the trial was stopped at phase IIb due to significant 
gastrointestinal (GI) toxicity.11,31,37,49,50 
Replacement of the 2’-α-OH group with a 2’-α-F group resulted in the discovery of a 
new class of potent RNA dependant RNA polymerase (RdRp) HCV inhibitors. Base 
variations revealed that the cytosine analogues were the most potent.11,31 The 
adenosine, guanosine and uridine analogues had EC50 values greater than 50 µM 
and were weakly active or inactive with significant cytotoxicity. The inactivity was due 
to poor phosphorylation in the first step of triphosphate formation.34,51 The cytosine 
analogue, PSI 6130 24 (table 1.1) has an EC50 of 4.5 µM, however, this was 
metabolised to the inactive uradine analogue PSI 6206 25 (table 1.1).34,39,51 The 
triphosphate of PSI 6206 was active with an IC50 of 1.19 µM.
31 In order to overcome 
the formation of the inactive metabolite, the 3’,5’-diisobutyrate ester prodrug of PSI 
6130 24 was synthesised to yield RG7128, mericitabine 26.11,27,31,50,52 In 
monotherapy RG7128 26 resulted in a -2.7 log10 reduction in viral load and 
progressed to phase IIa clinical trials for genotypes 1, 2, and 3. The genotypes are 
differences in the genetic make-up of the same type of virus. HCV has 6 genotypes 
in its family. In phase IIa there was a response in 85 – 90% of patients with a -5 log10 
reduction in viral load with no significant adverse effects observed. RG7128 in 
combination with two PI’s: MK7009 vaniprevir and RG7227 danoprevir, in the 
absence of PEG IFN and RBV, showed -4.9 to -5.1 reductions in viral load and is 
expected to enter phase III trials.31  
Further exploration of 2’-substituted nucleosides resulted in the identification of TMC 
647078 27 (table 1.1) with an EC50 of 7.3 µM, no cytotoxicity, with broad genotype 
coverage.31 However, TMC 647078 27 was metabolised to the inactive uridine 
metabolite with a low plasma concentration in rats.31 3’-O-isobutyrate and 3’,5’-O-
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diisobutyrate prodrugs of TMC 647078 27 to yield compounds 28 and 29 (table 1.1). 
The prodrugs had reduced activity (EC50 = 42.8 µM and 20.3 µM for compounds 28 
and 29 respectively) in bioassays but had increased exposure by 10 fold in 
compound 29 and 24 fold in compound 28. 
1.2.2.5.3 Development of Phosphoramidates  
The nucleosides discussed thus far have been shown to be active potent inhibitors of 
HVC RdRp, however, as has been stated, the nucleosides must be converted to 5’-
triphosphates by intracellular kinases to act as active inhibitors.31 Many potential 
compounds have failed to demonstrate activity in whole cell assays as they have 
been found to be poor substrates for one or more of the kinases in the 
phosphorylation cascade.31 Formation of the monophosphate is the most problematic 
step because the first kinase in the cascade is the most discriminatory of the three 
kinases, therefore bypassing the first kinase by delivering a 5’-monophosphate can 
result in higher levels of the active triphosphate in cells (figure 1.15).4,31,37-39,53 
However, 5’-monophosphates are enzymatically dephosphorylated and are 
negatively charged (compound 33, figure 1.15), the latter preventing entry to the cell, 
therefore making 5’-monophosphates poor drug candidates. However, 5’-
monophosphate prodrugs have been synthesised to overcome this problem.31,37  
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Figure 1.15: The phosphorylation steps of the three kinases to the active triphosphate using 
Zidovudine 14 as an example. Kinase 1 creates the nucleotide monophosphate (NMP) 30, kinase 2 
creates the nucleoside diphosphate (NDP) 32 and kinase 3 creates NTP 33. As shown, the NMP can 
be enzymatically cleaved to an inactive form. 
The 5’-monophosphates nucleoside prodrugs must have sufficient chemical stability 
for formulation into an orally administered drug and be stable to the gastrointestinal 
tract so as to reach the site of absorption. The prodrug must then be efficiently 
absorbed and reach the liver intact after which hepatic enzymes remove the 5’-
monophosphate group allowing for the conversion to the active nucleotide 
triphosphate (NTP). Since HCV is a liver disease, this strategy allows for significantly 
improved liver targeting.31,37-39 
The phosphoramidate prodrugs are a class of 5-monophosphates that have excellent 
liver targeting and good potency. They exist as ProTides, HepDirect and SATE 
compounds.31 HepDirect compounds are prodrugs released by cytochrome P450 
mediated mechanism and produce aryl vinyl ketone by products which are potentially 
cytotoxic. SATE compounds (bis(S-aryl-2-thioethyl) phosphate esters) are prodrugs 
which are released by initial ester hydrolysis followed by expulsion of the free 5’-
hydroxy nucleoside by via liberation of an episulfide.31 ProTide compounds will only 
be discussed in this section as they have no associated toxicity that both HepDirect 
and SATE compounds do. For a review of HepDirect and SATE compounds, see 
reference 31. In the ProTide, HepDirect and SATE compounds, the phosphoramidate 
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group masks the negatively charged monophosphate thereby increasing lipophilicity 
and subsequently, cell permeability. However, a major setback for the 
phosphoramidate group is that the phosphorus atom is chiral and diasteromeric 
mixtures are always obtained upon synthesis. It has been shown in some cases that 
isolation and assessment of the anti-viral activity of each diastereomer shows 
different activities. One diastereomer may be significantly active and the other not 
active. In a mixture, the activity of the drug is diminished due to the presence of the 
inactive counterpart. Separation of the diastereomers is difficult and hampers their 
development.31,37,38  
NM107 21 (table 1.1) has limitations such as poor conversion to the active NTP, it 
has only modest potency and some adverse clinical effects have been reported.31,37 
When NM107 21 was converted to the phosphoramidate prodrug 34 (figure 1.16), 
there was improvement in potency and increased levels of NTP conversion. When 
compared to NM283 22, phosphoramidate 35 had improved potency (EC50 = 0.22 
µM) relative to NM283 22 with increased levels of NTP observed in hepatocytes. Low 
oral bioavailability was assumed in hamster studies which showed only a 2 fold 
increase in hepatic NTP levels.31,37 In an attempt to increase liver NTP levels, the 
chain length of the ester moiety in phosphoramidate 35 was explored, which resulted 
in phosphoramidate 35 (figure 1.16). Although potency was the same (EC50 = 0.24 
µM), there was no improvement in liver NTP levels. Further efforts to increase 
hepatic NTP levels resulted in phosphoramidate 35 (figure 1.16) which had inferior 
potency when compared to phosphoramidates 34 and 36. It did have higher levels of 
the active NTP in human hepatocytes when dosed by subcutaneous IV. However, 
phosphoramidate 36 when dosed orally did not have the same level of hepatic 
NTP.31 
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Figure 1.16: Phosphoramidate prodrugs of NM107 21 
The uridine derivative PSI6206 25 was found to be inactive, however its NTP was 
found to have significant activity (table 1.1), so phosphoramidate prodrugs of 
PSI6206 25 were developed which yielded two highly potent compounds, PSI7851 
37 and PSI7977 38 (figure 1.17).4,31,52 
 
Figure 1.17: PSI7851 and PSI7977 (Sofosbuvir) 
PSI7851 37 was developed as a 1:1 diastereomeric mixture as a drug candidate. It 
was found to have synergistic effects with PEG IFN and RBV with a PI in quadruple 
therapy. No viral resistance or adverse effects were observed.31 
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PSI7977 38 (sofosbuvir) was developed as a single isomer as it was tenfold more 
active than its diastereomer. In genotype 1 patients, the viral load was decreased by 
-5 log10 with between 85 – 90 % having no detectable viral RNA. In genotype 2 and 3 
patients, 96% of patients achieved SVR in phase IIb trials. In 2014 it was approved 
as the first in class DAA nucleoside prodrug for the treatment of HCV infected 
patients.4,31 
Extending the work on guanosine analogues, PSI353661 41 (figure 1.18) was found 
to be a very highly potent drug candidate for HCV genotype 1 and 2 patients with an 
EC90 of 0.008 µM and is currently entering clinical trials.
31,38 
 
Figure 1.18: Guanosine based phosphoramidates 
Although new developments in targeting HCV RdRp show promise, new drug 
candidates are hampered by poor bioavailability, toxicity issues, poor conversion to 
the active triphosphate, and have poor genotype coverage.4,11,31,54 Only one 
candidate TMC 647078 27 (table 1.1) showed coverage for all six HCV genotypes, 
however was converted to the inactive uridine derivative and had low plasma 
concentrations.31 Synthesis of isobutyrate prodrug did not improve efficacy either. 
Phosphoramidate prodrugs show promise however; these are hampered by synthetic 
issues, are slow to develop, and are currently only able to target genotypes 1 to 3.31 
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As of 2014, sofosbuvir 38 the first in class phosphoramidate DAA nucleoside for 
treating HCV was approved for use. This means that current treatment regimes are 
combination therapy of sofosbuvir 38 with ribavirin and boceprevir 7 or telaprevir 8 
(figure 1.5); or combination therapy without ribavirin. This does away with the 
significant side effects of ribavirin and IFN 2α. However, due to the cost of sofosbuvir 
38, the limited genotype coverage, and the risk of evolving viral resistence occurring, 
newer DAAs are required.55 
A major setback for ProTide, HepDirect and SATE compounds is that to release the 
free nucleoside before conversion to the triphosphate is enzymatically controlled.56 
Efficient anabolism to the free nucleotide is limited by deamination or cleavage of the 
glycosidic bond, therefore the therapeutic utility of these phosphoramidates are 
limited.56 Meier devised cycloSal pronucleotides which are chemical Trojan horses 
that are chemically cleaved, circumventing the problems with enzymatic cleavage of 
the phosphate bond.56 Figure 1.19 shows the chemical cleavage of a Meier 
compound. 
 
Figure 1.19: Chemical hydrolysis of Meier pronucleotides 
1.2.2.5.4 Conformationally Restricted Nucleosides 
A major issue in the activity of ribose and deoxyribose based nucleosides is the bias 
of cellular kinases and DNA and RNA polymerases towards the conformational 
structure of the sugar moiety (figure 1.20).57,58 It has been experimentally confirmed 
that kinases require south puckering nucleosides for phosphorylation to the active 
triphosphate, and the polymerases require north puckering nucleotides. Polymerases 
will not incorporate south puckered nucleotides into a replicating genome as the 
nucleotide will not be in the correct conformation to bind into the polymerase active 
site.59 The energy expenditure to ring flip from the south pucker to the north pucker is 
large (about 17 KJ mol-1).57-60 This must be overcome before incorporation of the 
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nucleotide into the replicating genome can occur. As such, this is the cause of 
observed inactivity, or lower than expected activity of ribose and deoxyribose anti-
viral agents, even where there is a high level of the NTP present in the cells.57-60 
 
Figure 1.20: North and south puckered nucleotides 
In order to overcome this problem, conformational locking of nucleotides into the 
north conformation has proven useful, but this is not the only method of avoiding this 
kinase-polymerase bias.61  A major issue with this method is that by locking the 
nucleoside into the north conformation, phosphorylation at kinases does not occur. 
Additional steps are required to phosphorylate or mask the 5’-OH group to avoid the 
kinases altogether (see section 1.2.3.5.3). Research into conformationally locked 
nucleosides is ongoing, though faces similar issues.59-63 Locking the nucleoside in 
the south conformation allows for phosphorylation, however, as stated north 
conformation nucleosides are required for incorporation into the viral genome.61 
Spironucleosides are one such method of locking nucleosides in the preferred 
conformation as the anomeric carbon on the sugar and the base are shared, though 
variations in where the spiro-component is incorporated can also determine 
conformational locking.33 Spironucleosides are able to enhance base stacking within 
the genome and increase the rate of backbone pre-organisation, ie, these types of 
nucleosides create stable interactions within the genome. However, the main pitfall is 
the fact that conformational locking affects phosphorylation and hence incorporation 
into the genome.33 Figure 1.21 shows an example of a spironucleoside where 
compound 46 showed anti-HCV activity with the spiro component at C-2 forcing the 
nucleobase conformation into the south comformation. (Note: The review by 
Soengas et al., goes into more detail on the topic of spironucleosides that is not 
within the remit of this thesis such as the differing mechanisms of action of C-1, C-2, 
C-3, and C-4 spironucleosides).33 
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Figure 1.21: Typical C-2 Spironucleoside active against HCV infection 
Nucleoside/nucleotide based drugs are the best class of anti-viral agent for the 
treatment of viral infection as they are able to prevent viral replication; and this in turn 
allows the immune system to fight the infection.8,10 Many modifications can be made 
to these nucleosides, such as phosphate modifications, sugar modifications, base 
modifications and conformational locking. These modifications are required to 
overcome the issues regarding kinase bias causing low levels of the active 
triphosphate, discrimination between kinases and polymerases, and solubility 
issues.31 Continued research in this area is necessary due to the ability of viruses to 
quickly evolve resistance against these drugs. Modifications to the polymerase active 
site can create less favourable binding interactions for these un-natural nucleosides. 
1.3 Summary and Conclusions 
 The major classes of anti-viral agents include receptor antagonists, inhibitors and 
interferons.14,16,19,22,31,51 The drawback with interferons is that they do not act on the 
life cycle of the virus, with their mechanism of action being to induce an immune 
response to a viral infection.7,8 This means that the infection can persist, and relies 
on the the immune system being able to stave off infection.7,13 As such, interferon 
treatment is limited to viruses that do not harm the host immune system. Receptor 
antagonists are another class of drug where their utility is limited.22,23 This class of 
drug relies on prophylactic treatment; where the drug is administered before 
infection.24 Like NNRIs, IIs, PIs, and NNRTIs, which are all highly specific, resistance 
evolves very quickly limiting the utility of all these classes of drugs.1  
Nucleoside based drugs are the best class of drugs to target viral infections. This 
class of drug is able to directly prevent viral replication in all stages of the viral 
infection pathway whereas other classes of drug act only in a specific stage of 
infection.31,39,64 Nucleoside drugs do not work when the virus is latent and not 
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replicating, however, these drugs are able to prevent replication once the virus has 
entered the cell, or has started to replicate.11,31  
Typical drug regimens now utilise a DAA (nucleoside drug) a NNRI or NNRTI (usually 
two) and a PI. This type of combination therapy allows rapid treatment of viral 
infections. The DAA prevents genome replication along with the NNRI or NNRTI. The 
PI is used to prevent the protease from cleaving the viral polyprotein before a new 
virion is assembled. This method has been used successfully to treat HIV and HCV. 
However, much work is required for new DAAs, and therefore, the major aim of this 
project is to develop nucleoside based drugs to treat viral infections.  
1.4 Aims and Objectives 
Since DAAs have shown the greatest potential in treating viral infections, the major 
aim of this project is to develop new nucleoside based DAAs. However, the 
conformation of ribose nucleosides has been shown to be a major factor in inactivity. 
Therefore, 4-membered ring nucleosides will be assessed for their anti-viral activity. 
(See introduction to chapter 2). Thietane nucleosides and thioribose nucleosides 
have shown significant promise due to their stability against kinases and nucleases. 
The sulfur atom makes these compounds less susceptible to nucleases cleaving the 
glycosidic bond. (See chapters 2 and 4 introductions for a detailed explanation). 
Therefore the project aimed to develop three libraries of compounds. 
Aims: 
To develop and optimise synthetic routes toward target sulfur containing nucleosides 
by exploiting available chemistry to synthesise the target nucleosides. The chemical 
strategies are to be assessed to enable efficient synthesis of the target compounds. 
Assess the anti-viral activity of the target thietane and 4’-thiohamamelose 
nucleosides in biological assays to determine SARs. Use this data to develop more 
potent nucleosides by varying the structure of the compounds in line with 
observations from the biological assays. 
Objectives: 
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1. Library 1: thietane nucleosides as anti-viral agents. This will involve the design 
and synthesis of 3,3-bis(hydroxymethyl)-thietan-2-yl nucleosides to probe the 
SAR of the nucleobases. This will then lead to  
2. Library 2: thietane nucleosides as anti-viral agents This will involve the design 
and synthesis of 4,4-bis(hydroxymethyl)-thietan-2-yl nucleosides. Here, the 
geminal hydroxyl groups position has been modified. The nucleobases are the 
same as those in library one, so that the SAR of the position of the hydroxyl 
methyl groups can be assessed. 
3. Library 3: 4’-thiohamamelose nucleosides. This will involve the design and 
synthesise a library of 4’-thiohamamelose nucleosides as potentially active 
anti-HCV nucleosides. 
4. Assessment of the anti-viral activity: The IC50, and CC50 will be determined in 
an anti-viral assay. Prior to these assays, cell viability studies will be 
performed on selected nucleosides to assess whether these compounds affect 
cell viability before more stringent cytotoxicity assays are performed. The IC50 
and CC50 data will be used to determine the SAR of these compounds 
5. Once the SAR is determined, a final library of compounds will be synthesised 
based on the biological data with the intention of increasing potency and 
decreasing any observed cytotoxicity. 
Objective 1 has been met with this programme and the cell viability of 4 candidate 
compounds, in line with the objective 4, has been determined with no significant loss 
in cell viability and is detailed in chapter 2. 
Objectives 2 and 3 have been partially with the optimisation of the synthetic routes 
towards the key intermediates for the synthesis of the respective target nucleosides 
and are detailed in chapters 3 and 4.   
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Chapter 2: 
The Design and Synthesis of 3,3-
bis(hydroxymethyl)-thietan-2-yl 
Nucleosides 
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Chapter 2: Synthesis of 3,3 bis(hydroxymethyl) thietane 
nucleosides 
2.1 Background 
A major issue in the anti-viral activity of ribose and deoxyribose based nucleosides is 
the bias of cellular kinases and DNA and RNA polymerases towards the 
conformational structure of the sugar moiety (figure 2.1).1,2 It has been experimentally 
confirmed that kinases require south puckering nucleosides for phosphorylation to 
the active triphosphate, and the polymerases require north puckering nucleotides. 
Polymerases will not incorporate south puckered nucleotides into a replicating 
genome as the nucleotide will not be in the correct conformation to bind into the 
polymerase active site.3 The energy expenditure to ring flip from the south pucker to 
the north pucker is large (about 17 kJ mol-1) and must be overcome before 
incorporation of the nucleotide into the replicating genome can occur, and as such, 
this is the cause of observed inactivity, or lower than expected activity, of ribose and 
deoxyribose anti-viral agents.1-4 
 
Figure 2.1: North and south puckered nucleotides 44 and 45 
In order to overcome this problem, conformational locking of nucleotides into the 
north conformation has proven useful, but this is not the only method of avoiding this 
kinase-polymerase bias.5  A major issue with this method is that by locking the 
nucleoside into the north conformation, phosphorylation by kinases does not occur. 
Additional steps are required to phosphorylate or mask the 5’-OH group to avoid the 
kinases altogether. As noted in chapter 1, the first kinase in the phosphorylation 
steps is the most discriminatory and hence the most important factor in inactivity of 
nucleosides is due to the first kinase in the phosphorylation step. In order to 
overcome this, several methods of masking the 5’-OH group as phosphonate esters 
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or phosphoramidates have been developed. These have been applied to north 
puckered conformationally locked nucleosides.6,7 
However, since this adds several steps, a more prudent method would be to change 
the sugar moiety altogether. Oxetane nucleosides have been extensively studied as 
alternative nucleoside analogues to ribose derivatives. In its unsubstituted form, the 
oxetane ring will flip between planar and two puckered forms (figure 2.2) with ease as 
the energy barrier is small (the total energy change for flipping through the planar 
state from either conformation is -1.2 kJ mol-1).8,9  
 
Figure 2.2: Conformations of oxetane 
The ring flip between these forms in oxetane is prevented once they are substituted, 
locking in place the conformation of the ring. This conformational locking is due to the 
fact that 4 membered ring closing mechanisms favour 4-exo-tet reactions.8,9 This 
leads only to the pseudo-south puckered conformation as formation of the 4-endo-tet 
cyclisation is disfavoured by Baldwin’s Rules. 
It seems counterintuitive that kinases will recognise the pseudo-south conformation 
given that kinases only recognise south conformations. Further, it seems that 
polymerases should not recognise pseudo-north conformation since polymerases 
only recognise north conformations. It would be expected that conformationally 
locked pseudo-south oxetanes would not be recognised or be phosphorylated by 
kinases. However, kinases recognise them as substrates and will phosphorylate 
them as described below.10 
2.1.1 Oxetane and Thietane Nucleosides 
Oxetane nucleosides have been extensively studied and have shown anti-viral 
activity against VZV, HSV-1,2, HIV, HBV and CMV.10-16 Oxetanocin A was first 
isolated in 1986 and showed anti-viral, anti-bacterial, anti-tumour and anti-fungal 
activity.10-13,17,18 Shown in table 2.1 are the oxetane nucleosides that are active 
against HIV, HBV, HSV and VZV. 
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Table 2.1: Anti-viral activity of oxetane nucleosides 
Nucleoside Virus  (EC50 μM)  (CC50 μM) 
 
Oxetanocin A 
47 
HIV
15
 1.4 
 
11
15
 
 
Oxetanocin G 48 
 
 
HIV
15,16
 
HBV
16
 
 
 
7.3 
1.5 
 
29
15
 
- 
 
Oxetanocin H  
49 
 
 
HIV
15
 
 
 
2.2 
 
 
28
15
 
 
Oxetanocin T  
50 
 
 
VZV
15
 
HSV-1
15
 
HSV-2 
 
 
0.003 
0.05 
1.0 
 
 
>100 
>100 
>100 
  
It was noted that the oxetanocin nucleosides were all converted to their active 
triphosphates hence their anti-viral activity.10 However, compound 47 did not 
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incorporate well into the DNA of HBV which would allow chain extension of the viral 
genome to occur even after nucleoside incorporation.16 Therefore, compound 47 is 
inefficient at inhibiting viral genome replication as it was not specific for the viral 
polymerase, with several host cell targets which resulted in some observed 
cytotoxicity. Cytotoxicity was observed in compounds 48 and 49 and was also due to 
the unspecific binding of these molecules. 
Through nucleobase modification, compound 50 was found to have a longer half-life 
than compound 47, the half-life of compound 50 being three hours versus 1.7 hours 
for compound 47.14 This was due to compound 47 being deaminated by adenine 
deaminase to form the inactive metabolite.11,16 The oxetane ring was found to be 
unstable toward cellular phosphorylases, which inactivates the nucleosides.10-13,19,20  
A way to overcome the problem of adenine deaminase and hydrolysis of the 
glycosidic bond is to replace the oxygen with sulfur.11,21 This kind of replacement has 
been shown to increase the stability of nucleosides to acid hydrolysis since sulfur 
atoms do not protonate as easily as oxygen atoms.20 
Since thietane nucleosides are predicted to be more stable towards acid glycosidic 
hydrolysis and cellular phosphorylases than the oxetane counterparts; it is predicted 
that the thietane nucleosides will still retain activity or have increased activity over the 
oxetane counterparts. It is also predicted that the thietane nucleosides will be 
phosphorylated. The thietane nucleosides should behave in exactly the same 
manner as the oxetane nucleosides; that is although the thietanes are predicted to be 
conformationally locked in a pseudo-south conformation in much the same way as 
the oxetanes, this should not impede activity. 
Choo et al., have synthesised several thietane nucleosides, based on the oxetanocin 
A scaffold, that are active against HIV (table 2.2).11 
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Table 2.2: Thietane nucleosides active against HIV 
Nucleoside  (EC50 μM) PBM (IC50 μM) CEM (IC50 μM) 
 
51 
 
 
6.9 
 
 
8.5 
 
 
4.9 
 
52 
 
 
1.3 
 
 
=1.0 
 
 
4.3 
 
53 
 
 
5.8 
 
 
<1.0 
 
 
19 
 
54 
 
 
11.5 
 
 
>100 
 
 
1.8 
55 
 
 
14.1 
 
 
13.1 
 
 
45.6 
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Thietanocin A 
56 
 
 
>100 
 
 
>100 
 
 
>100 
 
Thietanocin G 
57 
 
 
>100 
 
 
>100 
 
 
>100 
 
Thietanocin H 
58 
 
 
>100 
 
 
>100 
 
 
>100 
 
Thietanocin T 
59 
 
 
>100 
 
 
>100 
 
 
>100 
 
Compounds 51 – 55 showed anti-viral activity against HIV, however, cytotoxicity in 
peripheral blood mononuclear cells (PBM) and CEM-T4 cells was an issue (CC50 for 
CEM T4 cells were highest at 45.6μM and CC50 for PBM cells were highest at 
13.1μM). The high CC50 values are problematic for these compounds as HIV-1 
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infects these blood cells, and death of these immune cells is a significant issue as 
this reduces the effectiveness of the host immune system at fighting infection. 
Addition of a halogen group to the 5-position of the pyrimidine ring reduced the 
cytotoxicity of these compounds, however, anti-viral activity was also reduced.11 The 
activity of the thietane compounds are comparable to the oxetane counterparts, 
however, the thietane purine derivatives were not active despite molecular models 
showing thietanocin A 56 binding in the exact same manner as the active oxetanocin 
A 47. The observed inactivity of thietanocin A 56 could be due to low levels of the 
active triphosphate being formed.11 Despite this, the pyrimidine thietane nucleosides 
show excellent promise as anti-viral nucleosides. Though cytotoxicity may be an 
issue, this can be controlled by analysing structure activity relationships. By focusing 
on groups which favour binding to viral polymerases over host cell organelles, 
cytotoxicity may be reduced and anti-viral activity should increase as the compounds 
become more selective and potent. 
The benefits of thietane nucleosides have been demonstrated (table 2.2). They are 
predicted to be more stable than the oxetane derivatives and may be more active 
when a more focused medicinal chemistry campaign is used to further develop them. 
These compounds have been shown to be recognised by kinases and to be 
incorporated into viral genomes. This suggests that thietane nucleosides are 
phosphorylated by kinases without discrimination of the ring conformation. It has 
been noted in the literature that the reason for the limited number of thietane 
nucleosides analysed thus far is due to the difficulty in synthesising the 
nucleosides.10-13,17-19,22 The key challenges to overcome are:  
1. synthesising the thietane scaffolds of interest,  
2. synthesising the nucleosides, of which two methods are known, one of which 
has low yields and reproducibility problems;10-13,17  
3. the lack of clinical data means that additional SAR studies are required to 
understand which components of the thietane scaffolds are important for 
activity. From this data, selectivity and potency could be fine-tuned toward the 
synthesis of a potent, active anti-viral thietane nucleoside. 
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2.2 Aims and Objectives 
Choo et al. have shown that thietane nucleosides have anti-viral activity and the 
major aim of the research described herein was therefore to determine the anti-viral 
activity of complementary 3,3-bis(hydroxymethyl) thietane nucleosides. In order to 
achieve this major aim several goals must be achieved first: 
 Exploratory chemistry: There are two known methods toward the synthesis of 
thietane nucleosides (section 2.2.1), the Pummerer Reaction and Vorbrüggen 
conditions. Both of these methods will be explored.10,11,13 
 Build a library of thietane nucleosides using the literature as a guide to identify 
key nucleobases that have been shown to confer anti-viral activity. 
 Determine the anti-proliferative profile: Pre-screening cell viability assays will 
be used to determine whether the nucleosides impact cell viability. Candidate 
compounds that are representative of the library will be screened to assess 
their impact on cell viability. 
 Once cell viability assays have determined whether or not the compounds 
affect cell viability, the compounds will be screened against a library of viruses 
to determine CC50 and their IC50; which is the concentration required to halt 
viral replication by 50%. 
2.2.1 Formation of Thietane Nucleosides 
Historically, thietane nucleosides were formed via the Pummerer reaction.10,17,22-25 A 
general mechanism is shown in scheme 2.1. Sulfoxide 60 and the sulfonium ylide 61 
exist as resonant structures. Sulfonium ylide 61 attacks acetic anhydride. The 
resulting acetate 62 forms, which is deprotonated by the carboxylate ion. This forms 
the Pummerer intermediate 63 which undergoes a reaction with the silylated 
nucleobase to yield nucleoside 64. 
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Scheme 2.1: General mechanism of the Pummerer reaction 
The yield of the Pummerer reaction depends upon the structure of the thietane 
precursor. Nishizono et al. first synthesised two sets of thietane nucleosides: one set 
with a 3,3-bis(hydroxymethyl)thietane core, compound 65, and one set with a 3-
hydroxy-4-hydroxymethyl thietane core compound 67.10 It was observed that in the 3-
hydroxy-4-hydroxymethyl thietane compounds, yields to the nucleoside were 30% 
overall, but for the 3,3-bis(hydroxymethyl)thietane compounds, the yield to the 
nucleoside was 70% under the same conditions (scheme 2.2). [Note, in this case, 
only the thymine derivatives were synthesised but showed no anti-viral activity 
against VSV for HSV-1,2].10 
 
Scheme 2.2: Thietane core structure affects product yield.  
The drop in yield was due to a major competing side reaction (scheme 2.3) which 
saw proton abstraction occurring at C-3 rather than at C-2 in thietane 67 (see 
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mechanism in scheme 2.1 for C-2 proton abstraction). Proton abstraction at C-3 in 
the 3-hydroxy-4-hydroxymethyl thietane compounds resulted in the unreactive 
product compound 72.10,23 
 
Scheme 2.3: Top: Pummerer rearrangement proceeds via neighbouring group participation of the –
OBz group shown by 69 and 70. The incoming nucleoside can only attack from the top face resulting 
in an diastereomerically pure product 68. Bottom: Major competing reaction resulting in an unreactive 
intermediate that does not undergo Pummerer rearrangement.  
Choo et al. also noted low yields for the formation of the nucleosides (see table 2.2 
for section 2.1.1) which were also attributed to proton abstraction at C-3 leading to 
the formation of the unreactive intermediate 72.11,23 The yields for the Pummerer 
rearrangement for the Choo compounds ranged from 30-75% depending on the 
nucleobase used (30% for thymine versus 75% for cytosine). The difference in yield 
was due to the lower nucleophilicity of the cytosine moiety making it more selective 
toward attacking at the sulfur ylide, whereas the thymine moiety may be more 
nucleophilic and therefore prone to proton abstraction at C-3.11 
In order to improve the yields of thietane nucleoside formation newer methods of 
introducing the nucleobase onto the thietane ring have been developed. Standard 
nucleoside reactions consist of the use of a glycosyl halide and a silylated 
nucleobase to furnish nucleosides and are known as Vorbrüggen conditions.26 
Nishizono et al. devised two methods for the introduction of a halogen atom onto the 
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thietane ring so that the ring could act as the glycosyl halide.13 By introducing a 
fluorine atom to C-2 by using diethyaminosulfurtrifluoride (DAST) or deoxofluor, the 
glycosyl fluoride 76 could be furnished in high yield. The fluoride was chosen as it is 
more stable than typically used glycosyl chlorides or bromides. The reaction 
mechanism proceeds via the fluoro-pummerer reaction to give the glycosyl fluoride 
from a sulfoxide (scheme 2.4) with yields of 86% (DAST) and 22% (Deoxofluor), and 
from a sulfide with yields of 92% DAST and 83% deoxofluor  (scheme 2.5).13,27 
 
Scheme 2.4: Fluoro-Pummerer reaction from a sulfoxide 65  
 
Scheme 2.5: fluoro-Pummerer reaction from a sulfide 77. Note[SbCl3F]
- 
liberates fluoride ions as the 
reaction proceeds. 
From sulfoxide 65, fluorination proceeds via a standard Pummerer rearrangement, 
but from sulfide 77, the fluoro-Pummerer rearrangement occurs via a six membered 
transition state to sulfur ylide 78.24,25,27 Two processes occur in this reaction: SbCl3 
catalyses the formation of the initial fluoride ions that form the first set of 2-
fluorothietane 76 molecules. Once the sulfur ylide 78 forms, the second process of 
liberating fluoride ions begins by reaction of fluoride ions at ylide 78.24,25,27 This 
means a slight excess of the deoxofluor or DAST is required when using sulfides. 
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The use of sulfides for the fluoro-Pummerer reaction is advantageous as it removes a 
step: the oxidation of the thietane to sulfoxide 65. Another advantage of using a 
sulfide is that the yields are comparable when DAST or deoxofluor are used (92% 
DAST and 86% deoxofluor).13,27 
Formation of the thietane nucleosides under the Pummerer reaction gave variable 
yields (scheme 2.2 page 41).28 Under the Vorbrüggen conditions utilised by 
Nishizono et al.,  using a fluorophilic activator complex of SnCl2-AgClO4 the thymine 
and 6-chloropurine derivatives were furnished with yields of 56% and 42% 
respectively.13,26 Though under the Pummerer reaction the 3,3-bis(hydroxymethyl) 
thietane nucleosides were furnished with a yield of 70%, the Pummerer reaction was 
only applied to one nucleobase (thymine).10 Choo et al. have shown utility of the 
Pummerer reaction, but yields were low and major competing reactions were an 
issue (see section 2.2.1).11 It is clear that at the start of this project, both the 
Pummerer reaction and the Vorbrüggen conditions must be assessed to determine 
the most viable synthetic method toward target thietane nucleosides. However, it is 
predicted that, based on the evidence presented in this section, that the Vorbrüggen 
conditions may give the most reproducible reactions compared to the Pummerer 
reaction. 
 
Scheme 2.6: Mechanism of thietane nucleoside formation under Vorbrüggen conditions 
From the literature, the 3,3-bis(hydroxymethyl)thietane nucleosides have not been 
fully assessed for their anti-viral activity as only one nucleoside (the thymine 
derivative 66) has been tested against VZV and HSV-1,2, which showed no activity.10 
It has been shown in section 2.1 that thietane nucleosides are more stable and 
potentially more active than their oxetane counterparts, despite their higher 
cytotoxicity in blood cells.11 Formation of the 3,3-bis(hydroxymethyl) thietane core will 
follow the synthesis of Nishizono et al., and both the Pummerer reaction and 
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Vorbrüggen conditions will be investigated to assess which reaction gives access to 
the nucleosides in good yields. 
The target compounds are shown in figure 2.3. The nucleobases chosen are based 
on the active compounds discovered by Choo et al., along with all of the standard 
nucleobases.11 
 
Figure 2.3: Target compounds 
Further to the initial aims in section 2.2, the structure activity relationship of the 
pyrimidine bases will be assessed. This will be used to guide the synthesis of 
compounds in subsequent compound libraries with the overall aim of fully assessing 
the complete SAR of the geminal bis(hydroxymethyl) thietane core; and using this 
information to guide the synthesise of highly potent nucleosides. The halogenated 
variants, nucleosides 84-87 and 90-91, have shown activity in several different anti-
viral agents and the purine derivatives 82 and 83 expected to be inactive or minimally 
active.3,6,11,29-40  
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2.3 Synthetic Strategy towards 3,3-bis(hydroxymethyl) thietane 
nucleosides 
Synthesis of the 3,3-bis(hydroxymethyl) thietane core proceeded with ease (scheme 
2.7) according to the synthesis reported by Nishizone et al.13 During the initial stages 
of the synthesis both the Pummerer reaction and the Vorbrüggen conditions were 
assessed for suitability to furnish the thietane nucleoside. Both fluoride 76 and 
sulfoxide 65 could be easily synthesised from the dibenzoate 77 with yields in excess 
of 80% on multi-gram scales. 
 
Scheme 2.7: Conditions: i) pTSA, 1,2-DMP, Acetone, RT, 24 hrs, 91% ii) Na2S.9H2O, DMF, 110° C, 
24 hrs, 94% iii) pTSA, MeOH, RT, 86% iv) BzCl, DMAP, DCM, RT, 24 hrs, 78% v) Deoxofluor, SbCl3, 
DCM, RT, 86% vi) NaIO4, MeOH, RT, 24 hrs, 64% 
The synthesis began from commercially available 2,2-bis(bromomethyl)-1,3-
propanediol 92 which was reacted with 2,2-dimethoxypropane to form the 
isopropylidene dibromide 93 on scales ranging from 1 g to 100 g from 2,2-
bis(bromomethyl)-1,3-propanediol 92. 1H NMR spectroscopic analysis (figure 2.4) 
confirmed that the isopropylidene group was present with the methyl group protons 
present at 1.4 ppm with an integration of 6 protons. Two distinct CH2 environments 
were evident at 3.6 and 3.8 ppm, both integrating to 4 protons each. 
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Figure 2.4: 
1
H NMR spectrum of isopropylidene dibromide 93 
This result is as expected as the CH2O methylene protons are more deshielded than 
the CH2Br methylene protons. Mass spectrometry gave three peaks for the 
isopropylidene dibromide M+H+ at 301, the M+2+H+ at 303 and M+4+H+ at 305, 
which are indicative of the bromine isotopic abundance (M+H+ 79Br-79Br, M+2+H+ 
79Br-81Br and M+4+H+ 81Br-81Br). 
Formation of the isopropylidene thietane 94 using Na2S.9H2O proceeded in high 
yield, on scales ranging from 1 g to 50 g. 1H NMR spectroscopic analysis (figure 2.5) 
showed the methylene peaks at 3.6 ppm shifting down to 3.0 for the CH2SCH2 
methylene protons whilst the CH2O protons shifted slightly to 3.9 ppm. These shifts 
are expected; the CH2O methylene protons moving by 0.1 ppm could be indicative of 
changing electronic structure due to ring strain provided by the thietane ring. The 
smaller peaks either side of the main peaks seem to indicate that the reaction 
concentration was too high, and that there is possibility that the thiol compound 96 
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has reacted with compound 93 to form a dimer. This can be avoided by reducing the 
concentration of the reactants. Low concentrations tend to favour intramolecular 
reactions, as this is entropically favoured. 
 
Figure 2.5: 
1
H NMR spectrum of isopropylidene thietane 94 
The CH2SCH2 upfield shift is indicative of the lower electronegativity of the sulfur 
atom, and hence less deshielding of the CH2 methylene protons occurred. However, 
due to the reaction mechanism, where SN2 displacement of the bromine atoms 
occurs (scheme 2.8) there is a possibility that a dithiol could have formed. This would 
give the symmetric NMR spectrum that was obtained and the change in chemical 
shifts that were observed.41-43 
 
Scheme 2.8: Reaction mechanism of thietane formation 
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Mass spectrometry data gave the M+H for thietane 94 at 175.0788 Da which 
confirmed that the thietane compound had been synthesised and was in agreement 
with the literature.13 
Deprotection of the isopropylidene thietane 94 to the diol 95 was achieved in 
quantitative yields using pTSA on scales ranging from 1 – 50 g from isopropylidene 
94. 1H NMR spectroscopic analysis of the purified diol 95 showed no peaks for the 
isopropylidene acetal at 1.4 ppm, which is in agreement with the literature, and the IR 
spectrum showed a broad peak at 3300 cm-1 for the diol.13 The CH2OH methylene 
protons shifted to 3.9 ppm as expected due to the greater deshielding effect of the 
free hydroxyls over the isopropylidene acetal. A mass spectrum of the diol 95 gave 
an M+H+ of 135 Da as expected.  
Next, diol 95 was reacted with benzoyl chloride on scales ranging from 10 – 20 g to 
furnish dibenzoate 77. The proton NMR showed the CH2OH methylene protons 
moving downfield from 3.9 ppm in diol 95 to 4.4 ppm. This is due to the greater 
deshielding effect of the benzoate protecting group. In diol 95 and dibenzoate 77 the 
CH2SCH2 methylene protons only moved by 0.2 ppm, which is attributed to the 
changing electronic structure at the CH2O groups. 
Once dibenzoate 77 had been synthesised, two potential routes to the thietane 
nucleosides were evident from the literature. From sulfoxide 65 a Pummerer reaction 
could be used to furnish the nucleosides, or from fluoride 76 the Vorbrüggen 
conditions could be used and hence both reactions were explored (scheme 2.9). 
 
Scheme 2.9: Top: Pummerer reaction. Bottom: Vorbrüggen conditions. 
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From dibenzoate 77, NaIO4 was used to furnish the sulfoxide 65 which gave an 
interesting 1H NMR spectrum (figure 2.6). 
 
Figure 2.6: 
1
H NMR spectrum of sulfoxide 65 
The CH2S=OCH2 protons were both doublets of doublets with J couplings of 3 Hz 
and 10.0 Hz respectively but the CH2OBz protons remained unchanged as singlets 
integrating to 2H for each CH2OBz group. This is due to the sulfoxide being chiral 
and hence the protons occupying slightly different chemical environments (figure 
2.7). The coupling of 10.0 Hz is attributed to geminal coupling between two protons 
on the same carbon atom, and the coupling of 3.0 Hz is attributed to a through bond 
coupling effect via the CH2S=OCH2 group.
43,44 
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Figure 2.7: Sulfoxide 65 coupling patterns. Ha/Hb are conformationally non-equivalent to Hx/Hy 
As can be seen from figure 2.7 both protons 1 and 2 are shown and can be seen as 
a pair of doublet of doublets. Fronza et al have shown that protons Ha and Hb are 
conformationally non-equivalent to Hx and Hy and are seen as separate doublets 
where Ha and Hb couple to each other as do Hx and Hy. This gives rise to a potential 
for an ABX system to arise, however, these doublets are not a true ABX system.45-47 
In an ABX system, Ha and Hb couple strongly to each other, and weakly couple to 
Hx. In the sulfoxide, this is not specifically seen as HAB and HX are not seen 
separately as would be expected.46,47 In sulfoxide 65 Ha couples to Hb and Hb 
couples to Ha to give the two doublets. The same is true for Hx and Hy. However, 
analysis of the doublet shows that they are not true doublets, with spurs that indicate 
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an interaction between Ha/Hb with Hx/Hy as they are conformationally non-
equivalent to each other. In order to resolve this, either temperature dependant NMR 
is required or a larger frequency spectrometer would be required to tease out the 
interaction between Ha/Hb with regards to Hx and vice versa. There is potentially an 
ABX interaction occurring, however, the J value for JAX/BX etc is not obvious from this 
data. 
The extreme change in chemical shift of the methylene protons in CH2SCH2 to 
CH2S=OCH2 methylene protons from 2.9 ppm to 3.9 ppm is due to the charge on the 
sulfur ylide. This significantly deshields the CH2S=OCH2 methylene protons giving 
rise to the higher chemical shift as the proton can interact with the applied magnetic 
field. 
Synthesis of glycosyl fluoride 76 from dibenzoate 77 (scheme 2.7) required 
optimisation as the fluorination reaction was very sensitive to air and moisture, the 
amount of SbCl3 catalyst and to the reaction time. Though Nishizono et al. formed the 
glycosyl fluoride from both sulfoxide 65 and dibenzoate 77, it was decided to only 
concentrate on fluoride formation from dibenzoate 77 as this removed one step from 
the synthesis allowing for quicker access to the fluoride. It must be noted that 
isopropylidene 93, isopropylidene thietane 94 and dibenzoate 77 were purified by 
recrystallization from isopropyl alcohol (IPA). Only diol 95 and fluoride 76 required 
purification by column chromatography. On scale up from isopropylidene 93, 
purification was avoided all the way to dibenzoate 77 and the yield of dibenzoate 77 
was unaffected which meant that time scales for reaction scheme could be reduced 
from 8 days to 5 days which includes reaction times and purifications. However, 
glycosyl fluoride 76 required column chromatography for purification which led to 
increased time scales.  
Initial small scale exploratory reactions using DAST and Deoxofluor gave mixed 
results (table 2.3). Two factors were found to be important to furnish gylcosyl fluoride 
76: the amount of SbCl3 catalyst and the equivalents of DAST or deoxofluor. 
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Table 2.3: Optimisation reactions to glycosyl fluoride 76: Effect of catalyst 
Reaction Reagent Equiv SbCl3  
(%) 
Time 
(hrs) 
Outcome Yield 
(%) 
1 DAST 1.5 1 24  13% mass recovery 
of total mass on 
column 
- 
2 DAST 1.5 1.5 24  37% mass recovery 
of total mass on 
column 
- 
3 DAST 1.5 10 24  Impure product - 
4 DAST 1.5 20 24  Degraded product - 
5 DeoxoFluor 1.5 1 24  Product isolated 15 
6 DeoxoFluor 1.5 1.5 24  Product isolated 19 
7 DeoxoFluor 1.5 10 24  Product isolated 46 
8 DeoxoFluor 1.5 20 24 Product isolated 38 
 
As table 2.3 shows, DAST was not an ideal reagent for furnishing fluoride 76 and it is 
thought that it generates fluoride ions quickly, resulting in excess HF in solution. The 
HF in solution would degrade the compound, and this was seen by analysis of the 1H 
NMR spectrum, where no peaks associated with the products were observed. For 
DAST, increasing the catalytic loading did not give rise to any product, however, for 
DeoxoFluor, increasing the catalytic loading did increase the yield of the final 
product. It was found that 10% SbCl3 was ideal for forming fluoride 76; however, 20% 
SbCl3 was found to lower the yield. Analysis of the 
1H NMR spectrum for reaction 8 
showed some degradation of the product. This could be due to the fact that at 20% 
catalytic loading, fluoride ions are forming at a greater rate than the thietane can 
react with them. This then could form HF in solution, which would destroy some of 
the compound. Table 2.4 shows that increasing the reaction time increased the yield 
of the fluoride 76. 
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Table 2.4: Effect of increased reaction time on the yield of fluoride 76 
Reaction Reagent Equiv SbCl3  
(%) 
Time 
(hrs) 
Outcome Yield 
(%) 
1 DeoxoFluor 1.5 10 24  Product isolated 46 
2 DeoxoFluor 1.5 10 48  Product isolated 58 
3 DeoxoFluor 1.5 10 72  Product isolated 86 
4 DeoxoFluor 1.5 10 96 Product isolated 83 
 
In general, table 2.4 shows that by increasing the reaction times increases in yields 
were observed. It was found that 72 hours was an optimal time for the reaction to go 
to completion. Any longer and no appreciable gains in yields were obtained, and at 
96 hours, a yield of 83% for fluoride 76 was obtained. Therefore, it was found that 
10% catalytic loading with 1.5 equivalents of deoxofluor reacting for 72 hours was the 
optimal reaction conditions. In order to try and bring the reaction time down, 2 
equivalents of deoxofluor were trialed; however, di-fluorination of the thietane ring 
resulted after 48 hours. Although this indicated the reaction rate did increase, the end 
result was a di-fluorinated thietane ring as the product, which was unwanted. 
An interesting feature of the NMR of glycosyl fluoride 76 is the doublet at 6.1 ppm 
(figure 2.8). This doublet has a coupling constant of 64 Hz which is the coupling 
between the H-1 and fluorine on C-1. 
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Figure 2.8: 
1
H NMR spectrum of fluorothietane 76 
One of the CH2O groups integrates to 2 and on the other CH2O group, geminal 
coupling is observed with a coupling constant of 10 Hz. Protons 3 and 4 also show 
geminal coupling, one as a doublet and one as a triplet. The triplet is geminal 
coupled to the proton on the same carbon and W coupled to the proton on the SCHF 
carbon. It would be expected that both protons on C-3 should be double doublets but 
is observed as a triplet in the 1H NMR spectrum due to the possibility that there is 
peak overlap (figure 2.9).  
 
Figure 2.9: Coupling of C-3 protons to the SCHF bond. As can be seen, the protons on C-4 occupy 
different environments. One proton couples to its neighbour giving rise to the doublet and the other 
proton couples to the proton and the fluorine on C-1 as a through bond effect.  
In the carbon NMR spectrum C-1 has a coupling of 248 Hz as expected since 
fluorine and carbon also couple. 19F NMR spectroscopic analysis shows the fluorine 
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is present as a doublet at -157 ppm (63.5 Hz) and is within the expected range for 
this compound (figure 2.10). 
 
Figure 2.10: 
19
F NMR of fluorothietane 76 
2.3.1 Synthesis of Thietane Nucleosides via the Pummerer Reaction 
Two routes to thietane nucleosides were explored: one route using the Pummerer 
reaction and one route using Vorbrüggen conditions. The reaction conditions chosen 
were identical to the first synthesis published by Nishizono et al. in 1996.10 First, 
thymine was heated at reflux in hexamethyldisilazane (HMDS) to effect silylation 
(scheme 2.10). By doing so, the thymine is soluble in the reaction conditions and 
should be able to react with sulfoxide 65. Once the HMDS is removed under reduced 
pressure, the silylated thymine is dissolved in toluene and the sulfoxide, triethylamine 
and TMSOTf are added followed by ZnI2. Two equivalents of the silylated thymine 
were used to one equivalent of sulfoxide 65 in all reactions.  
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Scheme 2.10: Pummerer reaction to thymine nucleoside 
Nishizono et al. reported yields of 70% when the reaction was performed in toluene 
or DCM under the conditions in scheme 2.10, however, these results could not be 
replicated even after leaving the reaction for 48 hours. Analysis of the crude 1H NMR 
spectrum showed only the presence of starting material peaks. Purification of the 
crude reaction material enabled starting material to be recovered and recycled with a 
yield of 90%. Table 2.5 shows the reaction conditions attempted. 
Table 2.5: Pummerer reaction conditions 
Reaction Temperature (°C) Scale (mg) Solvent Time (hrs) Result 
1 0 100 Toluene 30 SM recovered 
2 0 100 Toluene 48 SM recovered 
3 25 100 Toluene 48 SM recovered 
4 0 100 DCM 30 SM recovered 
5 25 100 DCM 48 SM recovered 
 
All reactions were stopped after 48 hours based on TLC analysis and analysis of the 
crude reaction by 1H NMR spectroscopy. TLC analysis of the crude reaction showed 
no changes in Rf or the number of spots and analysis of the crude reaction mixture 
by 1H NMR spectroscopy did not show product formation. Initially, it was thought that 
the reaction was not left for long enough, and so the reaction was left for 24 hours. 
However, no change was observed and thus the reaction temperature was raised as 
it was thought that raising the temperature would give favourable kinetics for product 
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formation. With no product forming, DCM was trialled as it was suspected that the 
silylated nucleobase was not dissolving adequately enough in toluene. However, as 
can be seen from table 2.4, no reaction was observed. It was also suspected that 
completely removing the HMDS (by azeotroping with toluene) could be causing 
deprotection of the trimethylsilyl groups on the silylated nucleobase. In subsequent 
reactions, the HMDS was removed under reduced pressure to leave an oily residue 
instead. In these reactions, no reactions were observed and it is highly likely that the 
TMSOTf was quenched by the residual HMDS left behind. 
2.3.2 Synthesis of Thietane Nucleosides under Vorbrüggen 
Conditions 
In parallel to the Pummerer reaction, the glycosyl fluoride 76 chemistry had been 
optimised and the Vorbrüggen conditions were trialled with great success.13,26 
Following the Nishizono et al. conditions for the thymine nucleoside 66, the 
nucleoside was furnished with a yield of 57% after reacting in DCM at room 
temperature for 18 hours.  
 
Scheme 2.11: General reaction scheme toward thietane nucleosides 
In all cases except for nucleoside 66, the reaction conditions set out by Nishizono et 
al. required optimisation either for silylation of the nucleobases, or application of the 
Vorbrüggen conditions. 
As with the Pummerer reaction for the synthesis of nucleoside 66, thymine was first 
silylated with HMDS (scheme 2.12).  
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Scheme 2.12: General conditions for the Vorbrüggen synthesis 
The HMDS was removed under reduced pressure before the silylated thymine was 
dissolved in DCM, then AgClO4, SnCl2 and glycosyl fluoride 76 were added. The 
reaction scales ranged from 100 mg exploratory reactions up to multi gram scale and 
the reaction mixtures were purified by flash column chromatography after 
optimisation of the column conditions were achieved. Nucleosides 66, 100 – 107 
were all synthesised and purified on these scales. 
HMDS was used in all silylation reactions except for the uracil derivative and the 5-
chloro, 5-bromo, and 5-iodo moieties. It was also noted that use of ammonium sulfate 
as a catalyst reduced the reaction times from 4- 24 hours to 1-4 hours. Initially, it was 
observed that silylation of uracil using HMDS worked well up until removal of the 
HMDS in vacuo, where loss of the TMS groups was observed. It is suspected that 
the TMS groups on uracil were labile under the conditions used for removing HMDS. 
No reaction between the fluorothietane and uracil was observed when HMDS was 
used as the silylating agent, further adding to suspicions that the TMS groups were 
labile. Instead, N,O-bis(trimethylsilyl) acetamide (N,O-BSA) was used.48 The general 
procedure required suspending uracil in MeCN and injecting 1.1 equivalents of N,O-
BSA under argon then heating to 70° C for an hour. Completion was determined 
when the solution became clear. At this point, the reaction was cooled to room 
temperature and the fluorothietane and Lewis acids were added in situ. The 
advantage here was that there was no need to remove the solvent or N,O-BSA under 
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vacuum. This prompted exploration of silylation methods that were quick and efficient 
and therefore both HMDS and N,O-BSA were assessed as silylating agents. 
Synthesis of the cytosine moiety 102 proved difficult however. Initial attempts to 
synthesise the silyl protected cytosine nucleobase following the method reported by 
Schütz et al., did not yield the silylated cytosine moiety even after heating to reflux in 
HMDS for 24 hours.49 Instead, N4-benzoylcytosine  was synthesised (later purchased 
from Sigma Aldrich) was heated to refluxed in HMDS for 24 hours to afford the 
silylated cytosine moiety. After removal of HMDS in vacuo, the cytosine moiety was 
suspended in DCM and the fluorothietane and Lewis acids were added. However, at 
room temperature the reaction was not complete at 24 hours. This was due to the 
observed insolubility of the N4-benzoyl-6-(trimethylsilyl)-cytosine moiety in DCM. 
Repeating the reaction in MeCN at room temperature did not improve the outcome; 
the reaction was not complete within 24 hours and required 48 – 72 hours to reach 
completion. Heating to 45° C over 24 hours resulted in a yield of 47% for nucleoside 
102 (scheme 2.13). 
 
Scheme 2.13: Synthesis of cytosine nucleoside 102 
Table 2.6 shows yields and structures of the compounds synthesised along with the 
1H NMR spectroscopic data for the SCH-nucleoside bond and the expected and 
observed mass spectrometry data. The SCH-nucleoside bond chemical shifts are 
broadly similar for all compounds, ranging between 5.8 – 6.0 ppm. The mass 
spectrum data revealed several important features of the molecules. For instance, for 
compounds 105 and 106 two mass ion peaks are observed. For compound 105 both 
35Cl and 37Cl are observed with a ratio of 3:1 as expected based on the natural 
abundance of  35Cl  relative to 37Cl. Both 79Br and 81Br mass ion peaks with a ratio of 
1:1 are observed for compound 107 since both bromine isotopes exist in a 1:1 ratio in 
Nature. 
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Table 2.6: Thietane nucleosides synthesised using Vorbrüggen conditions 
Structure Yield (%) Key 
1
H NMR MS Expected MS Observed 
 
66 
57 5.9 467.1271 467.1265 
 
100 
45 6.0 471.1021 471.1017 
 
101 
64 5.8 453.1115 453.1118 
 
102 
47 6.0 556.1537 556.1539 
 
103 
45 5.9 481.1427 481.1428 
 
104 
38 5.8 489.1089 489.1089 
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105 
51 5.9 487.0725 
489.0693 
487.0725 
489.0696 
 
106 
66 5.9 553.0039 
555.0019 
553.0044 
555.0022 
 
107 
37 5.9 579.0081 579.0082 
 
Attention was then turned to synthesis of the purine nucleosides. Attempts to 
synthesise the adenine and guanine moieties using Nishizono conditions were met 
with failure however. Nishizono et al. reported the synthesis of the 6-chloropurine 
substituted thietane 108, however this reaction could not be reproduced (scheme 
2.14). 
 
Scheme 2.14: Nishizono synthesis of 6-chloropurine substituted thietane 108 
Although on small scales (100 mg) the compound could be observed by analysis of 
the crude reaction mixture by 1H NMR spectroscopic analysis, with the key signal at 
6.32 ppm being observed for the SCHN proton, purification via column 
chromatography proved difficult and the desired compound could not be isolated.  
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 Attention was turned to alternative methods of synthesising the guanine derivative 
using diphenyl carbamoyl chloride to mask the ketone group and acetic anhydride to 
protect the –NH2 group (scheme 2.15).
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Scheme 2.15: Attempts to synthesise carbamoyl protected guanine 110 
Though this literature method was attempted several times, the 1H-NMR 
spectroscopic data did not match the reported data in any of the attempts. 
Nishizono et al. also reported the synthesis of the adenine moiety 111 (scheme 
2.16), via 6-chloropurine using gaseous ammonia at 100° C at 10 ATM.  
 
Scheme 2.16: Nishizono synthesis of adenine 111 using gaseous ammonia. 
A milder set of conditions could be used to achieve adenine 114 by suspending 
adenine 115 in THF and t-Boc to make the di-Boc adenine moiety (scheme 2.17).51 
 
 
Scheme 2.17: Synthesis of diBoc adenine 114 
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The di-Boc 114 adenine moiety was synthesised on a several gram scales. Initially, 
the tri-Boc 113 moiety is formed which is deprotected with sat NaHCO3 in methanol 
to form the diBoc moiety as illustrated in scheme 2.17. Reaction with the 
fluorothietane and Lewis acids showed consumption of the fluorothietane over a 24 
hour period however, purification was a problem. Although analysis of the crude 
reaction mixture by 1H NMR spectroscopy showed product formation with the key 
signal at 6.5 ppm indicative of the proton on the same carbon as the bound 
nucleobase, TLC analysis showed several products were formed. Isolation of these 
individual components was not possible by column chromatography. Analysis by 1H 
NMR showed the mixed fractions to contain varying amounts of product (36%), 
mono-Boc (36%) and free amine components (29%). At this stage, after many 
iterations of synthesis and attempts to isolate the diBoc adenine moiety, it was 
decided that after synthesis and purification through a plug of silica, the impure 
products would be globally deprotected. 
Initial attempts with TFA in DCM to remove the Boc groups were successful, 
however, analysis of the crude reaction mixture by 1H NMR spectroscopy showed 
that the adenine was no longer bound to the thietane ring. The key peak at 6.3 ppm 
for the SCHN proton was no longer observed. Use of formic acid in methanol and 
water gave the same result. Due to low yields, unreproducible reactions, and the 
instability toward acidic deprotection, the synthesis of the purine nucleosides was not 
pursued further.  
2.3.2.1 Deprotection of the benzoate groups 
Removal of the benzoate groups from compounds 66, 101 – 107 was required prior 
to anti-viral screening as the free hydroxyl groups are required for anti-viral activity. 
These free hydroxyls covalently bond to phosphate groups on preceding nucleotides 
in the viral genome.  
 
Figure 2.11: Structure showing the SCH bond that was indicative of product formation 
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Solubility of the products was the main driver behind the method of deprotection 
used. In all cases, MeNH2 in EtOH was first used, the benefit being that the 
deprotection reactions took 2-6 hours, though purification was sometimes 
problematic. Compounds 66, 100, 102 - 107 were reacted for 2 hours, however, 
cytosine derivative 102 required 96 hours before completion was observed.  
It was observed that reactions lasting more than 4 hours tended to cleave the 
nucleoside thietane bond, and the reason for this is unknown, but it is suspected that 
the methylamine is able to react as a nucleophile causing expulsion of the 
nucleobase. All that was observed by analysis of the 1H NMR spectrum of the crude 
reaction mixtures were broadened peaks, masses of peaks that could be assigned to 
an elimination product nor could any peaks be found that could be associated with 
products.  The low yield of cytosine derivative 102 is attributed to instability in the 
highly basic reaction conditions. 
It was also noted that uracil derivative 101 did not react with methylamine in ethanol. 
It was suspected that this was due to a solubility issue so NaOMe was employed as 
the base in methanol. The reaction proceeded overnight and the product was 
isolated with a yield of 93%. NaOMe was used for the deprotection of all compounds 
66, 100 - 101 and 103 - 107 as NaOMe was milder and all compounds were found to 
be more stable to NaOMe over MeNH2 for the reasons outlined above. Derivative 
102 could not be reacted with NaOMe as this reagent was insufficiently basic to 
cleave the N4-Bz group. Table 2.7 shows the free hydroxyl thietane nucleosides 
including key 1H NMR spectroscopic data (SCH-nucleobase bond), HPLC purity data 
and expected and observed MS data. The HPLC purity data was obtained using 
MeCN:water under gradient elution conditions. The expected purity for each 
compound was intended to equal or exceed 95%. 
 
Scheme 2.18: General scheme for the removal of benzoate groups 
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Table 2.7: Free hydroxyl thietane nucleosides with key data. Reaction conditions: a = NaOMe in 
MeOH, RT, 24 hrs b = MeNH2 in EtOH, RT, 2 hrs 
Structure Yield 
(%) 
Key 
1
H 
NMR 
HPLC 
Purity  
MS 
Expected 
MS 
Observed 
Conditions 
 
79 
98 5.86 ppm 98.6% 259.0747 259.0749 b 
 
84 
77 5.9 ppm 94.5% 263.0496 263.0498 a 
 
80 
93 5.86 ppm 97.9% 245.0591 245.0591 a 
 
81 
96 5.81 ppm 75.1% 244.0750 244.0752 b 
 
89 
95 5.91 96.4% 295.0723 298.0725 a 
 
88 
98 5.86 47.1% 259.0746 
281.0564 
259.0747 
281.0566 
a 
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85 
88 5.9 98.5% 279.0200 
281.0170 
279.0201 
281.0171 
a 
 
86 
96 5.9 95.6% 322.9696 
324.9674 
322.9698 
324.9675 
a 
 
87 
90 5.9 97.7% 370.9557 
245.0591 
370.9557 
245.9813 
a 
 
 All 1H NMR spectroscopic data gave similar chemical shifts for the SCH-nucleobase 
bond. The halogenated nucleobases tended to give chemical shifts of 5.9 ppm or 
greater and the non-halogenated nucleobases tended to give chemical shifts sub 5.9 
ppm and this is attributable to the greater deshielding effect of the halogenated 
nucleobases on the SCH-nucleobase bond. In figure 2.12 the 1H NMR spectroscopic 
data is shown for derivative 80.  
 
Figure 2.12: 
1
H NMR spectrum of spectroscopic data for uracil 80.  
The mass spectrum for compound 87 confirmed the compound but also showed the 
presence of the uracil compound too. The mass ion peak for the sodium salt of 
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iodouracil (m/z = 368.9422 Da) was observed along with the uracil adduct (245.0593 
Da). This suggests that the iodide is labile and along with the 1H NMR spectroscopic 
data, it can be concluded that two compounds are present, the iodouracil moiety and 
the uracil moiety in a 1:1 ratio by 1H NMR spectroscopic analysis after column 
chromatography. It is assumed that the iodide is labile under column conditions used 
and is hydrolysed on silica. Since the column conditions used 10% methanol in 
chloroform with 1% triethylamine, it is possible that the iodine was eliminated and a 
proton abstracted from the solvent to give rise to 80 from 87. 
 
Figure 2.13 Mass spectrum and 
1
H NMR spectroscopic data revealed two compounds present: uracil 
80 and iodouracil 87 
No second mass ion peak was observed in the mass spectrum data for the benzoyl 
protected iodouracil moiety 87 lacking the iodine atom. 
Compounds 79 – 81 and compounds 84 – 89 were tested for their purity by HPLC. A 
purity of 95% or greater was required for anti-viral testing and this purity level is the 
minimum level required for confidence that the compound is causing an observed 
outcome and not an impurity. All compounds bar cytosine 81 and 6-methyluracil 88 
meet this standard.  
2.4 1H NMR Features of Thietane Nucleosides 
The 1H NMR spectra selected thietane nucleosides are tabulated in table 2.8. The 
selected nucleosides were chosen based on their spectroscopic charactersitics; 
where the spectroscopic data differed significantly from other nucleosides. 
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Table 2.8: Key 
1
H NMR spectra for the thietane ring in thietane nucleosides. The ppm values are 
given first, followed by the signal type (s – singlet, d – doublet, t – triplet etc). The number of protons 
per signal is 1 proton as all the protons on the ring are non-equivalent. 
R H1 H2 H3 H4 H5 H6 H7 H8 H9 
 
5.86  
s 
2.80 
d 
J = 9 
Hz 
2.88 
d 
J = 9 
Hz 
3.34 
d 
J = 11 
Hz 
3.48 
m 
 
3.60 
d 
J = 11 
Hz 
3.48 
m 
4.66 
t 
J = 4 
Hz 
5.00 
t 
J = 4 
Hz 
 
5.86 
s 
2.75 
d 
J = 9 
Hz 
2.90 
d 
J = 9 
Hz 
3.35 
d 
J = 11 
Hz 
3.50 
m 
3.60 
d 
J = 11 
Hz 
3.50 
m 
4.70 
t 
J = 4.5 
Hz 
5.00 
t 
J = 4.5 
Hz 
 
5.81 
s 
2.77 
d 
J = 4 Hz 
3.17 
d 
J = 11  
3.39 
d 
J = 11  
3.44 
d 
J = 11  
3.70 
d 
J = 11  
4.60 
d 
J = 4 
Hz 
4.91 
d 
J = 4 
Hz 
 
5.27 
s 
2.23 
d 
J = 9 
Hz 
3.07 
d 
J = 9 
Hz 
3.40 
d 
J = 5 
Hz 
3.82 
m 
3.50 
d 
J = 5 
Hz 
3.82 
m 
4.5 
t 
J = 5 
Hz 
5.15 
t 
J = 5 
Hz 
 
5.90 
s 
2.80 
d 
J = 9 
Hz 
2.88 
d 
J = 9 
Hz 
3.31 
d 
J = 11 
Hz 
3.42 
d 
J = 11 
Hz 
3.53 
d 
J = 11 
Hz 
3.61 
d 
J = 11 
Hz 
4.90 
s 
5.10 
s 
 
X-ray crystallographic data by Nishizono and Choo separately has shown that the 
nucleobases are equatorial on thietane rings, hence the R group in the compound 
above table 2.8 being equitorial.10,52 This is intuitive as the nucleobase being 
equatorial reduces ring strain in the thietane ring by reducing diaxial interactions 
between the nucleobase and protons H3 and H4.  
Table 2.8 shows some interesting features in the 1H NMR spectroscopic data for the 
thietane nucleosides. In general, protons H2, H3, H4, H5, H6 and H7 are non-
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equivalent. This is expected as these are conformationally non-equivalent with 
respect to the R group. Protons H4 and H6 are spatially facing the R group 
nucleobase, whilst protons H5 and H7 are facing away from the R group nucleobase. 
Protons H2 and H3 are conformationally non-equivalent as H3 is equatorial and H2 is 
axial, meaning that these protons are occupying different chemical environments with 
respect to the R group nucleobase. 
The data shows that, in genral, protons H2 and H3 are found at 2.80 and 2.88 ppm 
for thymine, 5-chloro, 5-bromo- and 5-iodo uracil nucleobases. The nucleobase 5,6-
dimethyl uracil has a large ppm range between H2 and H3 at 2.23 ppm for H2 and 
3.07 ppm for H3. This indicates that there is an interaction occurring between H3 and 
the methyl group on this nucleobase. A NOSEY spectrum should confirm whether an 
interaction is due to the methyl group interacting with H3. It is assumed that there is a 
diaxial interaction occurring between the 5,6-dimethyl uracil and proton H3, indicating 
the nucleobase may not be bound equatorially. If there the nucleobase is axially 
bonded, one of the methyl groups on 5,6-dimethyl uracil would interact strongly with 
proton H3.  
Interestingly for the cytosine nucleobase, protons H2 and H3 are two closely spaced 
doublets integrating to two protons. This is very different to the rest of the 
nucleosides in the library, which are seen as a set of two doublets, spaced further 
apart by 0.8 ppm. Analysis of the COSY spectrum shows that H2 and H3 are only 
interacting with themselves, with no interaction with any other proton, ruling out a 
doublet of doublets interaction, which would require the interaction of a third non-
equivalent proton. The small J value indicates an increase in ring strain for these 
protons. Pople and Bothner showed in 1965 that increased strain due to electronic 
effects in geminally coupled protons can affect the J coupling values. Pople showed 
that unstrained bonds in cyclic compounds typically have J values of 12 Hz, and 
increased strain (among other factors) can decrease the J value.53 Therefore, it can 
be assumed that the lower than expected J value of 4 Hz for protons H2 and H3 is a 
result of ring strain 
The OCH2 protons H4, H5, H6 and H7 are non-equivalent and are observed as 
doublets. Where R is thymine, uracil, or 5,6-dimethyl uracil, protons H5 and H7 are 
seen as integrating to 2 as multiplets, whereas with the other nucleosides, these 
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protons integrate to 1. COSY spectra for nucleosides where R is thymine, uracil or 
5,6-dimethyl uracil, the OCH2 protons are observed as two sets of correlations, where 
one proton from each set overlaps. This indicates that one proton on each hydroxyl 
methyl group is equivalent to a proton on the other hydroxymethyl group. This 
explains why the integration pattern is 1:2:1 for the four protons of the di-
hydroxymethyl groups on the thietane ring for nucleosides where R is thymine, uracil, 
or 5,6-dimethyl uracil. For the rest of the nucleosides, each proton correlation in the 
COSY is seen as independent projections that correlate only to the proton on the 
same hydroxymethyl group. Thus, in these nucleosides, H4, H5, H6, and H7 are truly 
non-equivalent. Typically, the J values for these protons are 11 Hz, however, where 
R is 5,6-dimethyl uracil, the J value is 5 Hz. This implies an increase in the strain in 
these bonds. As stated previously, Pople and Bothner showed that increased ring 
strain due to electronic effects in geminally coupled protons can affect the J coupling 
values of these protons. It can be assumed therefore, that the nucleobase bound to 
the thietane ring has a direct effect on the bond angle of the substituents bound to 
the ring. In the case of 5,6-dimethyl uracil, the interaction seems to only affect one of 
the hydroxymethyl groups. 
H1 also varied significantly depending on the nucleobase bonded to the thietane ring. 
Most nucleobases had a chemical shift of 5.86 ppm for H1. However, the largest 
chemical shift was 5.9 ppm and the lowest was 5.27 ppm. This is due to the 
shielding/de-sheilding effect of the R group nucleobase. The effect of the applied 
magnetic field depends on how shielded H1 is. If H1 is not shielded, the proton 
interacts with the applied magnetic field strongly, and H1 is observed more downfield. 
If H1 is shielded, it is observed more upfield. The nucleobase 5-fluorouracil 
decreases electron density on H1 via the inductive effect, resulting in the chemical 
shift moving downfield to 5.90 ppm. However, 5,6-dimethyl uracil increases electron 
density via the inductive effect, onto H1, resulting in an upfiled chemical shift to 5.27 
ppm. 
It can be seen therefore, that the type of nucleobase bound to the thietane ring can 
affect ring strain of the thietane ring and the inductive effect of the nucleobases can 
affect the chemical shift of H1. Inductive effects from the attached nucleobase could 
affect ring strain due to increased electron density around some bonds, as could be 
the case with the observed decrease in the J values for protons H2 and H3 in the 
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cytosine nucleoside moiety. Spatial and steric effects of the nucleobases is not fully 
known, however, it is assumed that 5,6-dimethyl uracil interacts diaxially with H3. To 
further probe these effects, temperature variable NMR and NOSEY experiments 
could give further insights into the NMR features of thietane nucleosides. These 
insights could be further elucidation of the conformational structure of the thietane 
ring, and the effect that the nucleobases have on ring conformation. 
2.5 Assessment of Cellular Viability 
The 11 thietane nucleosides that have been synthesised require preliminary cell 
viability testing to be performed prior to full anti-viral screening in order to potentially 
eliminate compounds that may cause cytotoxicity before an anti-viral response can 
be measured. A representative sample of 4 thietane nucleosides were chosen from 
the library for testing in an XTT assay, and the compounds were chosen based on 
structural considerations (figure 2.14). 
 
 
Figure 2.14: Candidate compounds chosen for cell viability assays.  
Thymine 79 was tested against HSV-1, HSV-2 and VZV by Nishizono et al, but it did 
not exhibit any anti-viral activity in an in vitro anti-viral assay.10 This could either be 
due to the nucleoside being inactive, or that the nucleoside was unable to enter the 
cell to exhibit anti-viral activity. However, neither cell viability nor cytotoxicity data is 
available for the compound. Both thymine 79 and uracil 80 were included in the initial 
screen as they represent the traditional nucleobases used in anti-viral therapies and 
can easily be compared to other active anti-viral thietane nucleosides shown by Choo 
et al (see section 2.1). 5,6-dimethyluracil 89 (DMU) was included in the screen since 
the effect of the 6-methyl substituent is unknown. The 5-fluorouracil moiety 84 (5FU) 
was included in the screen as it is representative of the halogenated class of 
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nucleosides in the library. 5-Fluorouracil itself used to be used as an anti-cancer 
agent for various cancers and it is predicted to show cytotoxicity or loss in cell 
viability.54,55 5-Fluorouracil is very polar and is used as a topical treatment and its 
route of entry is by diffusion into the skin. It is predicted that 5FU 84 will have 
significant cytotoxicity since the additional thietane ring may increase its solubility into 
the cell. 
2.5.1 The XTT Assay 
The XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) 
assay measures cell viability, and indirectly, cytotoxicity, by measuring cellular 
respiration.56 The assay measures the activity of NADPH oxidoreductase enzymes in 
mitrochondria and therefore measures ATP synthesis. It is assumed that viable cells 
will be undergoing respiration and therefore, the cell will be constantly producing ATP 
via the mitochondrial enzyme NADPH oxidase.56 In general, a known concentration 
of cells are plated into a 96 well plate in cell culture media and incubated for 24 hours 
to allow them to reach confluence.57,58 The cell culture media is removed and known 
concentrations of the drugs being tested are added to the 96 wells and incubated for 
24 hours further. XTT is mixed with phenazine methasulfate (PMS) in known 
concentrations and added to the 96 well plate and incubated for a further 4 hours. 
PMS is an activator reagent that acts as an intermediate electron acceptor that aids 
in the reduction of XTT to the active formazan derivative that is detected.59  The XTT 
assay is a colormetric assay that determines cell viability by measuring the 
concentration of the XTT formazan derivative that is only present in respiring cells. 
The mitochondria reduce the XTT to give the yellow-brown formazan derivative that 
is able to be assessed by a spectrophotometer. The concentration of the formazan 
derivative gives an approximation of the number of respiring cells, therefore, cell 
viability can be assessed by the absorbance of a specific wavelength of light at 475 
nm.56,59 
A colour change to yellow-brown indicates viable cells, and no colour change 
indicates total cell death or the presence of non-viable cells. However, the major 
limitation of this assay is that it is highly susceptible to metabolic interference.56 An 
increase in cellular respiration can give false positives by indicating the cells are 
more viable than would be expected. In some cases, cell viability figures in excess of 
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100% can be observed, and this is due to an increase in cellular metabolism.56 The 
XTT assay is very useful to obtain preliminary information on cell viability prior to anti-
viral screening as it can be used to eliminate compounds that may cause potential 
problems in anti-viral activity studies as any compound that affects cell viability may 
reduce or eliminate any anti-viral activity observed. This is due to the fact that viruses 
require viable cells to replicate, and a compound that reduces cell viability will reduce 
the cellular responses measured for viral activity.  
2.5.2 Results and Discussion: General Background 
With the 4 candidate compounds chosen cell viability testing could begin. The cell 
line used was the SH-SY5Y cell line which are neuroblastoma cells and these were 
chosen because the exponential growth phase lasted 32 hours versus 44 hours for 
fibroblast like cells.60 This means that the saturation density of neuroblastoma cells 
versus fibroblast cells is greater in a short period of time. Bieder et al. found that the 
SH-SY5Y cell line had on average 115 x 104 cells per cm2 versus 9 x 104 cells per 
cm2.60 This means that SH-SY5Y cells will give a more intense signal in the cell 
based assay versus fibroblast cells as there are more of the SH-SY5Y cells per 
cm2.60  
2.5.2.1 Results and Discussion 
In figures 2.15, 2.16, 2.17, and 2.18 the cell viability results for thymine 79, uracil 80, 
5,6-dimethyluracil (5,6-DMU) 89, and 5-fluorouracil (5FU) 84 are shown. The results 
shown are of the biological triplicates of the assay and the individual assay data 
along with the raw data can be found in the appendix.  
 
Figure 2.15: Cell viability data for thymine 79 
0
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Figure 2.16: Cell viability data for uracil 80 
 
Figure 2.17: Cell viability data for DMU 89  
 
Figure 2.18: Cell viability data for 5FU 84  
Over the three biological replicates the data for thymine 79 suggests that the 
compound does not affect cell viability at any concentration. At 1 μM the cell viability 
is 105%, at 10 μM it is 108% and at 100 μM it is 103% with standard error means 
(SEM) of ± 3.4%, ± 4.4% and ± 4.9% respectively. Though this data may suggest that 
cell viability has increased, the limitation of this assay is that the reduction of XTT to 
the is affected by cellular respiration, and therefore, any increase in cellular 
respiration, for whatever reason, will be detected by this assay. The higher than 
expected SEM for each concentration is due to this limitation and therefore it cannot 
be concluded that cell viability has been affected. The positive control of H2O2 shows 
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a decrease in cell viability to 20% ± 0.52 % and confirms cell viability is being 
measured.     
The biological replicates for uracil 80 show 96% ± 1.6% cell viability at 1 μM, at 10 
μM the data shows 96% ± 2.2% cell viability and at 100 μM the data shows 95% ± 
2.3 cell viability. This data does not suggest that uracil 80 is affecting cell viability as 
there does not seem to be a correlation between the observed decrease in cell 
viability and the concentrations used. The observed decrease in the number of viable 
cells by 4 – 5% at each concentration (± 2%) could be attributed to experimental 
error, or, 5% of the cells are viable but not actively respiring, which the XTT assay 
would detect as non-viable.  
The data for 5,6-DMU 89 at 1 μM shows the cell viability is 91% ± 2.9% and 
increases to 97% ± 2.3% at 10 μM, but at 100 μM, the cell viability decreases to 82% 
± 4.1%. Therefore, the data shows at least 80% cell viability up to 100 μM.  
It was predicted that 5FU 84 would be cytotoxic due to the fact that 5-fluorouracil on 
its own is used as a cancer treatment, and since 5FU 84 is less polar than 5-
fluorouracil alone, it was predicted that 5FU 84 would be able to cross the cell 
membrane much easier than 5-fluorouracil. Though the mechanism of action of 5FU 
84 is not as yet known, 5-fluorouracil causes thymineless death of cells. It was 
assumed that 5FU 84 would exert a similar cytotoxic response by preventing cellular 
replication.60,61 If cellular replication was halted, the assay would show significantly 
lower numbers of viable cells than expected. However, as can be seen from figure 
2.4, the expected inhibition of cellular replication was not observed. At 1 μM the cell 
viability was observed to be 98% ± 1.7%, at 10 μM it was observed to be 94 % ± 
2.9% and at 100 μM the cell viability was observed to be 98% ± 7.5%. It can 
therefore be concluded that 5FU 84 does not affect cell viability at any concentration 
up to 100 μM of compound.  
2.6 Conclusions 
In all, a library of 9 thietane nucleosides, 7 of which are novel, has been synthesised 
via key intermediate fluorothietane 76 using Vorbrüggen conditions. An optimised 
route has been established for quick access to thietane nucleosides that can be 
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applied to any pyrimidine nucleobases. Further optimisation toward purine 
nucleobases is required as the purines have been shown to be unreactive or 
unstable to the employed reaction conditions for their formation and/or deprotection. 
Thymine 79, uracil 80 and 5FU 84 did not show any appreciable loss of cell viability. 
However, the limitation of this assay is that it measures the number of viable cells as 
a product of their respiration. This means that if the cells are alive but not actively 
respiring, the assay is unable to determine whether these cells are viable. Also, if an 
external stressor increases the rate of respiration in the cells, the assay will detect 
this increased respiration and thus the number of viable cells will be higher than 
expected. 5FU 84 did not show the expected decrease in cell viability and the 
hypothesis that it would be the most cytotoxic was shown not to be true. In the case 
of 5,6-DMU 89, the data suggests that at least 80% cell viability is observed up to 
100 μM. 
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Chapter 3: 
The Design and Synthesis of 4,4-
bis(hydroxymethyl)-thietan-2-yl 
Nucleosides 
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Chapter 3: Synthesis of 4,4-bis(hydroxymethyl) thietane 
Nucleosides 
3.1 Background 
The intention of the work in chapter 2 was to explore the SAR of the nucleobases 
and to determine the anti-viral activity of the 3,3-bis(hydroxymethyl) thietane core. In 
this chapter, derivatives were selected for synthesis in order to allow further SAR 
data to be established, by moving the hydroxymethyl groups around the ring. To 
allow conclusions to be made about the effect of this transformation, the nucleobases 
were kept constant and both of the hydroxymethyl groups are moved around by one 
carbon bond on the thietane ring (figure 3.1).  
 
Figure 3.1: Target thietane nucleosides for the 4,4-bis(hydroxymethyl) thietane core compounds 
By comparing and contrasting the biological data between the 3,3-dihydroxymethyl 
series and the 4,4-dihydroxymethyl series, it was anticipated that the SAR of the 
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molecules can be assessed in detail. This information can then be used as a guide to 
design and synthesise a highly active thietane nucleoside. 
3.1.1: Aims and Objectives 
The following aims and objectives are detailed and are similar to the aims in chapter 
2: 
 Explore potential chemical methods toward the 4,4-bis(hydroxymethyl) 
thietane core. Since the substitution pattern on the thietane is novel, several 
synthetic strategies are to be explored. 
 Build a library of thietane nucleosides with the same nucleobases as the 
previous library in chapter 2. This will enable more direct comparisons to be 
made between these two libraries. 
 Assess anti-viral activity by measuring CC50 and IC50 in biological assays.  
 Determination of a structure activity relationship based on the biological data 
between both nucleoside libraries. This information will be used to guide the 
synthesis of a final set of compounds with the intent that these compounds will 
have a better anti-viral profile. 
3.2 Synthetic Strategies towards 4,4-bis(hydroxymethyl) thietane 
nucleosides 
In scheme 3.1 the retrosynthetic steps to potentially allow synthesis of the 4,4-
bis(hydroxymethyl) thietane nucleosides is shown. 
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Scheme 3.1: Retrosynthetic steps toward 4,4-bis(hydroxymethyl) thietane nucleosides 
Formation of nucleoside 124 in step i) requires fluoride 125 to be formed harnessing 
the chemistry developed in chapter 2. Next, a functional group interconversion (FGI) 
to alcohol 126 in step iii) is required and another FGI to ketone 132 allows for a 
cyclisation reaction to furnish thietane 127 from carboxylic acid 128 in steps iv) and 
v). A thia-Michael addition to allyl methyl ester 131 allows for the incorporation of the 
sulfur moiety, and a further FGI reveals ketone 132 with which a Wittig reaction can 
be performed in steps vi), vii) and viii). Reduction of the ketone to triol 133 reveals 
the readily available starting material glycerol in step ix).  
Synthesis from ketone 132 can begin with Gringard reagents, or lithium salts of 
ethanol derivatives could potentially be used to form the thietane ring by use of 
Na2S.9H2O as per the chemistry in chapter 2 (scheme 3.2). 
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Scheme 3.2: Potential chemistry toward the thietane target using already established chemistry 
Despite the appeal of the chemistry in scheme 3.2, with the already established 
chemistry of thietane formation using Na2S.9H2O, several problems persist with this 
route.1 In solution, Na2S.9H2O produces sodium sulfide, sodium hydroxide and water 
(see chapter 2 for detailed chemistry), and as such is highly basic. Under these basic 
conditions, both the bromide and mesylate in compound 135 are susceptible to 
elimination. Several potential side reactions could occur using these conditions to 
furnish the thietane (scheme 3.3). 
 
Scheme 3.3: Potential side reactions that could occur by using Na2S.9H2O to furnish thietane 142 
from compound 143. 
As can be seen from scheme 3.3, if the HS- ion is able to undergo an SN2 reaction 
with the bromide in compound 137 to form compound 139, several competing 
reactions are possible from compound 139. It can be seen that the intramolecular 
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SN2 reaction of the sulfur in compound 139 with the mesylate group is not favourable 
as the mesylate carbon is tertiary and tertiary compounds do not undergo SN2 
reactions. Backside attack of a nucleophile is impossible and hence this reaction 
cannot occur. For the reaction to thietane 138 to be plausible, the reaction must 
undergo an SN1 reaction, ie, the mesylate must leave first to form the carbocation, 
which is a stable intermediate as hyperconjugation stabilises the ion. This then allows 
intramolecular attack of the thiol group in compound 139 to yield thietane 138. 
However, the carbocation could react with hydroxide or sulfide ions in solution to give 
compounds 144 and 145 respectively. 
Since the reaction is run in basic conditions with Na2S.9H2O, several elimination 
reactions from compound 139 are possible and the compounds 140 – 143 are the 
possible elimination products that could form. Therefore it can be concluded that the 
use of the optimised reaction conditions in chapter 2 for the formation of thietane 
rings is not feasible for accessing the 4,4-bis(hydroxymethyl) thietane core. 
Therefore, the set of reaction conditions in scheme 3.1 shows more promise as the 
potential for side reactions is significantly minimised.  
3.3 Initial Synthetic Steps Toward 4,4-bis(hydroxymethyl) thietane 
nucleosides 
From the retrosynthetic strategy in scheme 3.1 it was revealed that the synthesis of 
the target thietane could begin from the cheap, commercially available compound 
glycerol 146. Scheme 3.4 shows the initial synthetic strategy toward the target 
thietane molecule. 
 
Scheme 3.4: Initial synthetic strategy toward 4,4-bis(hydroxymethyl) thietane nucleosides i) glycerol, 
pTSA, Toluene, 40° C, 6 hrs, 62% ii) DMP, DCM, 0° C, 4 hrs, 82% iii) NaH, methyl 
diethylphosphonoacetate, THF, RT, overnight, 61%  
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The acetal protecting group was chosen for the protection of glycerol 146 to afford 
acetal 147, as the acetal is easy to install and it was expected to be stable to the first 
six steps of the synthesis based on literature precedent.2 Also, since the introduction 
of the acetal in chapter 2 gave high, reproducible yields, the acetal protecting group 
was thought to be an effective protecting group for this synthesis.2 Oxidation of acetal 
147 to ketone 148 has been achieved using mild oxidation reactions (see section 
3.3.3.1) and incorporation of the allyl methyl ester 149 was also achieved using the 
Horner-Wadsworth-Emmons (HWE) reaction (section 3.3.3.1).3-6 From methyl ester 
149, two possible methods exist for the formation of the target thietane core: use of 
hydrogen sulfide or use of benzyl mercaptan on derivatives of ester 149 have been 
shown.7,8 
Givaudan et al. have shown that 4-methyl-thietan-2-ol 151 can be synthesised from 
crotonaldehyde 150 by reacting it with hydrogen sulfide in excess triethylamine at -
10° C (scheme 3.5).7 
 
Scheme 3.5: Givaudan synthesis of 4-methyl-thietan-2-ol using crotonaldhyde and H2S 
Applying the Givaudan synthesis to the synthesis of target thietane 126 in scheme 
3.1 would first require reduction of methyl ester 149 to aldehyde 152 by use of 
diisobutyl aluminium hydride (DIBAL-H) prior to formation of thietane 153 shown in 
scheme 3.6. (Here, the target thietane number has changed from 126 in scheme 3.1 
to 153 in scheme 3.6 to highlight the acetal protecting group versus the R group). 
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Scheme 3.6: Application of the Givaudan synthesis to methyl ester 149 to give target thietane 153 i) 
DIBAL-H, THF, -78° C, 3 hrs ii) H2S, Et3N, -10° C, 6 hrs. 
Pattenden et al. showed that α,β-unsaturated carboxylic acids could be used to form 
thietanone compounds: 2-methyl-buten-oic acid 154 was heated at reflux in excess 
piperdine with benzylmercaptan (BnSH) to afford 2-thiobenzyl-2-methyl-butanoic acid 
155.8 From here, use of sodium in liquid ammonia furnished 2-thio-2-methylbutanoic 
acid 156 which was then cyclised to thietanone 157 (scheme 3.7).  
 
Scheme 3.7: Pattenden synthesis of thietanone compounds i) BnSH, piperidine, reflux, 24 hrs ii) Na, 
NH3, -78° C, 2 hrs iii) Isobutyl chloroformate, Et3N, DCM, -10° C, 20 mins 
The Pattenden synthesis would require incorporation of two additional steps for the 
synthesis of target thietane 153 from ester 149; which would have to be hydrolysed 
to carboxylic acid 159 prior to use of the Pattenden conditions. Once thietanone 161 
is successfully cyclised, thietanol 153 can be synthesised by reduction of thietanone 
161 with DIBAL-H (scheme 3.8) 
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Scheme 3.8: Proposed conditions to methyl ester 149 i) NaOH or LiOH, IPA, water ii) Na, NH3, -78° C, 
2 hrs iii) Isobutyl chloroformate, Et3N, DCM, -10° C, 20 mins iv) DIBAL-H, THF, -78° C, 3 hrs.   
From thietane 153, incorporation of the fluorine atom to fluorothietane 162 can be 
achieved using already established chemistry from chapter 2. Use of deoxofluor will 
give key intermediate 162 and the nucleosides can be furnished using the already 
established chemistry from chapter 2 (scheme 3.9).1 
 
Scheme 3.9: Proposed condition: (this chemistry was established in chapter 2 i) deoxofluor, SbCl3, 
DCM, RT, 24 hrs ii) silylated nucleobase, AgClO4, SnCl2. 
The Givaudan thietane synthesis will be used to furnish thietane 153 as there are 
fewer  steps to the target than with the Pattenden synthesis.  
3.3.1 Results and Discussion: Initial Synthesis and Optimisation of 
Synthetic Route Toward 4,4-bis(hydroxymethyl) thietane 
Nucleosides 
 The literature synthesis of acetal 147 was optimised by acetal protection of glycerol 
146 to acetal 147 (scheme 3.10) using pTSA and benzylidene dimethyl acetal 
(BDMA). 
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Scheme 3.10: General synthesis of acetal 147 using either benzaldehyde or BDMA to furnish acetal 
147. 
Reproduction of the literature synthesis of acetal 147 used excess benzaldehyde and 
the reaction was heated at reflux for a minimum of 12 hours and typically gave low 
yields of the acetal 147 with yields ranging from 5 – 15%, which was lower than the 
reported yield of 46%.9 The solvent was switched to DMF and 1.1 equivalents of 
benzaldehyde were used. The yields improved to 50%. Toluene was then used as a 
solvent with a Dean-Stark apparatus to remove the water. It was suspected that any 
water formed during the reaction would shift the equilibrium away from product 
formation (table 3.1) using the reaction conditions set out by Patwardhan et al. where 
the reaction was heated at reflux for 5 hours.2 
Table 3.1: Reaction conditions attempted for the synthesis of acetal 147 
Reaction Conditions Yield 
1 Glycerol, pTSA (0.01 equiv), benzaldehyde (excess), RT, 48 hrs 5% 
2 Glycerol, pTSA (0.02 equiv), benzaldehyde (excess), RT, 48 hrs 15% 
3 Glycerol, pTSA (0.02 equiv), benzaldehyde, toluene, 130° C, 24 hrs 29% 
4 Glycerol, , pTSA (0.1 equiv), BDMA DMF, 65° C, 5 hrs 40% 
5 Glycerol, pTSA (0.1 equiv), BDMA, DMF, 50° C, 5 hrs 50% 
6 Glycerol, pTSA (0.1 equiv), , BDMA, toluene, RT 5 hrs 62% 
 
Although yields were slightly improved to 50%, the decision to move to BDMA was 
taken as it was a) more reactive than benzaldehyde and b) more moderate reaction 
conditions could be used. The use of BDMA gave acetal 147 as a 1:1 mixture of the 
6 membered ring acetal and the 5 membered ring acetal 164 (table 3.2 for key 1H 
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NMR spectroscopic data). Toluene was then used as a solvent due to the fact that 
the reaction could be performed at ambient temperature, whereas with DMF, the 
reaction had to be heated before it would occur. The reason for this could be that 
DMF is too polar to favour product formation at low temperatures and as such, the 
activation energy for the reaction is higher in DMF than in toluene.10 This could be 
because the solvent interaction with the product in DMF is disfavoured as it is 
relatively non-polar with respect to DMF, but in toluene, the phenyl ring in the product 
and the BDMA starting material may have more favourable solvent-reagent 
interactions.10 
It was observed that the reaction to afford acetal 147 gave both the cis and trans 
isomers of both the 6 membered ring acetal 147 and its 5 membered ring counterpart 
acetal 164, which were observed in a 1:1 mixture for each ring. The 1H NMR 
spectroscopic data of the crude reaction mixture showed 4 singlet peaks at 5.38 and 
5.54 ppm, which corresponded to the benzylidene proton in the cis and trans isomer 
of the 6 membered acetal 147; and 5.83 and 5.91 for the benzylidene proton for the 5 
membered acetal 164 (table 3.2). Attempts to purify the reaction mixture using 
column chromatography were unable to resolve acetal 147 from the 5 membered ring 
acetal 164. The crude reaction mixture was dissolved in minimal chloroform and the 
6 membered ring product, acetal 147, was precipitated out of solution using 
petroleum ether.2 Table 3.2 and figure 3.2 shows the key 1 H NMR spectroscopic 
data for both the 5 membered ring acetal 164 and the 6 membered ring acetal 147. 
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Figure 3.2: 
1
H NMR spectrum for acetal 147 which shows both cis and trans isomers are present 
Table 3.2: Key 
1
H NMR spectroscopic data for both acetal 147 and the 5 membered ring acetal. The 
bold protons are the protons of interest and uses acetal 147 as the reference compound. (d) doublet, 
(s) singlet, (m) multiplet (t) triplet (q) quartet 
Fragment Acetal 147 chemical shift Acetal 164 chemical shift 
 
Cis isomer: 5.54 ppm (s) 
Trans isomer: 5.38 ppm (s) 
Cis isomer: 5.91 ppm (s) 
Trans isomer: 5.83 ppm (s) 
 
Cis isomer: 3.61 ppm (t) 
Trans isomer: 3.01 (t) 
Cis/trans isomer: 3.52 ppm (m) 
 
OCH2 Cis isomer: 4.63 ppm (m) 
Trans isomer 4.00 ppm (m)  
Cis/trans isomer: 4.92 ppm (m) 
 
 
Despite the very different 1H NMR spectroscopic data for the cis and trans isomers of 
acetal 147, the cis and trans isomers were not resolved as the next step to ketone 
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148 would create symmetry in the molecule, and as such any isomerism would cease 
to exist. 
The low yields ascribed to formation of acetal 147 only account for the yield of the 6 
membered ring acetal 147. The total yields for both the 5 and 6 membered rings of 
acetal 147 and 164 were 70 - 75% after work up and drying of the crude reaction 
material. Although analysis of the crude reaction mixture by 1H NMR spectroscopy 
revealed a 1:1 mixture of the 5 and 6 membered rings of acetal 147 and 164, 
recrystallization gave only the acetal 147, but the total yield dropped to around 28%.   
1H NMR spectroscopic analysis revealed that the product had formed, IR 
spectroscopy confirmed the presence of the hydroxyl group on at 3347 cm-1. MS data 
gave the mass ion peak at 180.0859 which corresponds to the mass ion peak of 
acetal 147 which is in the expected range as the calculated value for acetal 147 was 
180.0786 Da. All of this data confirmed the successful synthesis of acetal 147 and 
matched literature data for this compound.2,9 
3.3.1.1 Oxidation Reactions toward 2-phenyl-1,3-dioxan-5-one 148 
After optimisation of the reaction toward acetal 148, oxidation of the hydroxyl group 
was required prior to installation of the allyl ester 149 via the HWE reaction. Classical 
oxidation reactions using acidified dichromate could not be used due to the sensitivity 
of the acetal group toward acids. A review of the literature revealed three potentially 
useful, mild oxidation reactions for the synthesis of ketones from secondary alcohols: 
Dess Martin Periodinane oxidation (DMP), Swern oxidation and the Parikh-Doering 
oxidation reactions.3-6 In scheme 3.11 the optimised conditions toward ketone 148 
are shown with DMP. 
 
Scheme 3.11: Optimised reaction conditions for the oxidation of acetal 147 to ketone 148 using DMP 
In table 3.3 the optimisation data is shown for this reaction. 
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Table 3.3: Optimised reaction conditions using DMP toward the synthesis of ketone 148 
Reaction Conditions Yield (%) 
1 1.1 equiv DMP, anhydrous DCM, 0°C 3 hrs 15 
2 1.5 equiv DMP, anhydrous DCM, 0° C 3 hrs 50 
3 1.5 equiv DMP, standard non-dried DCM, 0° C 3 hrs 80 
4 1.5 equiv DMP, standard non-dried DCM, 0° C 3 hrs 45 
5 - 7 1.5 equiv DMP, 0.5 equiv water, DCM, 0.5 equiv water, 0° C 3 hrs 6.4 
8 As reaction 4, dry DCM, 6 hrs - 
9 2 equiv DMP, standard non dry DCM, 0° C, 6 hrs 40 
10 3 equiv DMP, standard non dry DCM, 0° C, 6 hrs 32 
11 - 12 As reaction 10 8 
13 1.5 equiv DMP, standard non-dried DCM, 0° C 4 hrs increased to 2 
equiv DMP react further 2 hrs 
49 
14 1.5 equiv DMP, standard non-dried DCM, 0° C 4 hrs increased to 2 
equiv DMP react further 2 hrs 
52 
15 1.5 equiv DMP, standard non-dried DCM, 0° C 6 hrs increased to 2 
equiv DMP react further 2 hrs 
10 
 
As can be seen from table 3.3, the initial reactions gave the product in good yield, 
though the high yield of 80% in reaction 3 was never reproduced. In the first reaction, 
although product was isolated, analysis of the crude reaction mixture by 1H NMR 
spectroscopy implied the acetal group might be unstable. This was determined by 
loss of the singlet peaks at 5.3 ppm. Purification by column chromatography gave 
15% yield of the product and analysis of the remaining fractions revealed some 
benzaldehyde was present, implying loss of the acetal group either during the 
reaction, during work up, or during column chromatography. However, the silica was 
neutralised with 1% triethylamine. This, coupled with the analysis of the crude 
material by 1H NMR spectroscopy, implies that the acetal group was unstable to the 
reaction conditions. 
The equivalents of DMP were increased to 1.5 equivalents and gave a yield of 50% 
in reaction 2. However, as with reaction 1, some acetal deprotection was observed, 
though less so than in reaction 1.  
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Reaction 3 showed the largest yield obtained with DMP at 80% and this is attributed 
to the use of standard DCM rather than anhydrous DCM. It is suspected that trace 
amounts of water aid this reaction and it has been shown in the literature that this 
reaction can be accelerated with the addition of water due to the fact that the water 
molecule is able to displace the acetate ligand from the iodo moiety in the DMP 
compound (scheme 3.12).  
 
Scheme 3.12: Oxidation reaction using DMP 
Therefore, the partially hydrated periodinane is far more reactive toward oxidation.11 
However, as reaction 5 showed, the direct addition of water reduced the yield 
significantly and it is suspected that this allowed the acetic acid to act as an acid 
rather than a nucleophile in the reaction, causing significant deprotection of the 
acetal group. From then on, non-anhydrous DCM was used for these reactions. 
In further reactions, no direct addition of water was used, but the reaction of DMP 
with acetal 147 became increasingly less reproducible and the acetal group was 
found to be unstable to these reaction conditions. As can be seen from reactions 6-8 
sometimes no product was seen by TLC analysis and analysis of the crude reaction 
by 1H NMR spectroscopy revealed no peaks that were consistent with the product 
(see section 3.2.2.3 for NMR data for ketone 148). Due to the unreproducible nature 
of the reactions and the instability of the acetal group towards the reagent meant that 
other oxidation reaction conditions were required. This variability in yields meant the 
reactions could not be optimised efficiently. 
3.3.1.2 Swern Oxidation Reactions toward Ketone 148 
The Swern oxidation is a useful oxidation reaction for secondary alcohols to ketones 
as it is relatively mild. Although the reaction is performed at -78° C, the reaction is 
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relatively quick and the products are easily isolated and purified. Scheme 3.13 shows 
the optimised reaction conditions used for this reaction. 
 
 
Scheme 3.13: Optimised reaction conditions for the Swern oxidation reaction toward ketone 148 
The Swern oxidation reactions were typically more reproducible than the reactions 
using DMP, but acetal stability was still an issue.6 The Swern oxidation reactions had 
isolated yields of 15 – 61% versus 6% - 80% for the DMP reactions. 
Analysis of the crude reaction material by 1H NMR spectroscopy did reveal that the 
acetal group was labile. It was suspected that order of addition was the issue, in that 
the reaction requires addition of oxalyl chloride and DMSO in solution followed by the 
alcohol starting material, and after 1 hour, addition of triethylamine. Since the 
reaction generates HCl as a by-product, it was suspected that addition of the 
triethylamine was occurring too late in the reaction to avoid acetal deprotection. To 
overcome this issue, the alcohol was dissolved in minimal DCM and the triethylamine 
added to it. However, yields remained low and lability of the acetal group was still 
observed by 1H NMR spectroscopic analysis. The benzylidene proton at 5.54 ppm 
and 5.83 ppm were no longer present which indicated the loss of the acetal group.  
However, the isolated yields remained consistent at 25% for the formation of ketone 
148, but this was problematic for the synthesis as at this early stage, low yielding 
reactions would result in significant mass loss. This would result in negligible 
amounts of the final product being synthesised. Coupled to this fact, the 
reproducibility of, and yields of, proceeding reactions in this synthesis were unknown 
and therefore, the Parikh-Doering oxidation reaction was screened as a potential mild 
oxidation reaction to overcome the issue of acetal lability and low yields. At this stage 
the ketone is a key intermediate as it will be used to create allyl ester 145 via the 
HWE reaction (scheme 3.4). From here, the thietane can be furnished. Without 
 97 
 
reliable oxidation reactions to ketone 148, the rest of the synthesis becomes 
significantly more difficult to achieve.  
3.3.1.3 Parikh-Doering Oxidation Reactions toward Ketone 148 
The Parikh-Doering oxidation reaction is a very mild reaction for the oxidation of 
alcohols into aldehydes or ketones using a sulfur trioxide pyridine complex in DMSO 
and triethylamine. The reaction is analogous to the Swern reaction in that the DMSO 
forms a sulfur ylid and reacts as a nucleophile with the sulfur trioxide.4 Scheme 3.9 
shows the standard Parikh-Doering oxidation method used (SO3.Py is the sulfur 
trioxide pyridine complex). 
 
Scheme 3.14: Parikh-Doering oxidation 
As shown in table 3.4, the Parikh-Doering reaction was not consistently reproducible. 
Either the yields were low or no reaction took place and the reason for this is 
unknown. No acetal deprotection was observed when the crude reaction mixture was 
analysed by 1H NMR spectroscopy.  
Table 3.4: Parikh-Doering Reaction toward the synthesis of ketone 148 
Reaction Conditions Yield (%) 
1 2.5 equiv SO3.Py 3 equiv Et3N, 0° C, 4 hrs, 1 g SM 26% product, 16% SM recovered 
2 2.5 equiv SO3.Py 3 equiv Et3N, 0° C, 5 hrs, 1g SM No reaction, SM recovered  
3 2.5 equiv SO3.Py 3 equiv Et3N, 0° C, 6 hrs, 2.5 g SM 52% 
4 2.5 equiv SO3.Py 3 equiv Et3N, 0° C, Overnight, 2.5g 
SM 
No reaction 
 
The low yields and variability in the reaction outcome indicated that the reactions 
were not reproducible. In reactions 2, at 6 hours TLC analysis showed that no 
product had formed. A further 2.5 equivalents of the SO3.Py complex and 3 
equivalents of triethylamine were added and the reaction left overnight. The next day, 
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the starting acetal 147 was recovered. This implied that the SO3.Py complex was not 
undergoing a reaction. However, upon scale up in reaction 3 a yield of 52% was 
observed, but repeating the reaction for reaction 4 showed the reaction no longer 
worked. At 6 hours TLC analysis did not show any product formation so more of the 
SO3.pyridine complex and base was added to the reaction and left overnight. All the 
starting material was recovered at this point and a new direction for the synthesis 
was chosen (see section 3.2.3). 
Despite the unreproducible reactions, the lability of the acetal group and generally 
low yields of the reaction, the 1H NMR spectrum of ketone 148 was indicative of its 
formation. Striking differences were observed between acetal 147 and ketone 148 as 
seen in table 3.5. In figure 3.3 the 1H NMR spectra for acetal 147 and ketone 148 are 
shown for a side by side comparison. 
Table 3.5: Comparisons between the 
1
H NMR spectra of hydroxyl acetal 147 and keto acetal 148 
Acetal 147 Acetal 147 chemical 
shift (ppm) 
Ketone 148 Ketone 148 chemical 
shift (ppm) 
 
Cis 5.54 (s) 
Trans 5.38 (s) 
 
5.9 (s) 
 
Cis 3.61 (t) 
Trans 3.01 (t) 
 
N/A 
OCH2 Cis 3.61 (m) 
Trans 3.01 (m) 
OCH2 4.50 (2xd) 
 
As can be seen in the 1H NMR spectra for both compounds, the chemical shift of the 
benzylidene proton increases markedly between hydroxyl acetal 147 and keto acetal 
148, and this is due to the electron withdrawing effect of the ketone on the ring. This 
proton becomes increasingly deshielded in ketone 148 which increases its chemical 
shift. This also affects the protons bound to positions 2 and 4 on the 1,3-dioxane ring. 
These protons are also deshielded in ketone 148 and are seen at a higher chemical 
shift than those in acetal 147. Also, it is noted that proton 3 in hydroxyl acetal 147 in 
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figure 3.3 is no longer present in ketone 148 (see figure 3.2 for the 1H NMR spectrum 
of acetal 147). 
 
 
Figure 3.3: 
1
H NMR spectrum of ketone 148 
The conversion of the hydroxyl group in acetal 147 to the ketone group in ketone 148 
was confirmed by comparisons between the IR spectra for these two compounds. 
Acetal 147 shows a clear broad peak at 3348 cm-1 which is not observed in ketone 
148 and is indicative of the hydroxyl group. The IR spectrum for ketone 148 does 
show a very sharp peak at 1740 cm-1 that is not present in acetal 147 and is 
indicative of the ketone group. Mass spectrometry data found the mass ion peak for 
ketone 148 at 178.0444 Da and confirmed that the ketone had been synthesised 
which is consistent with the expected mass ion peak of 178.0630 Da. 
3.3.2 Results and Discussion: Modification of the Protecting Group 
Although the acetal protecting group can be a versatile and resilient protecting group, 
it was found to be unsuitable for this synthesis. Although the oxidation reactions were 
mild, the acetal group was found to be unstable toward these reactions, the yields 
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were often low and the major problem was that these reactions were not 
reproducible. Two solutions to these problems were identified: the first solution was 
to remove the oxidation reaction altogether and the second solution was to change 
the protecting group. In scheme 3.15 a new approach to thietane 174 is shown, the 
key intermediate toward the target nucleosides. The tert-butyldimethylsilyl (TBS) 
group was chosen as it is stable to a pH range of 3-12, high temperatures and almost 
every stage of the synthesis except for the addition of fluorine. This would require a 
change in protecting group to the benzoyl protecting group as was used in the 
synthesis of thietane nucleosides in chapter 2. 
 
Scheme 3.15: Proposed synthetic strategy toward 4,4-bis(hydroxymethyl)-thietane nucleosides i) 
TBS-Cl, imidazole, DCM, RT ii) NaH, Methyl diethylphosphonoacetate, THF, RT iii) DIBAL-H, THF, -
78° C iv) H2S, Et3N, -10° C v) BnBr, DMF, RT vi) nBu4NF, THF vii) BzCl, Et3N, DMAP, DCM, RT viii) 
H2 Pd/C, MeOH ix) Deoxofluor, SbCl3, DCM, RT x) silylated nucleobase AgClO4, SnCl2 various 
solvents and conditions (see chapter 2) xi) NaOMe, MeOH, RT  
The reaction starts from 1,3-dihydroxyacetone 165 (DHA) a cheap starting material 
that is also the simplest keto-sugar known. Starting from DHA 165 removes the 
problematic oxidation reaction and allows for the installation of the TBS protecting 
group immediately and from here, the reactions generally follow the reaction 
conditions in scheme 3.4. 
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3.3.2.1 Results and Discussion: Synthesis of the Allyl Aldehyde 
In scheme 3.16, the reaction conditions and yields of the first three steps are shown.  
 
Scheme 3.16: Proposed synthetic steps to the allyl aldehyde: i) TBS-Cl, imidazole, DCM, RT, 18 hrs, 
quantitative yield ii) NaH, Methyl diethylphosphonoacetae, THF, 1 hr then ketone 171, RT, overnight, 
61% iii) DIBAL-H, THF -78° C product not observed, however, compound 181 was (see text) isolated 
From  aldehyde 168, H2S can be used to synthesise the thietane from methyl ester 
167, but, as seen in scheme 3.17, methyl ester 167 can also be used to furnish the 
thietane using the steps developed by Pattenden et al. should the former scheme fail 
to yield usable results.8,12 
 
Scheme 3.17: Modification of the Pattenden synthetic steps toward thietanes: i) LiOH or NaOH ii) 
BnSH, piperidine, 116° C iii) Na/NH3, THF, -78° C iv) Isobutyl chloroformate, Et3N, DCM, -10° C 
The synthesis of TBS ketone 166 from DHA 165 proceeded with ease after reacting 
overnight. The initial reaction conditions of 4 – 6 hours were too short to force the 
reaction to completion and this was due to the solubility of DHA 165, it was poorly 
soluble in DCM. However, after 24 hours, TLC analysis coupled with analysis of the 
crude reaction mixture by 1H NMR spectroscopy revealed that the reaction had gone 
to completion with a quantitative yield after purification. The quantitative yield was 
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comparable to the 98% yield obtained by Weissflock et al.13 The 1H NMR spectrum 
ketone 166 is shown in figure 3.4 
 
Figure 3.4: 
1
H NMR spectrum of TBS Ketone 166  
The spectrum in figure 3.4 clearly shows the TBS groups are present with the CH2 
groups shown as a sharp singlet at 4.3 ppm. The IR spectrum for ketone 166 
confirmed the presence of the ketone group as a sharp peak at 1738 cm-1, and mass 
spectrometry data gavean m/z of 341.2000 Da which was found to be the sodium 
adduct of ketone 166. The expected m/z for this compound was 341.1994 Da for the 
sodium adduct. With small scale synthesis of ketone 166 successful, several 50 g 
batches were subsequently synthesised and all were purified through a plug of silica 
to give quantitative yields of ketone 166.  
Optimisation of the reaction conditions towards methyl ester 167 were required as 
table 3.6 shows. Initial reaction conditions showed incomplete reactions and this was 
suspected to be due to the first step of the reaction where sodium hydride in THF 
was used as a base to deprotonate the phosphonate (see scheme 3.18 for the 
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overall scheme and the reaction mechanism). Increasing the equivalents of sodium 
hydride significantly increased the yields.  
Table 3.6: Optimisation of reaction conditions toward methyl ester 167 
Reaction Conditions Yield (%) 
1 1.1 equiv NaH, 1 equiv phosphonate, THF, RT, overnight 17 
2 1.1 equiv NaH, 1 equiv phosphonate, THF, RT, overnight 39 
3 1.5 equiv NaH, 1 equiv phosphonate, THF, RT, overnight 43 
4 1.5 equiv NaH, 1 equiv phosphonate, THF, RT, overnight 43 
5 1.5 equiv NaH, 1 equiv phosphonate, THF, RT, overnight 56 
6 1.5 equiv NaH, 1 equiv phosphonate, THF, RT, overnight 61 
 
Initial reactions showed that 1.1 equivalents of NaH did not satisfactorily deprotonate 
the phosphonate. Increasing the equivalents of NaH to 1.5 showed an increase in 
yield and the reaction gave more reproducible yields such that upon scale up 
(reactions 4 – 6) 25 g scale reactions could be performed with good to moderate 
yields. All reactions were quenched by cooling to 0° C by dropwise addition of ice 
cold water, and then extracted with DCM. The reactions were then purified by flash 
column chromatography and the column was optimised by using a gradient elution 
(100% petroleum ether to 95:5 petroleum ether:ethyl acetate) to give an isolated yield 
of 70% of methyl ester 167. 
 
Scheme 3.18: Synthetic scheme and reaction mechanism toward methyl ester 167 
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As can be seen from the 1H NMR spectrum (figure 3.5) for methyl ester 167, the 
singlet at 4.3 ppm which is indicative of the CH2 groups for ketone 166, is now 
observed as two singlets for the same CH2 groups in methyl ester 167 (figure 3.5). 
 
Figure 3.5 
1
H NMR spectrum of methyl ester 167 
The key peak that determined whether the alkene had formed was the peak at 5.9 
ppm which is indicative of the C=CH proton. HMBC confirmed that the C=CH proton 
was 4 bonds away from the CH2OSi protons. IR spectroscopy data showed a sharp 
peak at 1718 cm-1, a drop of 20 cm-1 versus the peak observed in ketone 166. A C-O 
stretch at 1100 cm-1 which is indicative of the C-OMe bond stretch was also 
observed. Mass spectrometry data confirmed the compound had been successfully 
synthesised with the m/z of 375.2384 Da which was close to the expected m/z value 
of 375.2309 Da. 
3.3.2.2 Divergence of the Synthetic Scheme 
As shown in schemes 3.6 (section 3.3), two methods were identified as plausible 
synthetic schemes toward thietane nucleosides: The Givaudan synthesis which uses 
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an aldehyde and hydrogen sulfide to form the thietane, and the Pattenden synthesis, 
which uses a carboxylic acid, benzyl mercaptan and two additional steps to cyclise 
the thietane (see section 3.3).  
The Givaudan synthesis of the thietane was first attempted as it allows quicker 
access to the target compound with only a reduction of methyl ester 167 to aldehyde 
168. The Pattenden synthesis requires ester hydrolysis followed by several steps 
prior to cyclising the thietane ring. However, use of DIBAL-H did not give the 
aldehyde, instead as table 3.7 and scheme 3.19 show, the reaction conditions were 
not conducive toward the aldehyde, and instead, alcohol 181 was isolated.14 
 
Scheme 3.19: DIBAL-H reduction of methyl ester 167 did not give aldehyde 168, but instead gave 
allyl alcohol 181 i) DIBAL-H, THF, -78° C, 80% for 181. 
Table 3.7: Optimisation of the DIBAL-H reduction reaction of methyl ester 167 to allyl alcohol 181. All 
reactions performed at -78° C in anhydrous THF 
Reaction Conditions Outcome 
1 250 mg 167, 2 equiv DIBAL-H react 3 hrs. Further 1 
equiv DIBAL-H added and reacted for 1 additional 
hour. 
TLC showed no change at 3 
hrs. After additional 1 equiv 
DIBAL-H, consumption of SM 
was observed. 28% yield of 181 
2 250 mg 167, 3 equiv DIBAL-H react 3 hrs 22% yield of 181 
3 500 mg 167, 3 equiv DIBAL-H react 3 hrs 26% yield of 181 
4 1 g 167, 3 equiv DIBAL-H react 3 hrs 80% yield of 181 
 
Optimisation of the reaction toward allyl aldehyde 168 could not be achieved, though 
careful control of the number of equivalents of DIBAL-H is known to give the 
aldehyde over the alcohol. No change by TLC analysis was observed for this reaction 
when less than 3 equivalents of DIBAL-H were used. Increments of 0.5 equivalents 
of DIBAL-H were added to the vessel in reaction 1 every 3 hours and no reaction was 
observed until 3 equivalents were reached. Increasing the number of equivalents of 
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DIBAL-H had the potential to increase the reaction rate as concentration of a reagent 
is tied to reaction rates. However, increasing the number of equivalents also 
increases the likelihood of allyl alcohol 181 forming. Analysis of the crude reaction 
mixture by 1H NMR spectroscopy revealed only ester 167 was present after 3 hours 
in the presence of DIBAL-H in reaction 1 which prompted the addition of more 
DIBAL-H as discussed. Subsequent reactions used 3 equivalents of DIBAL-H and in 
all cases allyl alcohol 181 was isolated. Failure to form aldehyde 168 is due to the 
fact that DIBAL-H is known to reduce α,β-unsaturated esters to the corresponding 
allyl alcohol. It could still be possible to synthesise aldehyde 168 by using 2 – 2.5 
equivalents of DIBAL-H over much longer periods of time. 
At this juncture, oxidation of allyl alcohol 181 to aldehyde 168 was considered as a 
means to access the aldehyde 168, and the Swern oxidation reaction was chosen as 
the easiest method to use as it showed greater reproducibility than the DMP and 
Parikh-Doering reactions for the oxidation of acetal 147 to ketone 148. However, 
using the  Swern oxidation conditions from the synthesis of ketone 148 for the 
conversion of allyl alcohol 181 to aldehyde 168 did not work and was not optimised 
for this system because success was being had with the reproduction of the 
Pattenden synthesis of thietanones using benzyl mercaptan to access 4,4-dimethyl 
thietanes (scheme 3.20).8 
 
Scheme 3.20: i) Benzyl mercaptan, piperidine, reflux, 24 hrs, quant ii) Na, NH3, THF, -78°  C, quant iii) 
Isobutyl chloroformate, Et3N, DCM, -10° C, 20 minutes 
Heating acid 154 in the presence of BnSH and piperidine gave thioether 155 with a 
quantitative yield. 1H NMR spectroscopic data for thioether 155 matched the literature 
data.8 The methyl groups were observed at 1.46 ppm which is close to the literature 
value of 1.50 ppm. Allyl acid 154 contains a singlet at 5.7 ppm which is the alkene 
proton. This is not observed in thioether 155, instead a CH2 singlet is observed at 
2.65 ppm, which matches the literature value. Thiol 156 was obtained after 
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optimisation of the thea reaction between thioether 155 and sodium in liquid 
ammonia. Reproduction of the Pattenden reaction conditions were followed gave a 
thick gel, and in subsequent reactions, the starting material was dissolved in THF 
before the liquid ammonia was condensed, which overcame this problem.  
The 1H NMR spectroscopic data again matched the literature for thiol 156. The 
methyl groups were observed at 1.46 ppm which exactly matched the literature data. 
The SH proton was observed at 2.68 ppm, which again, matched the literature.  
Cyclisation toward thietanone 157 was achieved after optimisation of the reaction 
conditions with isobutyl chloroformate. The Pattenden conditions called for 1 
equivalent of triethylamine and 2 equivalents of isobutyl chloroformate. However, 
attempts to replicate this method were met with failure as a solid white mass was 
formed. Analysis of the white solid revealed that the reaction did not go to completion 
and contained starting materials. The optimised reaction used 2 equivalents of 
triethylamine and 2.2 equivalents of isobutylchloroformate for 1 hour. TLC analysis of 
the crude reaction mixture showed that the reaction had reached completion. 
However, due to the high volatility of thietanone 157, purification was not achieved 
and instead the 1H NMR spectroscopic data of the crude reaction mixture was 
obtained which showed peaks consistent with the product. The methyl groups were 
observed at 1.44 and 1.45 ppm with literature values of 1.31 and 1.38 ppm. The CH2 
group was observed at 3.74 ppm with a literature value of 3.72 ppm.  
3.3.3 Ester Hydrolysis Reactions 
With successful replication of the Pattenden reaction conditions, the synthetic 
strategy toward the target thietane was modified in order to successfully synthesise 
the novel thietane core (scheme 3.21). As stated in section 3.3, the Pattenden 
synthesis introduces two additional steps into the synthetic strategy when using 
methyl ester 167. Ester hydrolysis is required prior to incorporation of the thiobenzyl 
moiety toward thioether 178, and deprotection of thioether 178 to thiol 179 must 
occur prior to cyclisation to thietanone 180. 
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Scheme 3.21: Modification of the synthetic route toward the target thietane i) LiOH or NaOH, various 
solvents, ii) BnSH, piperidine, 116° C, overnight iii) Na/NH3, THF, -78° C 2-3 hrs iv) isobutyl 
chloroformate, Et3N, DCM, -10° C, 1-2 hrs 
Several methods were attempted to hydrolyse methyl ester 167 to acid 177 using 
mineral bases as the TBS group is reported to be stable up to pH 12 and the TBS 
group was stable at pH 12 with 5% NaOH in MeOH for 24 hours.15,16 A literature 
search for hydrolysis of conjugated methyl esters with TBS protecting groups 
revealed two methods for the hydrolysis reaction and implied that the TBS groups 
were indeed stable to base: One where six equivalents of LiOH are used and is 
heated to 60° C for one hour and another reaction where 10 equivalents of LiOH are 
used at room temperature for 8 hours.17,18 Neither reaction was conducive to 
hydrolysing the methyl group of methyl ester 167, and analysis of the reaction by 1H 
NMR spectroscopy revealed significant deprotection of the TBS groups. Table 3.8 
summaries each reaction attempt and variations of solvents and equivalents of base 
used. Scheme 3.22 shows the general reaction scheme for this hydrolysis. 
 
Scheme 3.22: General hydrolysis reaction of methyl ester 167 with mineral bases 
Table 3.8: Mineral base hydrolysis of methyl ester 167 to acid 177 
Reaction Base Conditions Outcome 
1 LiOH 6 equiv base 4:1 IPA:Water 60° C 1 hr TBS group deprotection 
2 LiOH 10 equiv base 8:1:1 THF:MeOH:Water RT, overnight TBS group deprotection 
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3 NaOH 1 equiv base, 1:1 THF:Water RT, overnight No reaction 
4 NaOH 1.5 equiv base, 1:1 THF:Water RT, overnight No reaction 
5 KOH 1.5 equiv base, 1:1 THF:Water RT, overnight TBS group deprotection 
6 LiOH 1.5 equiv base 2:1 MeOH:Water 6 hrs No reaction 
7 LiOH 6 equiv base 4:1 IPA:Water, RT, 6 hrs TBS group deprotection 
8 LiOH 3 equiv base, IPA, RT, overnight No reaction 
9 LiOH 3 equiv base, 4:1 IPA:Water dropwise addition of 
base over 8 hrs, RT, overnight 
No SM, some TBS 
deprotection 
10 LiOH 10 equiv base, dropwise addition over 8 hrs, 8:1:1 
THF:MeOH:Water, RT, overnight 
Hydrolysis observed by 
TLC analysis and 
1
H 
NMR spectroscopy. Still 
observed TBS group 
deprotection 
11 LiOH 2.5 equiv base, dropwise addition over 8 hrs, 8:1:1 
THF:MeOH:Water, RT, overnight 
No reaction 
12 LiOH 2.5 equiv base, dropwise addition over 8 hrs, 8:1:1 
THF:MeOH:Water, 45° C, overnight 
TBS group deprotection 
and some product 
isolated 
 
The literature reaction conditions failed to yield the desired product (reactions 1 and 
2). Initially LiOH was trialled as it is the least soluble of the mineral bases. The slow 
release of the hydroxide ion means that the reaction kinetics could be controlled. The 
low concentration of hydroxide in solution would allow selective reaction at the methyl 
ester rather than the silyl protecting groups. The number of equivalents was changed 
to further aid reaction kinetics. The base was changed to NaOH and KOH as these 
were stronger bases and as such would react more readily than LiOH. This was in 
order to bring down reaction times by increasing reaction rates. Analysis of each 
reaction by TLC analysis showed consumption of the starting material, however, after 
work up, analysis by 1H NMR spectroscopy revealed multiple peaks around 0 ppm 
and 1.5 ppm where the TBS groups are present. Here, instead of the expected 
doublets, several peaks were observed which indicated that the TBS groups were 
hydrolysing. This implied that the hydroxide ion was acting as a nucleophile at TBS 
groups (see scheme 3.23). 
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Scheme 3.23: Suspected hydrolysis reaction at the TBS group.   
Since hydrolysis of the TBS group was a significant problem with the use of mineral 
bases, more mild conditions were sought. A literature search revealed three mild 
reaction conditions: the use of potassium trimethylsilanolate, trimethyltin hydroxide or 
lithium iodide in pyridine as potential mild reagents for this hydrolysis.19-21 
3.3.3.1 Use of Potassium Trimethylsilanolate 
Potassium trimethylsilanolate (KOSiMe3) is a mild nucleophilic reagent that is useful 
for the hydrolysis of a wide range esters.20 It has been shown that potassium 
trimethylsilanolate does not act as a base and therefore can be used to hydrolyse 
esters where there could be potential for elimination reactions or where abstraction of 
a proton is possible.19,20 Since potassium trimethylsilanolate is soluble in a multitude 
of organic solvents, esters that cannot be hydrolysed using mineral bases in 
alcohol/water solvent systems can be hydrolysed with this reagent in THF, diethyl 
ether, or toluene.19,20 
A model reaction with methyl benzoate and 1.2 equivalents of KOSiMe3 was 
performed in THF and after 4 hours the benzoic acid was recovered with a 
quantitative yield. The method followed the report by Laganis et al for the use of 
KOSiMe3.
20 With successful synthesis of the literature method toward benzoic acid, 
the hydrolysis reaction with this reagent and methyl ester 167 was attempted several 
times and the reactions are summarised in table 3.9. 
Table 3.9: Hydrolysis reactions with KOSiMe3 
Reaction Equivalents of KOSiMe3 Solvent and Temperature Outcome 
1 1 THF, RT No reaction after 24 hrs, SM 
recovered 
2 1.5 THF, heated at reflux No reaction after 48 hrs, SM 
recovered 
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3 1.5 Toluene, heated at reflux No reaction after 72 hrs, SM 
recovered 
4 2 Toluene, heated at reflux No reaction after 168 hours, 
SM recovered 
5 10 Toluene, heated at reflux 
1
H NMR analysis did not 
show peaks consistent with 
SM or products 
 
Although the model reaction was successful, the use of KOSiMe3 for the hydrolysis of 
methyl ester 167 was not. Intial reaction conditions followed the paper but no reaction 
was observed. In reaction 2, 1.5 equivalents of KOSiMe3 was then tried but no 
reaction was observed at room temperature in the first 24 hours. The reaction was 
heated at reflux for a further 24 hours to increase the rate of reaction. The solvent 
was changed to toluene to aid solubility of the starting materials, however, no 
reactions were observed when the number of equivalents were increased or when 
the reaction time was increased. The 1H NMR spectrum of each crude reaction 
showed some lability of the TBS groups but this is suspected to be due to the 10% 
KOH that is present in the silanolate reagent due to the manufacturing method. 
However, in all but one reaction, no methyl ester hydrolysis was observed. In 
reaction 5, 10 equivalents of the silanolate reagent was used and heated to reflux but 
by the next day the 1H NMR spectrum revealed complete hydrolysis of the 
compound. No peaks consistent with the starting material or the product were 
observed.  
The use of anhydrous LiI in pyridine that is heated to reflux has been used to 
hydrolyse methyl esters.21 However, use of these conditions on methyl ester 167 did 
not yield any product and the starting material was totally recovered.  
3.3.3.2 Trimethyltin Hydroxide Hydrolysis of Esters 
Trimethyltin hydroxide (Me3SnOH) has been used as a mild reagent for the selective 
hydrolysis of methyl and ethyl esters in sensitive substrates.22 Scheme 3.24 shows 
the optimised reaction conditions for the hydrolysis of methyl ester 167. 
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Scheme 3.24: Optimised reaction conditions toward acid 177 i) 8 equivalents of Me3SnOH, 1,2-DCE, 
80° C, 96 hrs, 93% yield 
Initially, 6 equivalents of the tin reagent were used but after 72 hours the reaction had 
not proceeded to completion. A further 2 equivalents of the tin reagent were used 
and after an additional 24 hours completion was observed and acid 177 was isolated 
pure with a yield of 93%. The number of equivalents were increased as the increased 
concentration of the tin reagent would have increased the likelihood of successful 
reactions occurring, and hence, an increase in reaction rate. No purification methods 
other than mildly acidic (pH 4) extractions were used. The 1H NMR spectrum of acid 
177 is shown in figure 3.6. 
 
Figure 3.6: 
1
H NMR spectrum of acid 177. No methyl ester protons are present at 3.6 ppm. 
The IR spectrum shows a sharp peak at 1682 cm-1 which is indicative of an α,β-
unsaturated carboxylic acid. The MS spectrum gives a mass charge ratio of 
361.2225 Da which was close to the expected value of 361.2230 Da.  
The synthesis continued with attempts to synthesise thioether 178 using BnSH and 
piperidine in a reaction analogous to the Pattenden reaction.8 The reaction shown in 
scheme 3.25 did not work and could not be optimised.  
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Scheme 3.25: Attempts to synthesis thioether 178 from acid 177 i) 1.1 equiv BnSH, piperidine (base 
and solvent), 116° C, 48 hrs no reaction 
TLC analysis of the crude reaction mixture showed a reaction was occurring but after 
24 hours there was still starting material present. Additional BnSH was introduced to 
the reaction to force it to completion but after 48 hours no change had been detected 
by TLC analysis in the proceeding 24 hours. Analysis of the crude reaction mixture 
by 1H NMR spectroscopy was inconclusive as to whether the reaction had worked or 
not. Work up involved slow addition of ice cold dilute HCl. Though the Pattenden 
synthesis used concentrated acid, the acid sensitive TBS groups in compound 177 
meant that milder conditions would need to be used. The aqueous phase was 
removed and dilute sodium carbonate was added, which deprotonated acid 177. 
Chloroform was used to wash the basic phase to remove any organic impurities. The 
basic phase was slowly brought to pH 5 to re-protonate acid 177 which was extracted 
with chloroform. TLC analysis showed a number of products present in the organic 
phase. Attempts to purify the resulting residue using column chromatographyc could 
not resolve the compounds observed from the TLC plate. Analysis of the 1H NMR 
spectrum for this reaction showed a multitude of peaks that could not be assigned to 
acid 177. This indicated that the work up procedure was not suitable for extracting 
acid 177. Though milder conditions were attempted, such as using dilute acetic acid, 
and milder bases such as sodium bicarbonate, extraction and purification of acid 177 
was not achieved. In order to proceed with this reaction, changing the protecting 
groups from TBS groups to acid and base stable groups such as benzyl groups, 
would be advantageous. However, as benzyl mercaptan is used to introduce the 
sulfur atom later, and sodium in liquid ammonia is used to remove the benzyl group 
from the sulfur, a protecting group change would be required again before the use of 
benzyl mercaptan. This introduces further steps, reducing the efficiency of the 
synthesis. 
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3.3.3.3 Steps Toward the Target Thietane Molecule 
The synthesis of thioether 178 was neither optimised nor repeated because in 
parallel to this reaction, methyl ester 167 was also reacted with BnSH in piperidine to 
give thioether 182 (scheme 3.26) with a yield of 82%. 
 
Scheme 3.26: Synthesis of thioether 182 i) 1.1 equiv BnSH in piperidine, heating to reflux over 24 
hours. 
The reaction did not require an acid work up because neither the starting material nor 
the product contains a carboxylic acid that requires re-protonation, and the piperidine 
could be washed out in the aqueous phase easily. However, purification of the 
product was difficult as a slight excess of BnSH was required to push this reaction to 
completion after 24 hours, the BnSH had a tendency to co-elute with the product. 
Despite the problems with purification, thioether 182 was isolated and batch 
reactions allowed enough material to be synthesised to proceed to the next stages. 
In figure 3.7 the 1H NMR spectrum is shown for thioether 182. The most significant 
differences between this spectrum and that of methyl ester 167 is that the alkene 
proton at 5.9ppm is no longer present (as expected) and a new CH2 group is present 
which is indicative of the SBn group.  
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Figure 3.7: 
1
H NMR spectrum of thioether 182 
IR spectroscopy showed peaks around 2952 cm-1 which are indicative of the 
benzene ring and the carbonyl stretch was observed at 1739 cm-1 which was not 
significantly different for the carbonyl stretch observed for methyl ester 167 which 
was observed at 1738 cm-1. Mass spectrometry data confirmed that thioether 182 
had formed with the mass ion peak observed with a mass of 521.2542 Da which was 
the sodium adduct, and was close to the expected value of the sodium adduct of 
521.2553 Da. 
 3.3.4 Ester Hydrolysis reactions of Thioether 178 
With successful synthesis of thioether 182, hydrolysis reactions were performed in an 
attempt to synthesise acid 178 (scheme 3.27).  
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Scheme 3.27: General hydrolysis reaction toward acid 178 
The mineral bases could not be used for this conversion as it has been shown that 
the TBS groups are labile (section 3.3.4.3). Also, with a tertiary thioether group 
present, the mineral bases may cause elimination of the thioether moiety. 
Although KOSiMe3 did not hydrolyse methyl ester 167, the small scale exploratory 
reactions were performed on thioether 182 as it was suspected that the conjugated 
nature of methyl ester 167 was resistant to hydrolysis with this mild reagent. 
However, as table 3.11 shows, KOSiMe3 as a reagent did not work adequately for 
this conversion. Elimination was observed in these reactions in almost all cases. 
According to Laganis and Lovric, KOSiMe3 does not act like a base and behaves only 
as a nucleophile.19,20 The reagent has been used on compounds where elimination is 
a risk; therefore it is a good reagent for sensitive compounds. However, since the 
reagent contains up to 10% KOH, the observed elimination reaction could be due to 
the presence of this strong base. As shown in table 3.11, the elimination product was 
found to be allyl ester 167 with the 1H NMR spectroscopic data revealing the 
indicative singlet at 5.9 ppm for the alkenic proton. In both reactions, the 1H NMR 
spectroscopic data revealed a mixture of thioether 182 and allyl ester 167. 
Although only two reactions were performed, the reactions were attempted because 
the equivalents of reagent used were low for the conversion of methyl benzoate to 
benzoic acid (1.2 equivalents), versus Me3SnOH which required 8 equivalents, 
significantly longer reactions times, and a significant work up protocol. However, 
immediate success was had with the tin reagent as seen in scheme 3.28. 
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Scheme 3.28: Ester hydrolysis using trimethyltin hydroxide 
Since immediate success was had with the tin reagent for this hydrolysis, it was used 
in subsequent reactions, including large scale (10 g) synthesis of acid 178 with yields 
ranging from 61 – 88%. Figure 3.8 shows the 1H NMR spectrum for acid 178 which 
shows no methyl ester peak at 3.9 ppm (figure 3.8). 
 
Figure 3.8: 
1
H NMR spectrum of acid 178 
The IR data showed a change in the wavenumber for the carbonyl stretch which was 
at 1739 cm-1 in thioether 182 and in acid 178, the carbonyl stretch is at 1707 cm-1. 
Mass spectrometry data gave the mass ion peak 507.2391 Da which was the sodium 
adduct. The expected mass for the sodium adduct was calculated to be 507.2397 
Da. 
With successful reproduction and optimisation of the benzyl group deprotection 
reaction for the Pattenden synthesis of 4,4-dimethylthietan-2-one (see scheme 3.7 
section 3.3) with sodium in liquid ammonia, the reaction optimised reaction conditions 
were trialled on thioether 178 to give thiol 179 (scheme 3.29). 
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Scheme 3.29: The synthesis of thiol 179 using sodium in liquid ammonia 
Initial reactions with thioether 178 did not go to completion in the same time frame as 
the Pattenden synthesis (scheme 3.7) (1 – 2 hours versus 3 – 4) and an end point 
was hard to determine because TLC analysis was impossible due to liquid ammonia 
evaporation. However, small (0.1 ml) aliquots were removed from the crude reaction 
mixture, worked up and analysed by 1H NMR spectroscopy which revealed the 
reaction had reached completion after 4 hours. After purification by mild acid work 
up, thiol 179 was fully characterised. Figure 3.9 shows the 1H NMR spectrum for this 
compound. 
 
Figure 3.9: 
1
H NMR spectrum of thiol 179 
The 1H NMR spectrum shows clearly the thiol proton at 2.5 ppm which is the key 
indicative peak for this compound. The IR spectrum for this compounds shows 
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several signals: 3345 cm-1 as a sharp peak for the –OH stretch, 2857 cm-1 for the –
SH stretch, and three sharp peaks at 1732 cm-1, 1687 cm-1 and 1645 cm-1 which are 
indicative of the carbonyl C=O stretches. The mass spectrum data revealed the mass 
ion peak +H+ at 395.2103 Da and the sodium adduct at 417.1922 Da with both 
corresponding to the calculated values of 395.2108 Da and 417.1927 Da. 
With optimised reaction conditions from the model reaction for the synthesis of 4,4-
dimethylthietan-2-one established, the synthesis of thietanone 180 was achieved with 
a yield of 37% after reacting for 4 hours (scheme 3.30). Figure 3.10 shows the 1H 
NMR spectrum for thietanone 180. 
 
Scheme 3.30: Synthesis of thietanone 180 i) isobutylchloroformate, triethylamine, DCM, -10° C, 4 
hours, 37% 
 
Figure 3.10: 
1
H NMR spectrum of thietanone 180 
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Interestingly, the IR spectrum of thietanone 180 was sufficiently different to the IR 
spectrum of thiol 179 that it was possible to distinguish between these compounds 
based by IR spectroscopy, as shown in figure 3.11. 
 
 
Figure 3.11: Top: The IR spectrum for thiol 179 and bottom: The IR spectrum for thietanone 180 
As can be seen from the IR spectrum for thietanone 180, only one band for the 
ketone is present at 1767 cm-1. This is rather high for a C=O stretch and is possibly 
due to ring strain, and is in the expected range for thietanone 180 as Pattenden et al. 
found that the C=O stretch for thietanone 180 was 1748 cm-1.8 
Immediate differences between the two spectra are: thietanone 180 does not contain 
the peak at 3345 cm-1 and confirms that cyclisation has occurred because the 
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carboxylic –OH stretch is no longer present. The shift in the vibrational frequency 
toward a higher wavenumber for the ketone in thietanone 180 confirms cyclisation 
has occurred as the frequency is within the range of 4 member ring ketones.8,23 The 
mass spectrometry data showed the mass ion peak for thietanone 180 was 399.1817 
Da as the sodium adduct and confirmed that the thietane had been made. The mass 
spectrum also showed a smaller peak at 377.1997 Da, which is the mass ion peak. 
The mass spectrum data closely matched the calculated values for the mass ion 
peak and the sodium adduct at 377.2002 Da and 399.1821 Da. 
With successful synthesis of thietanone 180 achieved, future work involves changing 
the protecting groups to benzoyl groups, reducing the ketone to the alcohol, 
converting the alcohol to the fluorine and then using already established chemistry 
from chapter two to furnish the nucleosides. 
Although the synthesis toward thietanone 180 was achieved, several key synthetic 
strategies required optimisation. The best approach toward this thietane ring at the 
moment is to form the benzyl thioether from ester 167 as it is far easier to achieve 
than reducing the ester to an aldehyde and converting to the thietane. The method 
where the benzyl thioether is formed removes the protecting group steps from the 
aldehyde method. A summary of the approach is presented in scheme 3.31. 
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Scheme 3.31: Top: Aldehyde method which requires additional protecting group chemistry and 
bottom: Optimised route toward thietanone 180 which was achieved after significant optimisation of 
the each step i) TBS-Cl, imidazole, DCM, RT, 24 hrs, quant ii) Methyl diethylphosphonoacetate, THF, 
NaH, RT, 24 hrs, 61% iii) BnSH, piperidine, 116° C, 24 hrs, 82% iv) 8 equiv Me3SnOH, 1,2-DCE, 80° 
C, 96 hrs, 88% v) Na, NH3, THF, -78° C, 2 – 3 hrs, 93% vi) Isobutylchloroformate, Et3N, DCM, -10° C, 
37% vii) nBu4NF, THF viii) BzCl, DMAP, Et3N, DCM, RT ix) NaBH4, THF x) Deoxofluor, SbCl3, DCM, 
RT xi) silylated nucleobase, AgClO4, SnCl2 various solvents and temperatures (see chapter 2) xii) 
NaOMe, MeOH, RT 
The exploratory chemistry objective has been met and has shown that the Givaudan 
synthesis of thietane rings could not be easily applied to the synthetic strategy due to 
the difficulty in synthesising aldehyde 168. Without this aldehyde the utility of the 
Givaudan synthesis could not be established. However, reproduction and 
optimisation of the Pattenden reaction conditions toward thietanones gave usable 
and productive results which led to the successful synthesis of thietanone 180 after 
some modification. Although the Pattenden conditions used a carboxylic acid as a 
starting material, conversion of 177 to thioether 178 could not be achieved. However, 
conversion of thioether 182 to acid 178 was achieved after significant optimisation of 
the reaction conditions. These modifications enabled the successful synthesis of 
thietanone 180, a novel thietanone precursor to the key intermediate fluorothietane 
174. 
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Chapter 4: 
The Design and Synthesis of 4’-
Thiohamamelose Nucleosides 
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Chapter 4: The Design and Synthesis of 4’-Thio-D-
Hamamelose Nucleosides as Anti-Viral Agents 
Ribose nucleosides are ubiquitous as scaffolds for DAAs as the ribose sugar moiety 
is present in the sugar backbone of DNA and RNA. Since viral replication requires 
replication of the viral genome, drugs that mimic endogenous 
nucleosides/nucleotides are an excellent method of halting viral replication.1-6 For a 
detailed explanation of how these drugs work see section 1.2.2.5.  
Nucleoside based drugs can be modified in several different ways; phosphate 
modification, sugar modification or base modification.7 The types of modifications 
used depend on several factors: 
 Susceptibility of the nucleoside to cellular kinases. Modification of the 
phosphate group can allow increased permeability of the drug through the cell 
membrane and also bypass kinases that may not phosphorylate the 
unmodified nucleoside (See section 1.2.2.5.3 for a detailed analysis).1,8-18 
 Binding interactions in the biological target. Modification of the sugar ring may 
be required to increase the binding interactions in the biological target, or to 
increase binding affinity in a pocket that the drug may not be binding to. Other 
factors such as ring conformation and ring size can be modified to overcome 
associated problems in these areas (see section 1.2.2.5.4).19-22 
 Base modifications are required as some nucleobases have better inhibitory 
characteristics than others. It is documented that purine nucleobases are 
typically inactive compared to the pyrimidine nucleobases (see chapter 1 
section 1.2.2.5). 
4.1 The 4’-Thioribose Nucleosides and their Derivatives 
A major factor in the inactivity of ribose based nucleosides is their susceptibility to 
cleavage by a variety of nucleases.23-26 Thioribose nucleosides and their derivatives 
have been found to resist enzymatic cleavage of the glycosyl bond by nucleases. 
Blood degradation studies via HPLC analysis by Toyohara et al found that thymidine 
184 was 50% degraded at 1 hour and fully degraded at 20 hours; whereas 4’-
thiothymidine 185 was only 3% degraded at 1 hour and only 25% degradation was 
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observed at 20 hours (figure 4.1).23  Ideally, the drug would be stable for at least 24 
hours as once a day dosing is the gold standard for patient compliance as this 
minimises missed doses.   
 
Figure 4.1: Thymidine and 4’-thiothymidine differ by the sulfur atom at the 4’-position 
The study by Toyohara et al. indicated that the 4’-thioribose nucleosides resist 
catabolism and are stable to nucleases (see table 4.1).23,25,26 Further to this, (E)-5-(2-
bromovinyl)-2’-deoxyuridine (BVDU) 188 and the 4’-thio derivative 189 also showed 
increased stability to pyrimidine phosphorylases. Dyson et al. showed (based on the 
work by Desgranges et al who measured the effect of pyrimidine phosphorylases in 
blood and showed that the nuclease was able to detach the uracil from the sugar ring 
in BVDU) that BDVU 188 was metabolised to the inactive metabolite (E)-5-(2-
bromovinyl) uracil moiety 190 and 2-deoxyribose-1-phosphate 191 by pyrimidine 
nucleoside phosphorylase (figure 4.2).26-29 The 4’-thio moiety 189 was found to be 
more stable and no (E)-5-(2-bromovinyl) uracil residue was observed indicating that 
the 4’-thio moiety 189 is stable to nucleases. When comparing the plasma half-lives 
of BDVU 188 and the 4’-thio moiety 189, there is 1.5 times more of the 4’-thio moiety 
189 at 2 hours than there is of BDVU 188 when both are dosed at 40 mg/kg. At 2 
hours BVDU 3 is found at a concentration of 35 μM versus 50 μM for 4’-thio moiety 
189. At 3 hours, no BDVU is measured, the concentration of the 4’-thio moiety 189 
remains constant.28,30 
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Figure 4.2: Action of pyrimidine nucleoside phosphorylase. No degradation was observed for the 4’-
thioribose moiety.  
Table 4.1 summarises the known 4’-thioribose nucleosides, their potency and 
therapeutic index. 
Table 4.1: Known 4’-thioribose nucleosides (only active nucleosides have been shown with 
compounds 186 and 187 shown as the ribose counterparts with their associated activity). 
Compound IC50 Stability (%) Therapeutic Index 
 
N/A 50% at 1 hour 
100% at 20 hours 
- 
 
0.02 μM 50% at 2 hours 10 000 
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0.08 μM 50% at 3 hours  62 500 
 
0.15 μM 3% at 1 hour 
25% at 20 hours 
- 
 
0.32 μM - - 
 
0.14 μM - - 
 
0.37 μM - - 
 
4.38 nM - - 
 
Note: L-series 4-thionucleosides have been synthesised as anti-cancer agents but 
these compounds are not included as they are outside the scope of this thesis.31  
It has been shown that as well as resisting nucleases, the 4’-thioribose moieties are 
more thermally stable; generally have higher binding affinities, and a higher 
chemotherapeutic index than the ribose counterparts that make them an attractive 
anti-viral target.24,25,27,32 Table 4.1 shows that nanomolar ranges of activity can be 
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achieved for 4’-thioribose nucleosides, and this is important as it reduces the 
chances of off target effects when drug concentrations are high.23,25-28,33 
4.2 Hamamelose Nucleosides 
Hamamelose 196 is a 5 membered ring sugar with a 2’-C-hydroxymethyl group 
(figure 4.3). No 4’-thiohamamelose nucleosides are known but 4’-thioribose 
nucleosides have shown promise as nucleosides due to factors outlined in the 
previous paragraph. The intention with this piece of work was to explore the anti-viral 
properties of 4’-thiohamamelose nucleosides. It is hypothesised that similar to the 4’-
thioribose counterparts, the 4’-thiohamamelose nucleosides will be more thermally 
stable and more biologically stable than their hamamelose counterparts. 
 
Figure 4.3: Hamamelose 
Although hamamelose nucleosides are known to be active against HCV infection, 
initial research into anti-HCV compounds found that 2-C’-methyl and 2-F’ groups 
were essential for activity. This was attributed to steric bulk preventing subsequent 
incoming nucleotides from binding into the HCV replicase complex and thus 
preventing genome replication.1,15-17,34-40 (See section 1.2.2.5.2 for a detailed 
description). Figure 4.4 shows the key compounds along with their anti-HCV activity. 
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Figure 4.4: Key anti-HCV compounds 
Both Yoo and Jeong separately hypothesised that the hamamelose 2-C’-
hydroxymethyl group would have favourable electronic and steric effects that would 
increase interactions in the HCV replicase complex.41,42 The increased bulk was 
hypothesised to be better at preventing incoming nucleotides from binding into the 
replicase complex, and the hydroxymethyl group is hypothesised to have binding 
affinity to the polymerase.41,42 It was observed by Yoo et al that the hydroxymethyl 
group in derivative 197 was essential to binding, and along with Jeong et al, both 
derivative 197 and derivative 198 (figure 4.4) were shown to inhibit viral replication by 
2% at 1μM and derivative 197 inhibited viral replication by 50% at 10μM. However, 
based on the low inhibitory values observed it cannot be concluded that the 
increased steric bulk of the hydroxymethyl group is essential for binding. 
 
Figure 4.5: Hamamelose nucleosides active against HCV 
However, despite these compounds being active against the HCV replicase complex, 
the inhibitory concentration was low and therefore significant research is required to 
optimise the activity of this class of compound.41 
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4.3 Aims  
As has been shown, the 4’-thioribose nucleoside derivatives are more thermally and 
metabolically stable than their ribose counterparts, as well as having generally higher 
binding affinities than their ribose counterparts. Therefore, the major aim of this piece 
of work is to design and synthesise a range of 4’-thiohamamelose nucleosides that 
are hypothesised to be more metabolically stable than their hamamelose 
counterparts. The main objectives are listed below: 
 Design and synthesise a series of 4’-thiohamamelose nucleoside libraries. 
 Perform anti-viral testing to determine the IC50, and CC50 values of the 
compounds. 
 Modify the structure of the nucleosides to gain a full understanding of the 
SAR. 
 Using the biological data, design and synthesise a new library of compounds 
with the aim of producing a highly potent, non-toxic nucleoside. 
No 4’-thiohamamelose nucleosides are currently known therefore it would be 
valuable to prepare a large and varied number of derivatives to explore the SAR of 
these nucleosides. 
4.3.1 SAR of 4’-thiohamamelose nucleosides 
In order to explore the SAR of the 4’-hamamelose nucleosides, several modifications 
will need to be explored. Figure 4.6 shows the potential areas where chemical 
modifications can be made. 
 
Figure 4.6: 4’-thiohamamelose showing potential areas of chemical modification 
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Since it has been shown that the 2’-C-hydroxymethyl group is essential to binding, 
and it has been shown that fluorine at C-2 is also essential for activity in the HCV 
replicase complex, figure 4.5 shows that several series of compounds can be 
synthesised to assess the importance of the C-3 OH, C-2 OH, and the 2’-CH2OH 
groups for binding by varying where the fluorine atom or hydroxyl group is bound. 
In the first series, X, Y, Z are all OH groups and the SAR of the nucleobases can be 
assessed. This first library was planned to have 11 members within it to give a 
comprehensive overview of how varying the nucleobases affects activity. Table 4.2 
shows the potential number of compounds that can be synthesised to assess the 
SAR of the 4’-thiohamamelose nucleosides. 
Table 4.2: Variations to sugar ring groups for assessment of SAR in 4’-thiohamamelose nucleosides 
Series X Y Z N
o 
of compounds 
1 OH OH OH 11 
2 OH OH F 11 
3 OH F OH 11 
4 F OH OH 11 
5 OH F F 11 
6 F OH F 11 
7 F F OH 11 
8 F F F 11 
 
The table shows that 8 series of compounds can be synthesised to assess the SAR 
of the 4’-thiohamamelose moiety for a total of 88 potential compounds since each 
series can have up to 11 nucleobases attached to the hamamelose ring. The 
nucleobases have been chosen to keep the libraries consistent with the thietane 
libraries in chapter 2. This way comparison between the libraries and each series can 
be made.  
In addition to the series shown in table 4.3, the L-4-thiohamamelose moieties can 
also be explored as L-series ribose based nucleosides have shown anti-HIV and anti-
HBV activity.11,14 Not only does this increase the number of compounds that can be 
potentially synthesised, but it also broadens to scope of potential viruses that these 
compounds can target, and therefore, a greater chance that a hit compound can be 
found. 
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4.3.2 Synthetic strategy towards the 4’-thiohamamelose 
nucleosides 
In scheme 4.1 the proposed synthetic route for potential entry to the 4’-
thiohamamelose nucleosides is shown. 
 
Scheme 4.1: Proposed synthetic steps to 4’-thiohamamelose nucleosides i) Acetone, H2SO4 RT 3 hrs 
ii) TrCl, Pyridine, RT, 20 hrs iii) Formaldehyde, Methanol, K2CO3, 70° C, 20 hrs iv) Br2, K2CO3, DCM, 
RT, 3 hrs v) TBDPS-Cl, Imidazole, DCM, RT, 12 hrs vi) NaOH, Me2SO4, DMSO, RT, 3 hrs vii) PPh3, 
Imidazole, I2, DCM, 120°C, 6 hrs viii) AcSH, TBA-OH, toluene, RT, 18 hrs ix) DIBAL-H, toluene, 2 hrs 
x) CBr4, PPh3, DCM, -25° C, 1 hr xi) AgOTf, 135°C, μwave, DCE/MeCN, 30 mins 
Synthesis of the 4’-thiohamamelose nucleosides can potentially be achieved using 
the Pummerer reaction by first converting thiohamamelose derivative 208 to the 
sulfoxide 212 (figure 4.7) using NaIO4.
43 
 
Figure 4.7: Pummerer Reaction for the formation of nucleosides 
However, due to problems using the Pummerer reaction for the synthesis of the 
thietane nucleosides as described in chapter 2, and the success of using Vorbrüggen 
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conditions for the thietane nucleosides in the same chapter, it was decided that 
conversion of thiohamamelose derivative 208 to bromide 209 would allow access to 
the nucleoside derivatives of compound 210 using AgOTf.44 
The synthetic plan utilises known chemistry. Conversion of ribose 199 to acetonide 
200 can be achieved using acetone and sulfuric acid.45 Protection using a trityl group 
is necessary and a large group such as the trityl group will favour protection of the 
primary C-5 hydroxy group over the anomeric hydroxyl group allowing for selectivity 
between them, to furnish the literature compound trityl 201.46 Adding the 
hydroxymethyl group to C-2 can be achieved by use of formaldehyde in methanol 
and potassium carbonate to furnish hamamelose 202.47,48 Oxidation of hamamelose 
202 to ribolactone 203 can be achieved using bromine oxidation which is useful as it 
is mild and selective for oxidation of the anomeric hydroxyl group.49 Next, protection 
of the 2’-C-hydroxymethyl group with a TBDPS group to afford ribolactone 204 will 
allow for selectivity toward deprotection as it can be removed with Bu4NF, whilst the 
acetonide and trityl group can be removed with acid or other means.50 Also, the 
TBDPS group is stable toward NaOH as are the acetonide and trityl group which 
allows for the formation of methyl ester 205.51 The next series of reactions form the 
4’-thiohamamelose sugar. First the ring is cleaved open with NaOH and then reacted 
with Me2SO4 to furnish methyl ester 205, which is then converted to the iodo moiety 
206 and cyclisation is achieved with thioacetic acid to yield 207 and DIBAL-H to give 
4,-thiohamamelose derivative 208.32,44,52,53  
4.4 Results and Discussion: Steps Toward the Synthesis of 4’-
thiohamamelose Nucleosides 
Two methods were trialled for the synthesis of acetonide 200 from ribose 199; the 
initial method used 0.01 equivalents of pTSA, acetone as a solvent and a reagent, 
and 2,2-dimethoxypropane to furnish acetonide 200 with a yield of 69% after 
purification by column chromatography using ethyl acetate as the eluent. The second 
method utilised ribose 199, acetone as a solvent and dropwise addition of 
concentrated sulfuric acid to furnish acetonide 200 with a yield of 85% after 
purification by column chromatography. The sulfuric acid method gave consistently 
more reproducible yields than the pTSA method (table 4.3) and as such the sulfuric 
acid method was used on subsequent scale up. 
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Table 4.3: Comparison of yields between the pTSA method and the sulfuric acid method 
Reaction Scale (g) pTSA yield (%) Sulfuric acid yield 
(%) 
1 2 62 85 
2 5 44 Quant 
3 10 69 Quant 
4 150 44 Quant 
5 200 - Quant 
 
The pTSA method showed more variation in total yield after purification by column 
chromatography than the sulfuric acid method. This variation in yield for the pTSA 
reaction could be accounted for by the production of the pyranose form of ribose 
being. There was some indication of the pyranose form of ribose being formed after 
13C NMR spectroscopic analysis of the reaction products. The data showed two 
peaks at 94 ppm which are indicative of the C5 carbon in the pyranose form (these 
two peaks are the α and β anomers). These peaks were not observed in the furanose 
form of ribose, with the C5 carbon for the CH2OH group being observed at 63 ppm. 
Comparison of the 1H NMR spectroscopic data of the crude reaction material and the 
purified material for the sulfuric acid method showed no real differences post work 
up, whereas the 1H NMR spectroscopic data for the pTSA crude reaction material did 
show differences, further indicating that the pyranose form was present. Since the 
sulfuric acid reactions did not show formation of a pyranose form in the crude or the 
pure proton and carbon NMR spectroscopic data, reactions 2 – 5, the organic phase 
was washed to remove any residual salts (NaHCO3 was used to neutralise the acids) 
and the crude material flushed through a plug of silica under vacuum and was used 
crude in subsequent steps. Though both 5 and 6 membered rings are 
thermodynamically stable, with 6 membered rings being more stable than 5 
membered rings, it would be expected to see more pyranose forms than furnanose 
forms of ribose for both reactions. However, formation of the furanose form may be 
kinetically more favourable than the pyranose form. Therefore, with shorter reaction 
times (1 – 2 hours) using sulfuric acid, versus overnight for the pTSA reaction, it 
would be expected that the pyranose form of ribose would be seen using pTSA. The 
rate of formation of the pyranose form may be slower than the rate of formation of the 
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furnose form when using either acid, so longer reaction times would allow more time 
for an equilibrium to be established, allowing for the pyranose form of ribose to form. 
 
Scheme 4.2: Large scale synthesis of acetonide 200 using acetone and sulfuric acid 
The 1H NMR spectroscopic data for acetonide 200 confirmed the presence of the 
acetonide methyl groups as two singlets at 1.3 and 1.5 ppm. The data also showed 
that the anomeric proton existed as 1:1 ratio of the α and β anomers, of which the α 
anomeric proton was observed at 5.4 ppm and the β anomeric proton was observed 
at 4.5 ppm (figure 4.8). This data matched the known literature values within 0.1 
ppm.50  
 
Figure 4.8: 
1
H NMR spectrum of acetonide 200 
The methylene protons were observed at 3.8 ppm. The characteristic doublets of the 
three remaining CH bonds on the ribose ring were also observed with J coupling 
constants of 6 Hz. This data matched closely with the literature values of 1.3 and 1.5 
ppm for the acetonide methyl groups, 3.8 ppm for the methylene protons and the 
expected CH protons were also observed with a coupling constant of 6 Hz.50 IR 
spectroscopy data confirmed the presence of the hydroxyl group at 3400 cm-1 and 
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the mass spectrum data gave the mass ion peak of the sodium adduct at 213.0744 
Da with the expected value at 213.0740 Da. 
Next, trityl protected moiety 201 was synthesised in several small batches ranging 
from 5 – 15 g (scheme 4.3). In initial reaction conditions where 1 equivalent of trityl 
chloride were used, the reaction failed to go to completion and thus the reaction was 
optimised (table 4.4). 
 
Scheme 4.3: Synthesis of trityl moiety 201 i) trityl chloride, pyridine, RT, 48 hrs, 82% 
Table 4.4: Optimisation reactions for the protection of the 5’-OH group using trityl chloride 
Reaction Trityl Chloride Equivs Outcome 
1 1 Reaction did not go to completion after 48 hours 
2 1.1 Reaction did not go to completion after 48 hours 
3 1.5 Reaction did not go to completion after 48 hours 
4 2 Isolated yield: 82% after 48 hours 
 
Reactions 1 – 4 are the same reaction with each equivalent added after 48 hours 
total reaction time. In the first 48 hours, analysis of the crude reaction mixture by TLC 
revealed starting material and product was still present. 0.1 equivalents was then 
added and reacted for a further 48 hours and this was repeated until a total of 2 
equivalents of trityl chloride was added and TLC analysis of the crude reaction 
mixture revealed total consumption of the starting material. After purification by 
column chromatography, the yield was found to be 61%. The reaction was repeated 
with 2 equivalents of trityl chloride and stirred at room temperature for 48 hours to 
give trityl moiety 201 with a yield of 82%. Since the reaction is an SN1 reaction where 
the chlorine atom must leave before formation of the trityl cation, increasing the 
number of equivalent should not increase the rate of reaction. However, increasing 
the number of equivalents of trityl chloride did improve the yield of the reaction, and 
this is possibly due to the trityl chloride hydrolysing in the reaction. Though 
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glassware, reagents and solvents were dry, the ribose 200 used may have absorbed 
water as it was weighed. (Ribose 200 was dried under high vacuum to remove water, 
but as it was a thick gel, it may have had residual water and would have absorbed 
water as it was weighed). Any water present in the ribose would have hydrolysed the 
trityl chloride to trityl hydroxide. By increasing the number of equivalents of trityl 
chloride, the effects of hydrolysis on reaction yields could be overcome. Significant 
optimisation of the column chromatography conditions were required to isolate trityl 
201 and this was due to the problem of trityl hydroxide co-eluting with the product.  
Analysis of the purified product by 1H NMR spectroscopy revealed the α:β ratio to be 
1:5 and this was found by comparing the α proton signal at 5.75 ppm to the β proton 
signal at 5.32 ppm and finding the ratio between them (figure 4.9). 
 
Figure 4.9: Proton NMR spectroscopic data for trityl moiety 201 
The methylene protons indicated by 4 in figure 4.8 are found as two doublets each 
integrating to 1. The anomeric protons, of which there are two, are the α and β 
anomeric protons giving the compound in a 1:1 α:β ratio. The IR spectroscopic data 
gave the anomeric hydroxyl group at 3308 cm-1 and the phenyl groups were 
observed at 2963 cm-1. Mass spectrometry data for the sodium adduct found the 
mass ion peak to be 455.1829 Da with the calculated mass found to be 455.1826 Da 
for the sodium adduct. 
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4.4.1 Model Formylation Reactions 
Prior to the formylation reaction to form hamamelose 202 from trityl 201 (scheme 
4.4), the formylation reaction was optimised using a model compound, using known 
chemistry.47,48  
 
Scheme 4.4: Synthesis of hamamelose 202 i) formaldehyde, methanol, K2CO3, 66° C, 97% (crude 
yield) 
Ho et al published a reaction in 1978 that showed synthesis of hamamelose 214 from 
acetonide 200 (scheme 4.5). However, as table 4.5 shows, this reaction could not be 
reproduced.48 
 
Scheme 4.5: Synthesis of hamamelose by Ho et al
48
 
Table 4.5: Formylation reaction conditions 
Reaction Conditions Outcome 
1 8 equiv CH2O 1.1 equiv K2CO3, methanol, Reflux 
20 hrs 
No reaction 
2 8 equiv CH2O 1.1 equiv K2CO3, methanol, 66° C 
20 hrs 
No reaction 
3 8 equiv CH2O 1.5 equiv K2CO3, methanol,  66° C 
24 hrs 
No reaction 
4 8 equiv CH2O 1.5 equiv K2CO3, methanol,  66° C 
20 hrs 
No reaction- Acetonide 
peaks were not seen at their 
expected chemical shift by 
 140 
 
1
H NMR spectroscopic 
analysis  
5 2 equiv CH2O 1.1 equiv K2CO3, methanol,  66° C 
20 hrs 
No reaction 
6 2 equiv CH2O 1.5 equiv K2CO3, methanol,  66° C 
24 hrs 
No Reaction 
7 8 equiv CH2O 1.1 equiv K2CO3, methanol,  75° C 
20 hrs 
No reaction- Acetonide 
peaks were not seen at their 
expected chemical shift by 
1
H NMR spectroscopic 
analysis 
8 2 equiv CH2O 1.5 equiv K2CO3, methanol,  65° C 
20 hrs 
1
H NMR spectroscopic 
analysis on isolated material 
(97.5:2.5 CHCl3:EtOH 
column) revealed an impure 
product. Subsequent 
attempts to purify the 
material could not isolate the 
product. 
 
Reaction 1 shows the conditions used by Ho et al., and these conditions could not be 
reproduced. (The reaction used 39% w/w CH2O in water as the reagent and solvent). 
No reaction was observed, and 1H NMR spectroscopic analysis of the crude reaction 
mixture post work-up showed only ribose 200 was present. Increasing the 
temperature and increasing the number of equivalents of potassium carbonate did 
not aid in a reaction occurring.  
In reactions 4 and 7, the acetonide methyl group peaks were observed as moving 
from 1.3 and 1.5 ppm to 1.5 and 2 ppm. However, the 2’-C-hydroxymethyl group 
protons were not observed. This indicates that what was observed was a side 
product; potentially due to a deprotonation at C-2 and subsequent reaction with water 
resulting in a hydroxyl group at C-2. Since chloroform was used as the solvent for the 
1H NMR spectroscopic data, this hydroxyl group may not have been observed. 
Changing the NMR solvent to DMSO and then utilising a D2O shake could have 
confirmed if this occurred for reactions 4 and 7.  
 141 
 
Reaction 8 did show that a reaction had occurred, however, the products could not 
be isolated. Spectroscopic analysis of reaction 8 using 13 C NMR was inconclusive as 
to whether the resulting impure product contained the pyranose and furanose forms 
of hammamelose 214 as there were multiple peaks at 94 ppm, which is indicative of 
the CH2 group in the pyranose form of ribose. From this data, it can be assumed that 
excess formaldehyde may have a negative impact on the rate of reaction. 
Although the reaction conditions by Ho et al. could not be reproduced, and 
optimisation of the reaction could not be achieved, the model reaction allowed 
confirmation that the 5’-OH group required protection prior to the formylation reaction 
being used.48  
Beigelman et al. showed that trityl hamamelose 202 could be synthesised from trityl 
ribose 201 using the same reactions conditions as Ho et al.47,48 The difference being 
that under Beigelman et al. reaction conditions, 30 equivalents of formaldehyde were 
required for the reaction (scheme 4.4) versus only 8 equivalents under the reaction 
conditions by Ho et al.47,48 Table 4.6 shows optimisation data for the conversion of 
trityl ribose 201 to trityl hamamelose 202. 
Table 4.6: Optimisation of the formylation reaction towards 5’-O-trityl-hamamelose 
Reaction Conditions Outcome 
1 30 equiv CH2O 1.1 equiv K2CO3 65° C 20 hrs Crude product 29% mass 
recovery 
2 30 equiv CH2O 1.5 equiv K2CO3 Reflux 20 hrs Crude product 33% mass 
recovery 
3 30 equiv CH2O 1.1 equiv K2CO3 65° C 24 hrs Crude product 46% mass 
recovery 
4 30 equiv CH2O 1.1 equiv K2CO3 65° C 24 hrs Crude product 71% mass 
recovery 
5 30 equiv CH2O 1.1 equiv K2CO3 65° C 20 hrs Crude product 82% mass 
recovery 
 
Initially the yields for the reaction were low and required optimisation. Although 
Beigelman et al. reported that the potassium carbonate and formaldehyde solution 
were to be added to the sugar in methanol, and reported a 72% yield; it was 
observed that following this method of addition resulted in low yields. In reactions 4 
 142 
 
and 5, the potassium carbonate and methanol were allowed to reach 65° C first, and 
then trityl ribose 201 was added. Then the formaldehyde was injected dropwise. This 
gave the high yields for reactions 4 and 5 and was done because it was suspected 
that if the formaldehyde was added all at once, in the reaction conditions, it could 
possibly oxidise to formic acid and thus deprotect the acetonide group.  
Attempts to purify the hamamelose 202 using 2.5% ethanol in chloroform could not 
adequately give a pure sample. However, comparing the 1H NMR spectrum of the 
crude reaction material to the post-column 1H NMR spectrum did show that some of 
the impurities had been removed. The crude material was found to have a purity of 
60 – 70% after analysis of the 1H NMR spectrum. Therefore, hamamelose 202 was 
used in its crude form in the next step after analysis of the 1H NMR spectrum 
revealed the additional CH2 methylene group at 3.7 ppm as a multiplet, and the CH 
proton at C-2 in trityl moiety 201 at 3.9 ppm is no longer present in hamamelose 205. 
The mass spectrum data for the crude material revealed the expected mass ion peak 
for the sodium adduct at 485.1935 Da which was calculated to be 485.1931 Da. This 
gave enough confidence to use the material in the next step. 
The attempted synthesis of hamamelose 202 shows that excess formaldehyde may 
be problematic, and is concordant with the data from the Ho model reactions. In both 
of these sets of reactions, excess formaldehyde either did not result in a reaction, or 
had a negative effect on product formation. Therefore, further reactions would involve 
optimising the number of equivalents of formaldehyde for the most efficient 
conversion to hamamelose, as it is suspected that formic acid may form with longer 
reaction times.To combat this, the number of equivalents of base would need to be 
optimised also as excess base may neutralise any formic acid present, and thus 
limiting the impact it potentially has on the reaction. 
4.4.2 Optimisation of the Oxidation Reactions 
The next reaction to be modelled was the bromine oxidation of hamemelose 202 to 
hamamelolactone 203 (scheme 4.6).  
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Scheme 4.6: Synthesis of hamamelolactone 203 
The reaction conditions by Stewart et al used water as the solvent for ribose, and 
DCM for any protected carbohydrate.49 Before using hamamelose 202 as the 
reactant, ribose 200 was used for the model reaction for the synthesis of ribolactone 
215 (scheme 4.7).  
 
Scheme 4.7: Synthesis of ribolactone 215. 1 equivalent bromine 1.1 equivalent K2CO3 in water, 98%. 
Ribose 200 was dissolved in water and the potassium carbonate was added in one 
portion and the reaction cooled to 0° C with an ice water bath. Bromine was added 
dropwise and the reaction stirred for several hours until completion was observed by 
TLC analysis (100% ethyl acetate as eluent). Excess bromine was removed using 
sodium thiosulfate solution and then ethyl acetate was added. The crude reaction 
was boiled in ethyl acetate momentarily and then cooled back to 0° C and the product 
was precipitated by the addition of hexane.45,49 Ribolactone 215 was successfully 
synthesised with a yield of 98%. However, though the oxidation reaction worked for 
the model compound, synthesis of the trityl protected hamamelolactone 203 would 
be difficult if not impossible in water as it is not soluble.  
The synthesis of hamamelolactone 203 was optimised using DCM using protocols 
established by Stewart et al by first optimising the reaction with trityl ribose 201 in 
DCM (scheme 4.8).49 
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Scheme 4.8: Optimisation of the bromine oxidation reaction toward ribolactone 216 from trityl ribose 
201. 1 equivalent of bromine, 1.5 equivalents of K2CO3 in DCM  
As table 4.7 shows, it was possible to optimise the reaction. Initially, use of 1.1 
equivalents of potassium carbonate was insufficient for the reaction to proceed well. 
Analysis of column factions using 1H NMR spectroscopic analysis revealed that the 
acetonide and the trityl group were labile. This could be due to the bromine forming 
HBr in solution in a greater excess than the 0.1 equivalent excess of potassium 
carbonate. When the equivalents of potassium carbonate were increased to 1.5 
equivalents, ribolactone 216 was isolated pure with a yield of 43%. The crude 
reaction mixture was analysed by 1H NMR spectroscopy which revealed the 
acetonide and trityl group were still labile, but not to such a great extent, and as such, 
the crude could be purified and the product isolated. 
Table 4.7: Optimisation of the bromine oxidation reaction in DCM shown in scheme 4.8 
Reaction Conditions Outcome 
1 0° C, 3hrs, 1.1 equiv K2CO3 DCM Unknown purity product 12% 
2 0° C, 3hrs, 1.1 equiv K2CO3 DCM Unknown purity product 9% 
3 0° C, 3 hrs, 1.5 equiv K2CO3 DCM Isolated pure 43% 
 
Since the bromine oxidation reaction was selective for the anomeric hydroxyl group 
(as seen in the oxidation of acetonide 200, no oxidation of the 5’-OH group was 
observed), and the reaction was optimised for the synthesis of ribolactone 216, 
synthesis of hamamelolactone 203 could proceed (scheme 4.6).  
Despite optimisation toward ribolactone 216, formation of hamamelolactone 203 
required further optimisation (table 4.8). 
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Table 4.8: Optimisation of the bromine oxidation toward 5’-O-tritylhamamelolactone 203 shown in 
scheme 4.8 
Reaction Conditions Outcome 
1 0° C, 3hrs, 1.5 equiv K2CO3 
DCM 
No observed reaction: Acetonide and trityl group no 
longer bound when the reaction mixture was analysed 
by 
1
H NMR spectroscopy 
2 0° C, 3hrs, 1.5 equiv K2CO3 
DCM 
No observed reaction: Acetonide and trityl group no 
longer bound when the reaction mixture was analysed 
by 
1
H NMR spectroscopy 
3 0° C, 3 hrs, 1.5 equiv K2CO3 
DCM 
12% of an impure product. Some peaks could be 
assigned to the product when 
1
H NMR spectroscopic 
data was analysed 
4 RT, 3 hrs, 1.5 equiv K2CO3 
DCM 
27% of an impure product. 
5 RT, 24 hrs, 1.5 equiv K2CO3 
DCM 
19% of an impure product 
 
Unfortunately the optimised conditions for the synthesis of ribolactone 216 did not 
work; therefore some further optimisation was required for the synthesis of 
hamameloacton 203. For reasons that are as of yet unknown, keeping the reaction at 
0° C did not yield any product that could be isolated. Though a reaction occurred in 
the first 3 reactions in table 4.6, analysis of the crude reaction mixtures and the 
impure column fractions by 1H NMR spectroscopic analysis revealed some peaks 
that could be assigned to the product, and a significant number of peaks that could 
not be easily assigned. Also, the 1H NMR spectroscopic data showed that the 
acetonide and trityl groups were labile under these reaction conditions, which means 
that an acid was forming or had formed in solution. This acid could have also been 
introduced from the bromine, as it can contain some HBr naturally.  
The reactions were repeated at room temperature and better yields were obtained. 
Initially, a 27% yield of crude hamamelolactone 203 was obtained, and in order to 
improve this yield, the reaction was left to react for 24 hours; however, this did not 
improve the yield. In fact, the yield dropped to 19%. Analysis of the crude reaction 
mixture by TLC analysis did show consumption of starting material, but several spots 
were identified therefore the end point was hard to judge. 1H NMR spectroscopic 
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analysis of the crude mixture confirmed that the reaction has gone to completion at 3 
hours, and leaving the reaction for longer was detrimental. However, subsequent 
purification steps using flash column chromatography did not yield a pure product. 
Comparing the 1H NMR spectra for trityl moiety 203 and hamamelolactone 203 
showed that no anomeric protons were present at 5.3 – 5.5 ppm in hamamelolactone 
203, which was expected. Mass spectrometry data of the partially purified 
hamalelolactone 203 gave a mass ion peak for the sodium adduct at 483.1791 Da 
with an expected mass of 483.1784 Da. This confirmed that the product had been 
recovered crude and was thus used crude in the next step. However, the purity was 
not possible to determine accurately by 1H NMR spectroscopy. 
With the synthesis of the hamamelolactone derivative 203 tentatively achieved, the 
2’-C-hydroxymethyl hydroxyl group was protected with a tert-butyldiphenylsilyl 
chloride (TBDPS) without the need to optimise this reaction with a yield of 44% 
(scheme 4.9). 
 
Scheme 4.9: Synthesis of hamamelolactone 204 i) TBDPS-Cl, imidazole, DCM, RT, 24 hrs, 44% 
crude product 
Purification by column chromatrography did not fully purify the compound, and 
analysis of the column fractions by TLC revealed that some of the TBDPS-OH had 
co-eluted with the compound. This at first implied that the TBDDPS group was labile, 
though the column contained 1% triethylamine to neutralise the silica in an attempt to 
reduce this risk. TLC of the crude reaction mixture prior to purification by column 
chromatography did reveal completion as total consumption of the TBDPS-Cl was 
observed. Therefore, it can be concluded that the TBDPS group was labile on the 
column. However, shown in figure 4.9 is the semi-purified 1H NMR spectrum for 
TBDPS moiety 204. 
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Figure 4.10: 
1
H NMR spectrum of TBDPS moiety 204 
As can be seen from the spectrum in figure 4.9, there are still significant levels of 
TBDPS impurity in the post column fractions that could not be removed as it co-
eluted with the product. The impurities in spectrum shown in figure 4.9 are at 1.5 ppm 
for the tert-butly groups and at 7.5 and 7.9 ppm for the phenyl groups of the TBDPS-
OH impurity. However, protons 5 and 7 are present as the two CH groups which 
integrate to 1 and the two methylene groups are also present and are shown as 
protons 4 and 6. The mass spectrum data for TBDPS moiety 204 was found to be 
721.3115 Da for the sodium adduct and the calculated mass was 721.2961 Da. This 
gave confidence that the compound had been successfully synthesised despite the 
large impurities present in the product. The impurities are the 1.2 ppm and 7.5 ppm 
and at 7.8 ppm for the tert-butyldiphenylsilyl hydroxide impurity that co-eluted with 
the product, TBDPS moiety 204. 
4.4.3 Hydrolysis Reactions Toward Methyl Ester 205 
In order to synthesise the 4’-thiohamamelose  206, the following transformations from 
TBDPS moiety 202 are required (scheme 4.10) 
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Scheme 4.10: Proposed synthetic steps toward 4’-thiohamamelose 208 i) NaOH, Me2SO4, DMSO, 
RT, 3 hrs ii) PPh3, Imidazole, I2, DCM, 120°C, 6 hrs iii) AcSH, TBA-OH, toluene, RT, 18 hrs iv) DIBAL-
H, toluene, 2 hrs 
In order to incorporate the sulfur atom, the proposed synthetic scheme in scheme 
4.10 utilises the reaction conditions used by Secrist et al. to furnish 4’-thio-2’,3’-
dideoxyribose nucleosides.32 In the first step, TBDPS 204 is hydrolysed to a 
carboxylic acid using NaOH and then dimethyl sulfate is added to furnish methyl 
ester 205. Then iodine is introduced to the compound to form the iodo derivative 206 
which is reacted with thioacetic acid to form thioether 207 which is cyclised to 4’-
thiohamamelose moiety 208. 
Before subjecting TBDPS moiety 204 to basic conditions, the hydrolysis reaction was 
first trialled with ribolactone 215 with the expectation of first isolating acid 217 
(scheme 4.11). 
 
Scheme 4.11: Model hydrolysis reaction toward acid 217 using NaOH  
Replication of the Secrist reaction conditions using 1 equivalent of NaOH in water did 
not yield any product. Analysis of the reaction mixture by TLC showed only the 
starting ribolactone 215 was present even after 24 hours. Table 4.9 shows the 
attempts to optimise the hydrolysis reactions. 
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Table 4.9: Attempted optimisation for the model hydrolysis reactions 
Reaction NaOH (equiv) Outcome 
1 1 No reaction 
2 1.5 No reaction 
3 2 No reaction 
4 5 No reaction 
 
In all cases, no reaction was observed by TLC analysis of the crude reaction mixture. 
The 1H NMR spectroscopic data also confirmed that no reaction had occurred in any 
of the reactions as the data matched that of the starting material, ribolactone 215 
(figure 4.11). Each reaction was first reacted at room temperature and initially for 1 
hour as per the conditions set out by Secrist. The reactions were left to react for 24 
hours at room temperature, and no reactions were observed. Increasing the number 
of equivalents was trialled as this could increase the rate of reaction, but this had no 
effect. The failure of the reactions to proceed could be due to room temperature (25 
°C) was not adequate enough to initiate the reaction, as this reaction may have a 
higher than expected activation energy. Increasing the reaction temperature would 
be the logical next step to assess whether this reaction is feasible. However, his was 
not done in this line of research as there were concerns for the stability of the TBDPS 
group towards mineral base for the formation of ester 205. The TBDPS group is 
stable to base up to pH 12 at room temperature, and heating ester 205 in base will 
lead to deprotection of the TBDPS group. 
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Figure 4.11: 
1
H NMR spectrum of ribolactone 215 
As can be seen, the methyl groups on the acetonide are present as are the CH 
protons on the ribose ring. If hydrolysis had occurred, an extra –OH peak at around 3 
– 4 ppm should be observed and a broad peak at 11 – 12 ppm should also be 
observed which would be indicative of the carboxylic acid. This 1H NMR 
spectroscopic data coupled with TLC analysis that showed no product formation 
confirmed that the hydrolysis reactions for the model compound were not working.  
Since the Secrist method for the hydrolysis of ribose 215 could not be replicated and 
were deemed inappropriate to use for the formation of ester 205, other methods were 
sought but a literature search did not reveal methods that were deemed acceptable 
to use for the hydrolysis of TBDPS moiety 204 such as boiling methanol with base as 
it was suspected that global deprotection would occur. Therefore, work toward the 
hydrolysis of TBDPS moiety 204 was stopped and further evaluation of the synthetic 
route is required. 
In general, the current synthetic scheme has shown several other areas where 
optimisation is still required. Although the formylation reaction was optimised towards 
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hamamelose 202, purification of this compound proved difficult and as such mass 
spectrometry and 1H NMR spectroscopic data of the crude product had to be used to 
determine if the reaction had indeed been successful. Further, oxidation to 
hamamelolactone 203 requires further optimisation of the purification reactions as 
this compound could not be isolated in its pure form either, though this is 
compounded by the fact that the starting material was not pure. This, however, did 
not hamper the synthesis of TBDPS moiety 204 as attempts to purify the product by 
column chromatography was sufficiently successful to remove the impurities from the 
previous two steps. However, the TBDPS-OH impurity did co-elute with the TBDPS 
moiety 204, therefore the purification step still requires optimisation. Therefore, 
coupled with the need to optimise the hydrolysis reaction toward methyl ester 205, 
significant work is required to optimise the purification and reaction conditions of the 
preceding steps in this synthetic plan. 
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Chapter 5: Conclusions and Future Work 
Viral infections are a common cause of illness and death in humans, but due to the 
rapid rate at which viruses are able to replicate, resistance to current drugs evolves 
quickly.1 Nucleoside drugs are the most powerful types of compounds for treating 
viral infections as they are able to completely halt viral genome replication.2-4 Without 
a fully functioning genome, the virus is unable to replicate and the infection is stalled. 
Practically all of the currently available nucleoside drugs available on the market are 
based upon ribose so as to closely resemble endogenous nucleosides. This ensures 
that the host and viral enzymes and transport proteins are able to utilize these drugs. 
However, inactivity of nucleoside drugs based on ribose is still a problem. The most 
prominent issue is the discrimination between kinases and polymerases. In order to 
be incorporated into a genome, the nucleoside must first be phosphorylated.5,6 
Ribose nucleosides exist in north and south conformations, but kinases only 
recognise south conformations and polymerases only recognise north conformations 
of the nucleoside.5,6 This means that the ribose nucleosides must be in the correct 
conformation to be phosphorylated, and then change conformation prior to entering 
the polymerase and being incorporated into the genome. This is a significant reason 
why potentially active ribose based nucleosides have low NTP concentrations in the 
cell. 
A further issue that compounds the problem of kinase-polymerase bias is that the 
first kinase in the phosphorylation step is discriminatory.7-12 This means that even if 
the conformation of the nucleoside is correct, the first kinase in the phosphorylation 
step may not recognise the nucleoside, and not phosphorylate it. This further reduces 
the NTP concentration in the cell. Both of these problems have been overcome by 
research into phosphoramidate chemistry. By masking the 5’-OH group with a 
phosphoramidate, the primary kinase could be bypassed.7,8 This led to higher levels 
of NTP in cells, and for nucleosides that were previously inactive, creating their 
phosphoramidate derivatives made the previously inactive drug, active. 
Despite overcoming the major problem of phosphorylation and kinase-polymerase 
bias, ribose based nucleoside drugs were also found to be prone to the action of 
PNPs.13-15 This is a class of enzymes that hydrolyse the glycosidic bond betweem the 
ribose and the nucleobase. This too is a significant cause of inactivity. A major 
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method to overcome this involves replacing the oxygen in the ribose ring with sulfur 
to make 4’-thioribose nucleosides. It was found that these were less susceptible to 
PNPs, with longer half-lives than their ribose counterparts, and stronger binding 
affinities.  
Another way to overcome conformational discrimination by kinases was to use 
alternative sugars. Oxetane nucleosides were shown to be phosphorylated by 
kinases, despite existing in pseudo-north and pseudo-south conformations, and were 
shown to be active, which meant that these compounds were being incorporated into 
viral genomes by polymerases. However, oxetane nucleosides were still susceptible 
to PNPs.16-27  
5.1 General Conclusions 
Thietane nucleosides have previously been shown to be active against HIV-1 and it 
is hypothesised that they will be resistant to PNPs. It is also assumed that these 
drugs will be phosphorylated and overcome kinase-polymerase bias as already 
active anti-HIV thietane nucleosides are known.25-27 The 3,3-bis(hydroxymethyl)-
thietan-2-yl nucleosides were explored in this programme as potential anti-viral 
compounds for the reasons outlined above. Although the thymine derivative for this 
scaffold is known, its anti-viral activity has not been explored. A library of nine 
nucleosides, seven of which are novel, were synthesised with the aim of exploring 
their anti-viral activity.  
The 4,4-bis(hydroxymethyl)-thietane scaffold is completely novel and the intention 
was to explore how modifications to the thietane ring would affect the anti-viral 
properties of the thietanes. This would have been achieved by creating analogous 
compounds to those in the 3,3-bis(hydroxymethyl)-thietan-2-yl nucleosides, and 
comparing their activity. 
The 4’-thiohamamelose nucleosides were of interest as hamamelose nucleosides 
were shown to be active against HCV, despite having low IC50 values due to 
metabolic instability. As already shown, converting ribose to 4’-thioribose increased 
the half-life of the nucleoside drug, meaning that its bioavailability increased. 
Exploration of the 4’-thiohamamelose nucleosides as a way to increase their 
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metabolic stability could have beneficial effects on the anti-viral properties of this 
class of compound.  
 
Figure 5.1: The two thietane scaffolds and the 4’-thiohamamelose scaffolds are shown. The scaffolds 
for the 3,3-bis(hydroxymethyl) (library 1) and 4,4-bis(hydroxymethyl)-thietane (library 2) nucleosides 
vary by the position of the hydroxymethyl groups. In library 1, nucleosides are varied. The biological 
activity of each nucleoside will give an indication of the SAR for this library. In library 2, the 
hydroxymethyl group position is altered. By using the same nucleobases as those in library 1, the 
effect of the hydroxymethyl group on the SAR can be determined. Library 3, the 4’-thiohamamelose 
nucleosides will also use the same nucleobases as the first two libraries, however, the SAR will 
determine whether 4’-thiohamamelose nucleosides have better anti-viral properties versus 
hamamelose nucleosides in the literature. From each library, the biological data will be used to 
determine the SAR with the intent of designing and synthesising more potent compounds for each 
scaffold. 
5.2 Future Work 
Detailed below is the intended work to determine the SAR of each scaffold discussed 
previously in section 5.1. In order to meet these requirements, the following scheme 
of work is proposed. 
5.2.1 Synthesis of 3,3-bis(hydroxymethyl) thietane nucleosides 
The synthetic route to 3,3-bis(hydroxymenthyl)-thietan-2-yl nucleosides required 
efficient synthesis of key precursor fluorothietane 76. It was found that the Pummerer 
reaction towards the synthesis of the nucleosides was not reproducible, and did not 
yield the desired nucleosides. However, from fluorothietane 76 it was found that the 
3,3-bis(benzoylmethoxy)-thietan-2-yl nucleosides could be synthesised with yields 
ranging from 39 – 75%. Deprotection reactions toward the target nucleosides using 
NaOMe or MeNH2 were achieved with yields in excess of 80 – 90% from the benzoyl 
protected moieties (scheme 5.1). This furnished nine thietane nucleosides, seven of 
which are novel.  
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Scheme 5.1: General synthetic scheme to target nucleosides from fluorothietane 76 i) silylated 
nucleobase, AgClO4, SnCl2, DCM, RT, 18 hrs,  57% ii) MeNH2, EtOH, RT, 2 hrs, 98% 
With the nine nucleosides synthesised determination of their anti-viral activities is 
now possible. Prior to an anti-viral screen, the cytotoxic effects of the nucleosides 
require assessment. The desired outcome would be that no cytotoxicity would be 
observed. Four candidate compounds that best represented the library were chosen 
for cell viability testing. The cell viability assay used SH-SY5Y neuroblastoma cells, 
since the density of the cells meant that a more intense signal could be detected. 
This was important as it meant that assessing cell viability could be attributed to the 
compounds and not to any other biological reasons. XTT was used as the agent to 
determine the number of viable cells by measuring the optical density. The XTT 
assay relies on cellular respiration, therefore, only measures respiring cells as viable. 
In cells that have long exponential growth phases, some of the cells may not be 
actively respiring, which the assay would determine as non-viable.  
The XTT assay was used to establish if the thietane nucleosides were affecting cell 
viability. If any compounds were shown to negatively affect cell viability, they would 
not proceed to the broad anti-viral screen. Therefore, the XTT assay was used as a 
pre-screening method to determine whether compounds proceeded to an anti-viral 
screen. Cytotoxic compounds would not be ideal candidates for the anti-viral screen 
as their anti-viral activities would be hard to determine if the cells were dead. 
The cell viabilities were established for four candidate compounds. In three 
compounds, thymine 79, uracil 80, and 5-fluorouracil 84, no significant cytotoxicity 
was observed at 100 μM, with the 5,6-dimethyluracil derivate 89 showing an 18% 
decrease in cell viability at 100 μM. Since the dose-response curve for biological 
systems is non-linear; a logarithmic scale can easily be used to drawn direct 
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comparisons between a biological response and the dose. If no response is observed 
at a very high concentration such as 100 μM, this shows that the compound does not 
elicit a cytotoxic event. With the four candidate compounds being a representative 
sample of the nine compounds in the library, each compound can now be progressed 
to a broad anti-viral screen to assess the inhibitory concentration (IC50) of the 
compounds and their cytotoxicity (CC50). This will allow SAR of the compounds to be 
determined. Viruses of interest include HIV, HCV, VZV, HSV and HBV since HIV, 
HCV and HBV currently infects more than 200 million people combined and they 
evolve resistenance to drugs quickly.3 This broad viral screen will allow multiple 
viruses to be assessed and a more targeted medicinal chemistry approach can be 
developed towards any potential viruses that show a response. 
5.2.2 Synthesis of 4,4-bis(hydroxymethyl) thietan-2-yl nucleosides 
The synthetic method for entry to the novel thietane core was significantly modified 
and the chemistry optimised to give 4,4-bis(tert-butyldimethylsilylmethoxy)-thietan-2-
one 180 with a yield of 37% from thiol 179. The introduction of the sulfur moiety via 
benzyl mercaptan was found to be a superior method than the Givaudan synthesis 
using H2S and an aldehyde.  
The 4,4-bis(hydroxymethyl)-thietan-2-yl nucleosides are of interest since the effect of 
the geminal hydroxyl groups on anti-viral activities are not known, therefore, 
comparing the anti-viral activities of the 3,3- and 4,4-bis(hydroxymethyl)-thietan-2-yl 
nucleosides could give potential insights into how these structures affect anti-viral 
activities. In order to assess the anti-viral activities of the 4,4-bis(hydroxymethyl) 
thietane nucleosides, thietanone 179 must first be reduced to alcohol 173. Scheme 
5.2 shows the proposed synthetic method required to achieve the intended 
nucleosides. 
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Scheme 5.2: Proposed synthesis of 4,4-bis(hydroxymethyl)-thietan-2-yl nucleosides i) nBu4NF, THF ii) 
BzCl, DMAP, Et3N, DCM, RT iii) NaBH4, THF iv) Deoxofluor, SbCl3, DCM, RT v) silylated nucleobase, 
AgClO4, SnCl2 various solvents and temperatures (see chapter 2) vi) NaOMe, MeOH, RT 
The proposed synthesis first requires removal of the TBS groups and incorporation of 
benzoyl groups the chemistry of which is described in chapter 2 for the synthesis of 
fluorothietane 76. In this proposed synthesis, the already optimised Vorbrüggen 
conditions from chapter 2 will be applied to this synthesis. As per the library in 
chapter 2, a library of nine nucleosides would be afforded (see introduction to chapter 
3 for the complete list of proposed compounds) so that a direct comparison of the 
anti-viral activity can be made. 
5.2.3 Synthesis of 4’-thiohamamelose Nucleosides 
The synthetic strategy towards 4’-thiohamamelose was optimised to TBDPS 207, 
and it was found that synthesis of hamamelose 205 first required trityl protection of 
the 5’-OH group prior to formylation of ribose 204. The purification processes for the 
compounds requires significant optimisation as some reactions could not be purified 
adequately, and carrying through crude material to the next step in the synthetic plan 
may have adversely affected yields. 
Despite the low yields and optimisation problems with the proposed synthesis, the 
synthetic scheme was successful in preparing TBDPS 204 as an important potential 
precursor to 4’-thiohamamelose. In scheme 5.3, the proposed synthesis towards the 
4’-thiohamamelose nucleosides is shown. The reaction conditions proposed uses 
chemistry established by Secrist et al.28,29 
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Scheme 5.3 Proposed synthetic method toward 4’-thiohamamelose nucleosides i) NaOH, Me2SO4 ii) 
PPh3, Imidazole, I2, DCM, 120°C, 6 hrs iii) AcSH, TBA-OH, toluene, RT, 18 hrs iv) DIBAL-H, toluene, 2 
hrs v) CBr4, PPh3, DCM, -25° C, 1 hr vi) AgOTf, 135°C, μwave, DCE/MeCN, 30 mins 
As stated in chapter 4 section 4.5.3, the hydrolysis step shown in scheme 5.2 using 
the Secrist conditions could not be replicated, therefore, further optimisation of the 
reaction conditions are required. Potential conditions could require using a strong 
nucleophile such as NaOMe to create the methyl ester, though no literature 
syntheses are known for ribolactone ring opening using NaOMe. Formation of the 4’-
thiohamamelose requires converting methyl ester 205 to iodide 206 using 
established chemistry with PPh3 and I2.
30 Conversion of iodide 206 to 4’-
thiohamamelose 208 first requires synthesis of the thioether intermediate 207, which 
is deprotected with DIBAL-H and cyclises to 4’-thiohamamelose 208 in an 
intramolecular cyclisation reaction. 
The protecting group strategy was chosen as it allows for selective deprotection of 
the hydroxyl group that requires conversion to the fluoride. Below are the planned 
synthetic steps toward 5’-OH, 3’-OH, 2’-OH and 2’-CH2OH substitutions from 
thiohamamelose nucleosides (schemes 5.4, figure 5.5, figure 5.6).  
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Scheme 5.4: Synthetic strategy for the conversion of the 2’-C-methylhydroxy group to the fluoromethyl 
group: i) nBu4NF, THF, ii) Deoxofluor, SbCl3, DCM 
 
Scheme 5.5: Conversion of the 2’-OH group to the 2’-Fluoro group first requires removal of the 
acetonide and formation of the benzylidene acetal. The 2’-OH group is converted to a leaving group 
(LG= Mesylate or tosylate or equivalent) and then deoxofluor is used to add the fluoride in an SN1 
fashion: i) H
+
 eg pTSA ii) Benzyaldehyde dimethyl acetal then a Mesylate or tosylate added iii) 
Deoxofluor, SbCl3, DCM 
 
Scheme 5.6: Conversion of the 3’-OH group to the fluoride requires removal of the acetonide and re-
protection of the trityl group. Since the 3’-OH is a secondary hydroxide, the reaction mechanism of 
deoxofluor allows displacement by the SN2 mechanism. The tertiary hydroxyl group will not react 
readily: i) pTSA ii) TrCl, pyridine iii) deoxofluor SbCl3 
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These derivatisations will allow access to a significant number of compounds that 
can be screened, giving a broader, more in depth analysis of how structure affects 
the anti-viral activity of these compounds.  
5.2.4 HPLC Stability Studies 
As has been stated in previous chapters, it has been predicted, and in some cases 
shown, that 4’-thioribose nucleosides are more stable toward nucleases and acidic 
conditions than ribose nucleosides.14,15,25,26,31 Thymidine 186 has a half-life of 1 hour 
versus the 4’-thioribose moiety 187, which has a half-life 40 hours (figure 5.2). 
 
Figure 5.2: Thymidine and 4’-thiothymidine  
Based on this and the data in chapter 4 section 4.1 (see table 4.1), it is proposed that 
the acid stability of 3,3- and 4,4-bis(hydroxymethyl)-thietan-2-yl nucleosides, and the 
4’-thiohamamelose nucleosides should be determined by HPLC. It is hypothesised 
that these compounds are more stable than their oxetane or hamamelose 
counterparts. In figure 5.3 the control compounds are shown versus the thiethane 
and 4’-thiohamamelose counterparts. The structures are similar allowing for direct 
comparison between them. 
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Figure 5.3: The control compounds (left) and the target compounds (right) 
The half-lives of oxetanes 226 and 227, and hamamelose 228 are unknown and 
would need to be determined prior to testing the candidate compounds from each 
library.  
Acid stability would be tested by HPLC using known methods.32 The acid stability of 
oxetane 226 would be assessed in triplicate to give a mean half-life for its stability 
under acidic conditions. The thietanes would then be assessed using this method. 
Time points for measuring stability or degradation products can be done per hour 
over 24 hours to determine a half-life for each compound. Next, cell culture media 
would be used with and without serum to determine stability of the thietane and 
oxetane nucleosides in the cell culture assay that was used.  
Further to HPLC stability studies being performed, assays would be performed to 
assess the stability of the thietane and hamamelose nucleosides toward pyrimidine 
nucleoside phosphorylases (PNPs), which have been shown to be a significant factor 
in inactivating oxygen containing ribose and oxetane nucleosides (see chapters 2 
and 4).15-18,31 A basic method to assess the stability of the compounds to PNPs would 
involve incubating the samples of oxetane nucleoside 226 with PNP at 1 hour, 2 
hours etc up to 24 hours to determine a half-life. The process would be repeated with 
each nucleoside and if the hypothesis that the sulfur containing nucleosides are more 
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stable to PNPs than the oxetanes or hamaleose nucleosides is true, a longer half-life 
for the thietanes should be observed. The ideal half-life would be close to 24 hours 
as this would limit the number of times a drug would have to be administered. Ideally, 
once a day administration of these drugs would combat patient compliance issues 
where doses are missed. 
5.2.5 Synthesis of Phosphoramidates 
As shown in chapter 1, the triphosphate of the nucleoside drug is the active 
compound; however, of the three kinases involved in phosphorylation, the first kinase 
is discriminatory. This leads to low levels of active NTP in the cell and is a key factor 
in inactivity for this class of compound. Phosphoramidate prodrugs of nucleosides 
have been shown to increase anti-viral activity by virtue of the increased levels of 
NTP. 
The solubility and therefore the ability of the nucleoside to cross the cell membrane 
(relying on transport proteins rather diffusion across the cell membrane) means that 
in cases where the nucleoside has a large negative log P, low levels of active NTP in 
the cell are also observed. This therefore affects the activity of the compound in that 
if the compound is unable to enter the cell, it cannot elicit a response. 
Phosphoramidates increase the solubility of nucleosides as well as circumvent the 
primary kinase in the phosphorylase chain that is known to be a source of nucleoside 
inactivity. 
It is proposed that synthesising phosphoramide versions of the 3,3- and 4,4-
bis(hydroxymethyl)-thietan-2-yl nucleosides, and the 4’-thiohamamelose nucleosides, 
will improve their anti-viral profiles. Shown in table 5.1 are three drugs with 
experimentally determined log P values, along with their calculated log P values of 
known compounds active against HCV. The clog P values were calculated herein 
using ChemDraw and compared to the know log P value where available. The log P 
or clog P values were compared to IC50 values to give an indication of how 
improvement to bioavailability of the drug improves the anti-viral properties. However, 
this does not mean that improving log P values will improve the anti-viral activity of 
the compound class. However, it means that where low levels of NTP in cells are 
present along with no or low anti-viral activity, if the cellular NTP levels can be 
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improved by making the drug more available, low activity can be attributed to the 
drug and not the low cellular NTP levels.  
Table 5.1: cLog P data for thietane nucleosides compared to known nucleosides 
Compound Log P cLog P IC50 
 
Sofosbuvir 38 
1.6 0.84 0.42 μM 
 
NM107 21 
-0.97 -1.68 7.6 μM 
 
NM283 22 
-1.34 -1.17 1.23 μM 
 
230 
-2.56 10 μM  
 
NM107 21 and NM283 22 have log P values of -0.97 and -1.34, and Sofosbuvir 
(trade name Sovaldi) 38 has a log P of 1.6. It is interesting to note that the IC50 
values for these compounds vary greatly, with the most active compound, Sofosbuvir 
38 being the most active at 0.42 μM and NM107 21 being the least active at 1.23 μM. 
It can be reasonably assumed that increasing the solubility of the compounds 
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improves the level of active NTP in the cell. This therefore leads to greater potential 
for an anti-viral response to occur. 
Table 5.2 shows the calculated log P values for the 3,3-, and 4,4-bis(hydroxymethyl)-
thietan-2-yl nucleosides, and the 4’-thiohamamelose nucleosides. Also shown is the 
calculated log P data for the phosphoramidate derivatives of these classes of 
compounds. 
Table 5.2: Calculated log P values for 3,3-, 4,4-bis(hydroxymethyl)-thietan-2-yl, 4’-thiohamamelose 
nucleosides, and the phosphoramidate derivatives 
Compound cLog P 
 
226 
-3.5 
 
79 
-1.6 
 
80 
-2.1 
 
231 
0.9 
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232 
0.4 
 
115 
-0.5 
 
 
116 
-0.84 
  
233 
0.54 
 
234 
0.42 
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235 
-1.34 
 
236 
0.42 
 
It can be seen that when comparing hamamelose 230 to 4’-thiohamamelose 235, the 
clog P value increased from -2.56 to -1.34. Conversion of the 4’-thiohamamelose 235 
to phosphoramidate 236 improves the clog P value further. The same is true of the 
3,3- and 4,4-bis(hydroxymethyl)-thietan-2-yl nucleosides. The clog P values improve 
from oxetane 226 to thietane 80, and the phosphoramidate moiety 231 has improved 
clog P value versus thietane 80. The ideal log P values lie between 0 and 5, so any 
improvement from more negative values to the specified range has the potential to 
improve availability of these compounds to the cell, and therefore increase the 
concentration of potentially active NTP in the cell. 
5.3 Closing Statement 
Small molecule nucleosides offer the greatest potential as potent anti-viral 
compounds versus other anti-viral agents as they are able to directly halt viral 
replication. The 3,3- and 4,4-bis(hydroxymethyl)-thietan-2-yl nucleosides could 
potentially overcome kinase-polymerase bias due to the fact that the pseudo-north 
and pseudo-south conformations are assumed to be recognised by kinases and viral 
polymerases. This is based on observations of active oxetane and thietane 
nucleosides which showed anti-viral activity that could only have occurred if the 
nucleoside was phosphorylated then incorporated into a viral genome to prevent 
replication. Phosphoramidate versions of these compounds offer the potential to 
improve their chemical properties still further, by increasing intracellular NTP 
concentrations. The 4’-thiohamamelose compounds also offer these potential 
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benefits, and along with the thietanes discussed, have the potential to overcome 
PNP hydrolysis that reduces the half-life and efficacy of ribose and oxetane 
nucleosides. Small molecule nucleosides in general are potent anti-viral compounds 
due the ability of these compounds to halt viral genome replication. Non-nucleoside 
compounds are known to act on allosteric sites, but have an increased rate of 
resistance evolving toward them versus nucleosides. Therefore, by improving the 
chemical properties and stability of thietane and 4’-thiohamamelose nucleosides, 
significant increases in anti-viral activities could be achieved whilst reducing the 
chance of viral resistance from evolving.  
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Chapter 6: Experimental 
1H and 13C NMR spectroscopic analysis was obtained using a Bruker DPX 400MHz 
or a Nanobay 400 MHz spectrometer and spectra were recorded in deuterated 
chloroform or DMSO unless otherwise stated. Infrared analyses were recorded using 
a Paragon 1000 FT IR (Perkin Elmer, UK) spectrometer and absorptions are quoted 
in wave numbers. The data was obtained by placing samples onto an ATR diamond. 
Mass spectrometry data was recorded on a Fisons VG Autospec Mass Spectrometer 
using electrospray ionisation. Data is reported as the mass/charge ratio. Melting 
points were determined using Electrothermal digital melting point apparatus and are 
uncorrected. Purification was performed using a Biotage SP1 automated column 
chromatography system unless otherwise stated. Purity reported obtained by HPLC 
using Waters Agilent 2 HPLC with a UV detector and is reported in percent. All 
reagents were used as supplied by Sigma Aldrich, Alfa Aesar, TCI, Fluorochem, and 
Fischer Scientific. TLC analysis was performed on aluminium back silica gel with 
pore size 60Å and stained with either KMNO4, CAM, Vanilin or sugar dip. Purification 
by column chromatography used silica gel with pore size 60Å and compounds were 
pre-absorbed onto silica prior to running the column. Cell viability assay: SHS-Y5Y 
cells were cultured in Dublecos eagle medium (thermofischer) with fetal bovine 
serum (labtech) and penicillin-streptomycin (thermofischer) antibiotics. The cells were 
plated for experiments using 96 well plates obtained from VWR. The absorbance was 
measured using a Spectramax spectrophotometer from Molecular Devices. 
General Procedures for the Synthesis of Thietane nucleosides 
General Procedure A: To an oven dried round bottom flask under argon the 
pyrimidine nucleobase (2 equivs) was suspended in HMDS (0.14M relative to the 
nucleobase) and (NH4)2SO4 (0.05 equivs) was then added to the reaction mixture. 
The reaction was heated to reflux (145° C) until the solution became clear. The 
solution was allowed to cool to room temperature and the HMDS was removed in 
vacuo to give a viscous oily residue. The residue was dissolved in DCM (0.2M 
relative to the fluorothietane) and the fluorothietane (1 equiv) was added followed by 
SnCl2 (1 equiv) and AgClO4 (1 equiv). The solution was reacted under argon at room 
temperature for 18 – 24 hours or until TLC analysis (1: 1 hexane : ethyl acetate) 
 176 
 
showed complete consumption of the starting material. The reaction was diluted with 
ethyl acetate (equal to reaction volume) and the inorganic material filtered off. The 
ethyl acetate was partitioned with water (equal to one reaction volume) and organic 
layer removed. The aqueous phase washed 3 times with 5 times the reaction volume 
of ethyl acetate and the combined organic phases were washed with 3 times the 
reaction volume of saturated brine. The combined organic phases were dried with 
Na2SO4, the solvent filtered then removed in vacuo. The residue was purified by 
column chromatography using 1:1 hexane:ethyl acetate unless otherwise stated. 
General Procedure B: To an oven dried round bottom flask under argon the 
pyrimidine nucleobase (2 equiv) was suspended in MeCN (0.48M relative to the 
fluorothietane) and then N,O-BSA (1.1 equiv) was added and then the reaction was 
heated to 70° C  for 1 hour or until the solution became clear. The reaction was 
cooled to room temperature and the fluorothietane (1 equiv) was added followed by 
SnCl2 (1 equiv) and AgClO4 (1 equiv). The solution was reacted under argon at room 
temperature for 18 – 24 hours or until TLC analysis (1: 1 hexane : ethyl acetate) 
showed complete consumption of the starting material. The reaction was diluted with 
ethyl acetate (equal to reaction volume) and the inorganic material filtered off. The 
organic phase was partitioned with water (equal to one reaction volume) and organic 
layer removed. The aqueous phase washed 3 times with 5 times the reaction volume 
of ethyl acetate and the combined organic phases were washed with 3 times the 
reaction volume of saturated brine. The combined organic phases were dried with 
Na2SO4 the solvent filtered then removed in vacuo. The residue was purified by 
column chromatography using 1:1 hexane:ethyl acetate unless otherwise stated. 
General Procedure C: To an oven dried round bottom flask under argon the benzoyl 
protected thietanose nucleoside was added (1 equiv) and methylamine (33% in 
ethanol, 14 ml, 17 equivs) was added. The reaction was stirred at room temperature 
for 3 hours. The mixture was concentrated in vacuo and purified by column 
chromatography using 9:1 chloroform:methanol as eluent unless otherwise stated. 
General Procedure D: To an oven dried round bottom flask under argon the benzoyl 
protected thietanose nucleoside (1 equiv) was dissolved in methanol (5 ml). Solid 
NaOMe was added (2.5 equivs) and the reaction stirred at room temperature for 24 
hours. The reaction was quenched with excess solid carbon dioxide and then the 
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solvent removed in vacuo. The residue was purified by column chromatography 
using 9:1 chloroform:methanol unless otherwise stated. 
Synthesis of 3,3-bis(benzoylmethoxy)-thietane-1-oxide 65 
 
This procedure was modified from Nishizono et al.1 To an oven dried round bottom 
flask under argon, 3,3-bis(benzoylmethoxy)-thietane 77 (1 g, 2.92 mmol, 1 equiv) 
was dissolved in methanol (60 ml) and sodium periodate (750 mg, 3.5 mmol, 1.2 
equiv) was added. The reaction was stirred vigorously for 24 hours at room 
temperature. The crude reaction mixture was filtered and the solvent was evaporated 
in vacuo. The residue was purified by column chromatrography using biotage on a 
100 g column eluting with hepatane : ethyl acetate 1 : 2 to yield the title compound as 
a white solid. Yield: 84%, 830 mg. MP 114 - 115° C Lit: 115 – 116 °C 1H NMR (400 
MHz CDCl3) δ: 3.44 (2H, d, J = 13.0 Hz, SCH2a) 3.80 (2H, d, J = 13.0 Hz, SCH2b) 
4.44 (2H, s, OCH2) 4.48 (2H, s, OCH2) 7.48 – 7.52 (4H, m, ArH) 7.61 – 7.66 (4H, m, 
ArH) 8.08 – 8.12 (2H, m, ArH) 13C NMR (100 MHz CDCl3) δ: 36.6 (C(CH2O)2) 56.1 
(2xCH2S) 66.7 (OCH2) 67.5 (OCH2) 128.7 (ArC) 129.7 (ArC) 133.6 (ArC) 166.0 
(2xC=O) ) IR (υmax = cm
-1) 3416, 3066, 3031, 2954, 2878, 2322, 1980, 1713, 1383, 
1277, 1069 HRMS EI calc: [C19H18SO4Na
+] 381.0773 obs: [C19H18SO4Na
+] 381.0767 
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Synthesis of 3,3-bis(benzoylmethoxy)-thietan-2-yl-thymine 66 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure A to give the title compound as a white powder after 
purification by column chromatography. Yield: 57%, 100 mg. 1H NMR (400 MHz 
CDCl3) δ: 1.80 (3H, s, CH3) 3.02 (1H, d, J= 9.5 Hz, CH2S) 3.26 (1H, d, J= 9.5 Hz, 
CH2S) 4.42 (1H, d, J= 12.0 Hz, OCH2) 4.58 (1H, d, J= 12.0 Hz, OCH2) 4.65 (1H, d, 
J= 11.5 Hz, OCH2) 4.83 (1H, d, J = 11.5 Hz, OCH2) 6.27 (1H, s, SCHN) 7.41 – 7.49 
(4H, m, ArH) 7.55 – 7.61 (2H, m, ArH) 7.93 – 8.11 (5H, m, ArH and NCH=C(CH3) 
13C 
NMR (100 MHz CDCl3) δ: 12.4 (CH3) 25.0 (CH2S) 53.5 (C(OCH2)2) 56.6 (SCHN) 63.0 
(OCH2) 65.8 (OCH2) 128.6 (ArC) 128.8 (ArC) 133.5 (ArC) 156.5 (NC=O) 156.8 
(CCH3C=O) 166.1 (OCH2C=O) 171.1 (NC=O) IR (υmax = cm
-1) 3004, 2360, 2342, 
1732, 1718, 1696, 1672, 1600, 1450, 1109, 1024 MP: 177 – 178 °C  HRSM EI calc: 
[C24H22N2O6SH
+] 467.1271 obs: [C24H22N2O6SH
+] 467.1265  
Synthesis of 3,3-bis(benzoyloxymethoxy)-2-fluorothietane 76 
 
This procedure was modified from Nishizono et al.1 To an oven dried round bottom 
flask under argon, 3,3-bis(benzoylmethoxy)-thietane 77 (250 mg, 0.73 mmol, 1 equiv) 
was added and it was dissolved in dry DCM (7 ml). SbCl3 (17 mg, 0.073 mmol, 0.1 
equiv) was added and Deoxo-fluor (2.92 ml, 1.5 equiv) was then added dropwise. 
The reaction was stirred for 72 hours at room temperature and completion was 
determined by TLC analysis. The reaction was quenched with cold ethyl acetate (14 
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ml) and washed with saturated sodium bicarbonate solution, then brine (50 ml), then 
dried over Na2SO4. The solvent was filtered and evaporated in vacuo. The crude 
material was purified by column chromatography using biotage on a 25 g column 
eluting with heptane ethyl acetate (6:1) to yield the title compound as a white solid, 
yield: 84%, 220 mg. 1H NMR (400 MHz CDCl3) δ: 2.98 (1H, t, J = 9.0 Hz, CH2S) 3.26 
(1H, d, J = 9.0 Hz, CH2S) 4.58 (2H, s, OCH2) 4.79 (1H, d, J = 2 Hz, OCH2) 4.83 (1H, 
d, J = 2 Hz, OCH2) 6.10 (1H, d, J = 63.0 Hz), CHF) 7.41-7.54 (4H, m, ArH) 7.57-7.61 
(2H, m, ArH) 8.00-8.07 (4H, m, ArH) 13C NMR (100 MHz CDCl3) δ: 25.6 (CH2S) 53.1 
(C(CH2SCHF)(OCH2)2 62.9 (OCH2) 65.0 (OCH2) 93.6 (CHF, d, J = 248 Hz) 128.6 
(ArC) 129.6 (ArC) 133.5 (ArC) 166.1 (CH2OC=O) IR (υmax = cm
-1) 3064, 2955, 1718, 
1601, 1584, 1492, 1261, 1095, 705. MP: 71 - 73 °C HRSM EI calc: [C19H18O4SFNa
+] 
383.0729 obs: [C19H18O4SFNa
+] 383.0722 
Synthesis of 3,3-bis(benzoylmethoxy)-thietane 77 
 
This procedure was modified from Nishizono et al.1 To an oven dried round bottom 
flask under argon, 3,3-bis(hydroxymethyl) thietane 95 (720 mg, 5.4 mmol, 1 equiv) 
was added and dissolved in dry DCM. Benzoyl chloride (3.10 ml, 27.0 mmol, 5 equiv) 
was added dropwise followed by triethylamine (2.55 ml, 16.1 mmol, 3 equiv) and 
DMAP (6.6 mg, 54 µmol, 0.01 equiv). The reaction was stirred overnight at room 
temperature and was monitored by TLC analysis (7:1 hexane : ethyl acetate) until all 
the starting material was consumed. The reaction was quenched by the addition of 
sat. NaHCO3 until a neutral pH was observed. The aqueous phase was washed with 
ethyl acetate (3 x 30 ml) and the combined organic phases were dried over Na2SO4, 
filtered and evaporated in vacuo. The crude was recrystallized from isopropyl alcohol 
to give a white solid. Yield: 78%, 1.44 g. 1H NMR (400 MHz CDCl3) δ: 3.14 (4H, s, 
2xCH2S) 4.42 (4H, s, 2xCH2O) 7.37 (4H, t, J = 4.0 Hz) ArH) 7.46-7.50 (2H, m, ArH) 
8.01 (4H, d, J = 8.0 Hz, ArH) 13C NMR (100 MHz CDCl3) δ: 28.8 (2xCH2S) 46.3 
(C(OCH2)2) 66.9 (2xOCH2) 127.1 (ArC) 129.7 (ArC) 134.5 (ArC) 166.4 (CH2OC=O) 
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IR (υmax = cm
-1) 3416, 3066, 3031, 2954, 2878, 2322, 1980, 1713, 1383, 1277, 1169 
MP: 79 - 82 °C Lit: 79 – 82 °C. HRMS EI calc: [C19H18O4SNa+] 343.0999 obs: 
[C19H18O4SNa
+] 343.1004 
Synthesis of 3,3-bis(hydroxymethyl)-thietan-2-yl-thymine 79 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure C to give the title compound as a white powder after 
purification by column chromatography. Yield: 98%, 68 mg. HPLC purity: 98.6%. MP: 
154-157 °C. 1H NMR (400 MHz DMSO) δ: 1.86 (3H, s, CH3) 2.80 (1H, d, J = 9.0 Hz, 
SCH2) 2.88 (1H, d, J = 9.0 Hz, SCH2) 3.34 (1H, d, J = 11.0 Hz, OCH2) 3.48 (2H, d, J 
= 13.0 Hz, OCH2) 3.60 (1H, d, J= 11.0 Hz, OCH2) 4.66 (1H, t, J = 4.0 Hz, OH) 5.00 
(1H, t, J = 4.0 Hz, OH) 5.86 (1H, s, SCHN) 8.20 (1H, s, CH=CCH3) 11.23 (1H, br, 
NH) 13C NMR (100 MHz DMSO) δ: 12.3 (CH3) 24.1 (SCH2) 55.8 (SCHN) 59.9 
(CH2OH) 63.6 (CH2OH)  79.2 (C(CH2OH)2 108.0 (CH=CCH3) 138.2 (CH=CCH3) 
151.0 ((CCH3)C=O)) 163.8 (NC=O) IR (υmax = cm
-1) 3411, 3362, 2931, 3602, 2496, 
1705, 1653, 1474, 1444, 1397, 1301, 1246, 1231, 1216, 1172, 1064 HRSM EI calc: 
[C10H14N2O4SH
+] 259.0747 obs: [C10H14N2O4SH
+] 259.0749 
Synthesis of 3,3- bis(hydroxymethyl)-thietan-2-yl-uracil 80 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure D to give the title compound as a white powder after 
purification by column chromatography. Yield: 93%, 138 mg. HPLC purity: 97.9% 
MP: 161 – 164 °C. 1H NMR (400 MHz DMSO) δ: 1H NMR (400 MHz DMSO) δ: 2.75 
(1H, d, J = 9.0 Hz, SCH2) 2.90 (1H, d, J = 9.0 Hz, SCH2) 3.35 (1H, d, J = 4.5 Hz, 
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OCH2) 3.50 (2H, m, OCH2) 3.60 (1H, d, J = 11.0 Hz, OCH2) 4.70 (1H, t, J = 4.5 Hz, 
OH) 5.00 (1H, t, J = 4.5 Hz, OH) 5.63 (1H, d, J = 8.0 Hz, CH=CH) 5.86 (1H, s, 
SCHN) 8.34 (1H, d, J = 8.1 Hz, CH-CH) 11.23 (1H, s, NH) 13C NMR (100 MHz 
DMSO) δ: 55.80 (SCHN) 24.0 (SCH2) 55.8 (C(CH2OH)2 60.1 (CH2OH) 63.5 (CH2OH) 
99.9 (CH=CH) 142.8 (CH=CH) 151.2 (=CHC=O) 163.6 (NC=O) IR (υmax = cm
-1) 3428, 
3356, 3051, 2952, 2925, 2534, 2494, 2303, 1705, 1667, 1650, 1457, 1418, 1240,  
HRSM EI calc: [C9H12N2O4SH
+] 245.0591 obs: [C9H12N2O4SH
+] 245.0591 
Synthesis of 3,3- bis(hydroxymethyl)-thietan-2-yl-cytosine 81 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure C to give the title compound as a white powder after 
purification by column chromatography. Yield: 36%, 47 mg. HPLC purity: 75.1%  MP: 
244-251° C 1H NMR (400 MHz DMSO) δ: 2.77 (2H, d, J = 4.0 Hz, SCH2) 3.17 (1H, d, 
J = 11.0 Hz, CH2OH) 3.39 (1H, d, J = 11.0 Hz, CH2OH) 3.44 (1H, d, J = 11.0 Hz, 
CH2OH) 4.60 (1H, d, J = 5.0 Hz, OH) 4.91 (1H, d, J = 5.0 Hz, OH) 5.76 (1H, d, J = 
7.0 Hz, CH=CH) 5.81 (1H, s, SCHN)  7.20 (2H, d, J = 43.0 Hz, NH2) 8.16 (1H, d, J = 
7.4 Hz, CH=CH) 13C NMR (100 MHz DMSO) δ: 24.3 (SCH2) 55.8 (C(CH2OH)2 58.1 
(SCHN) 61.8 (CH2OH) 64.7 (CH2OH) 93.9 (CH=CH) 143.4 (CH=CH) 156.6 (CNH2) 
165.6 (NC=O) IR (υmax = cm
-1) 3332, 3175, 3916, 2868, 1665, 1639,1592, 1519, 
1476, 1395, 1297, 1178, 1146, 1116 HRSM EI calc: [C9H13N3O3SH
+] 244.0750  obs: 
[C9H13N3O3SH
+] 244.0752 
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Synthesis of 3,3- bis(hydroxymethyl)-thietan-2-yl-(5-fluoro)uracil 84 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure C to give the title compound as a white powder after 
purification by column chromatography. Yield: 77%, 64 mg. HPLC purity: 94.5%. 1H 
NMR (400 MHz DMSO) δ: 2.80 (1H, d, J = 9.0 Hz, SCH2) 2.88 (1H, d, J = 9.0 Hz, 
SCH2) 3.31 (1H, d, J = 11.0 Hz, CH2OH) 3.42 (1H, d, J = 11.0 Hz, CH2OH) 3.53 (1H, 
d, J = 11.0 Hz, CH2OH) 3.61 (1H, d, J = 8.0 Hz, CH2OH) 4.9 (1H, s, OH) 5.1 (1H, s, 
OH) 5.90 (1H, s, SCHN) 8.57 (1H, d, J = 7.0 Hz, CH=CF) 13C NMR (100 MHz 
DMSO) δ: 24.5 (SCH2) 56.4 (SCHN) 60.0 (CH2OH) 63.6 (CH2OH) 127.7 (CH=CF) 
137.8 - 140.1 (d, J = 228 Hz, CH=CF) 149.6 (CFC=O) 157.2 (NC=O) IR (υmax = cm
-1) 
3378, 2944, 1702, 1660, 1558, 1434, 1136 HRSM EI calc: [C10H14N2O4SH
+] 
263.0496 obs: [C10H14N2O4SH
+] 263.0498 
Synthesis of 3,3-bis(hydroxymethyl)-thietan-2-yl-(5-chloro)-uracil 85 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure D to give the title compound as a white powder after 
purification by column chromatography. Yield: 88%, 102 mg. MP: 182-183° C. 1H 
NMR (400 MHz DMSO) δ: 2.80 (1H, d, J = 9.0 Hz, SCH2) 2.88 (1H, d, J = 9.0 Hz, 
SCH2) 3.29 (1H, d, J = 10.0 Hz, CH2OH) 3.40(1H, d, J = 10.0 Hz, CH2OH) 3.48(1H, 
d, J = 10.0 Hz, CH2OH) 3.59(1H, d, J = 10.0 Hz, CH2OH) 4.8 (1H, s, OH) 5.05 (1H, s, 
OH) 5.83 (1H, s, SCHN) 8.58 (1H, s, CH=CCl) 13C NMR (100 MHz DMSO) δ: 23.8 
(SCH2) 55.5 (C(CH2OH)2 60.1 (CH2OH) 63.6 (CH2OH) 105.7 (CH=CCl) 139.9 
(CH=CCl) 150.2 (CClC=O) 159.1 (NC=O) IR (υmax = cm
-1) 3432, 3384, 3016, 2935, 
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1713, 1673, 1618, 1456, 1424, 1204, 1060 HRSM EI calc: [C9H11N2O4S
35ClH+] 
279.0200 obs [C9H11N2O4S
35ClH+] 279.0201 calc [C9H11N2O4S
37ClH+] 281.0170 obs 
[C9H11N2O4S
37ClH+] 281.0171 
Synthesis of 3,3-bis(hydroxymethyl)-thietan-2-yl-(5-bromo)-uracil 86 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure D to give the title compound as a white powder after 
purification by column chromatography. Yield 96%, 285 mg. MP: 191-192° C. 1H 
NMR (400 MHz DMSO) δ:  13C NMR (100 MHz DMSO) δ: 2.79 (1H, d, J = 9.0 Hz, 
SCH2) 2.87 (1H, d, J = 9.0 Hz, SCH2) 3.30 – 3.60 (4H, m, CH2OH) 4.80 (1H, m, OH) 
5.0 (1H, m, OH) 5.8 (1H, s, SCHN) 8.6 (1H, s, CH=CBr) 13C NMR (100 MHz CDCl3) 
δ: 25.0 (SCH2) 53.2 (C(OCH2)2 57.5 (SCHN) 62.8 (OCH2) 66.2 (OCH2) 96.7 
(CH=CBr) 149.9 (CH=CBr) 166.1 (CH2OC=O) IR (υmax = cm
-1) 3015, 2813, 1708, 
1994, 1609, 1495, 1450, 1423, 1357, 1325, 1215, 1154, 1059, 1040, 1027 calc: 
[C9H11N2O4S
79BrH+] 322.9696 obs [C9H11N2O4S
79BrH+] 322.9698 calc 
[C9H11N2O4S
81BrH+] 324.9674 obs [C9H11N2O4S
81BrH+] 324.9675 
Synthesis of 3,3-bis(hydroxymethyl)-thietan-2-yl-(5-iodo)-uracil 87 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure D to give the title compound as a colourless oil after 
purification by column chromatography. Yield: 90%, 173 mg. 1H NMR (400 MHz 
DMSO) δ: 2.79 (1H, d, J = 9.0 Hz, SCH2) 2.89 (1H, d, J = 9.0 Hz, SCH2) 3.3 – 3.6 
(4H, m, CH2OH) 4.79 (1H, t, J = 5.0 Hz, OH) 5.03 (1H, t, J = 5.0 Hz, OH) 5.81 (1H, s, 
SCHN) 8.63 (CH=CI) 13C NMR (100 MHz DMSO) δ: 23.7 (SCH2) 55.4 (C(CH2OH)2) 
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56.6 (SCHN) 60.2 (CH2OH) 63.6 (CH2OH) 146.9 (CH=CI) 150.8 (CH=CI) 160.5 
(=CIC=O) IR (υmax = cm
-1) 3432, 3004, 1707, 1662, 1598, 1417, 1297, 1153, 1059 
calc: [C9H11N2O4SIH
+] 370.9557 obs [C9H11N2O4SIH
+] 370.9557 
Synthesis of 3,3-bis(hydroxymethyl)-thietan-2-yl-(6-methyl)-uracil 
885 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure D to give the title compound as a white powder after 
purification by column chromatography. Yield: 98%, 174 mg. MP: 173 - 174° C. 1H 
NMR (400 MHz DMSO) δ: 2.01 (3H, s, CH3) 2.39 (1H, d, J = 9.0 Hz, SCH2) 3.0 – 3.7 
(5H, m, 1H=SCH2 4H=CH2OH) 4.53 (1H, s, OH) 5.1 (1H, s, OH) 5.48 (1H, s, 
CH3C=CH) 5.85 (1H, s, SCHN) 11.21 (1H, s, NH) 
13C NMR (100 MHz DMSO) δ: 17.8 
(CH3) 28.6 (SCH2) 53.5 (SCHN) 54.3 (C(CH2OH)2) 61.3 (CH2OH) 63.0 (CH2OH) 
101.9 (CH3C=CH) 154.9 (=CHC=O) 162.9 (NC=O) IR (υmax = cm
-1) 3367, 2944, 1651, 
1417, 1363, 1032 HRSM EI calc: [C10H14SO4N2Na
+] 281.0564 obs: 
[C10H14SO4N2Na
+] 281.0566 
Synthesis of 3,3-bis(hydroxymethyl)-thietan-2-yl-(5,6-dimethyl)-
uracil 89 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure D to give the title compound as a white powder after 
purification by column chromatography. Yield: 95%, 129 mg. MP: 176 - 177° C. 1H 
NMR (400 MHz DMSO) δ: 1.79 (3H,s, CH3) 2.20 (3H,s, CH3)   2.23 (1H, d, J = 9.0 
Hz, SCH2) 3.07 (1H, d, J = 9.0 Hz, SCH2) 3.40 (1H, d, J = 5.0 Hz, OCH2) 3.50 (1H, d, 
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J = 5.0 Hz, OCH2) 3.82 (2H, d, J = 5.0 Hz, OCH2) 4.50 (1H, t, J = 5.0 Hz, OH) 5.15 
(1H, t, J = 5.0 Hz, OH) 5.27 (1H, s, SCHN) 11.26 (1H, s, NH) 13C NMR (100 MHz 
DMSO) δ: 11.4 (CH3) 16.8 (CH3) 29.2 (SCH2) 55.1 (C(CH2OH)2 59.7 (SCHN) 61.1 
(CH2OH) 62.7 (CH2OH) 149.9 (CCH3C=O) 163.3 (NC=O) IR (υmax = cm
-1) 3350, 
3167, 3038, 2946, 2604, 2498, 1720, 1614, 1472, 1266, 1109, 1050 HRSM EI calc: 
[C11H16SO4N2Na
+] 295.0723 obs: [C11H16SO4N2Na
+] 295.0725 
Synthesis of 2,2-bis(bromomethyl)-1,3-O-isopropylidene-1,3-
propanediol 93 
 
This procedure was modified from Nishizono et al.1 To an oven dried round bottom 
flask under argon 2,2-bis(bromomethyl)-1,3-propanediol 92 (50 g, 0.25 mol) and 
dissolved in acetone (380 ml). 2,2-Dimethyoxypropane (164 ml, 1.76 mol) and p-
toluene sulfonic acid monohydrate (476 mg, 2.5 mmol) were then added. The 
reaction was stirred for 2 hours. The reaction was monitored by TLC analysis (6:1 
hexane : ethyl acetate) until all of the starting material was consumed. The reaction 
was quenched with sat. NaHCO3 (380 ml) and the organic phase separated and 
concentrated in vacuo. The residue was partitioned between ether (380 ml) and 
water (380 ml) and extracted with ether (3 x 380 ml). The organic phases were 
combined and dried over MgSO4. The solvent was evaporated in vacuo and the 
residue was recrystallized from isopropanol to give the title compound as a white 
solid. Yield: 91 %, 68.62 g. 1H NMR (400 MHz CDCl3) δ: 1.42 (6H, s, 2xCH3) 3.58 
(4H, s, 2xCH2Br), 3.80 (4H, s, 2xOCH2) 
13C NMR (100 MHz CDCl3) δ: 23.5 (2xCH3) 
35.9 (2xCH2Br) 64.9 (2xOCH2) 98.9 (CH3 CCH3) 38.3 (OCH2OCH2CCH2BrCH2Br) IR 
(υmax = cm
-1) 2994, 2982, 2868, 1209 MP: 60 – 62 °C Lit: 59 – 60 °C HRMS EI calc: 
[C8H14O2Br2H
+] 300.9438 obs: [C8H14O2Br2H
+] 301.1416 
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Synthesis of 3’,3’-isopropylidene-3,3-bis(hydroxymethyl)-thietane 
94 
 
This procedure was modified from Nishizono et al.1 To an oven dried round bottom 
flask under argon 2,2-bis(bromomethyl)-1,3-O-isopropylidene-1,3-propanediol 93 (5 
g, 16.56 mmol) was dissolved in dry DMF (60 ml). Na2S.9H2O (5.97 g, 25.48 mmol) 
was added and the mixture was heated to 110° C for 24 hours whilst stirring. The 
reaction was cooled to room temperature and then diluted with ether (60 ml) and then 
partitioned between water (60 ml). The aqueous phase was then extracted with tert 
butyl methyl ether (3 x 60 ml) and the combined organic phases were washed with 1 
M LiCl solution (120 ml). The organic phase was dried over MgSO4, filtered, and then 
evaporated in vacuo. The residue was recrystallized from isopropyl alcohol to give 
the title compound as a yellow solid. Yield: 94%, 2.71 g. 1H NMR (400 MHz CDCl3) δ: 
1.40 (6H, s, 2xCH3) 2.96 (4H, s, 2xCH2S), 3.87 (4H, s, 2xOCH2) 
13C NMR (100 MHz 
CDCl3) δ: 23.8 (2xCH3) 30.6 2xCH2S) 68.1 (2xOCH2) 98.4 (CH3CCH3) 41.1 
(CCH2SCH2S) IR (υmax = cm
-1) 2997, 2931, 2861, 1182, 1193, 1370, 1378, 1430, 
1480 MP: 48 – 52 °C Lit: 51 – 52 °C. HRMS EI calc: [C8H14O2SH+] 175.0787 obs: 
[C8H14O2SH
+] 175.0788 
Synthesis of 3,3-bis(hydroxymethyl)-thietane 95 
 
This procedure was modified from Nishizono et al.1 To an oven dried round bottom 
flask under argon, 3’,3’-isopropylidene-3,3-bis(hydroxymethyl) thietane 94 (5.1 g, 
0.03 mol, 1 equiv) was added and dissolved in methanol (263 ml). p-Toluene sulfonic 
acid (1.14 g, 6 mmol, 0.2 equiv) was added and the reaction was monitored by TLC 
analysis (2:1 toluene : acetone) until all the starting material was consumed. The 
crude reaction mixture was quenched with solid NaHCO3 until a neutral pH was 
observed with pH paper, and then the solvent was evaporated. The residue was 
 187 
 
dissolved in DCM (100 ml) and filtered to remove inorganic compounds. The 
compound was purified by gradient elution on a biotage 100 g column (100% toulene 
to 2:1 toluene:acetone over 20 CV) to give the title compound as a white solid. Yield: 
86%, 3.48 g. MP: 73 – 74 °C 1H NMR (400 MHz CDCl3) δ: 2.17 (2H, d, J = 5.0 Hz, 
OH) 2.96 (4H, s, 2xCH2S), 3.89 (4H, d, J = 5.0 Hz, OCH2) 
13C NMR (100 MHz CDCl3) 
δ: 28.7 (2xCH2S) 48.0 (2xOCH2) 68.2 (C(CH2OH)2(CH2)2S)IR (υmax = cm
-1) 3224, 
2963, 2933, 2869, 1489, 1451, 1121, 1023 MP: 72 – 74 °C. HRMS EI calc: 
[C5H10O2SH
+] 135.0479 obs: [C5H10O2SH
+] 135.0479 
Synthesis of 3,3-bis(benzoylmethoxy)-thietan-2-yl-(5-fluoro)-uracil 
100 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure A to give the title compound as a white powder after 
purification by column chromatography. Yield: 45%, 60 mg. MP: 219 – 220 °C. 1H 
NMR (400 MHz DMSO) δ: 3.17 (1H, d, J = 10.0 Hz, CH2S) 3.28 (1H, d, J = 10.0 Hz, 
CH2S) 4.51 (1H, d, J =12.0 Hz, OCH2) 4.64-4.74 (3H, m, OCH2) 6.20 (1H, s, SCHN) 
7.52-7.61 (4H, m, ArH) 7.20-7.74 (2H, m, ArH) 7.92 (2H, d, J = 7.5 Hz, ArH) 8.11 
(2H, d, J = 7.6 Hz, ArH) 8.78 (1H, d, J = 7.1 Hz, CH=CF) 12.00 (1H, s, NH) 13C NMR 
(100 MHz DMSO) δ: 24.6 (CH2S) 52.3 (C(OCH2)2CH2S) 56.3 (SCHN) 62.5 (OCH2) 
66.3 (OCH2) 126.5 (C=CF) 128.7 (ArC) 129.4 (ArC) 133.6 (ArC) 149.6 (C=CF) 156.5 
(NC=O) 156.8 (CFC=O) 165.5 (CH2OC=O)IR (υmax = cm
-1) 3069, 2922, 1704, 1651, 
1451, 1341, 1269, 1243, 1111, 1025 MP: 219 – 220 °C HRSM EI calc: 
[C23H19N2O6SFH
+] 471.1021 obs: [C23H19N2O6SFH
+] 471.1017 
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Synthesis of 3,3-bis(benzoylmethoxy)-thietan-2-yl-uracil 101 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure B to give the title compound as a white powder after 
purification by column chromatography. Yield: 64% 404 mg. MP 196 – 198 °C. 1H 
NMR (400 MHz DMSO) δ: 3.19 (1H, d, J = 10.0 Hz, CH2S) 3.25 (1H, d, J = 10.0 Hz, 
CH2S) 4.52 (1H, d, J = 12.0 Hz, OCH2) 4.58 – 4.69 (2H, m, OCH2) 4.73 (1H, d, J = 
12.0 Hz, OCH2) 5.68 (1H, d, J = 8.0 Hz, CH=CH) 6.26 (1H, s, SCHN) 7.52 – 7.61 
(4H, m, ArH) 7.73 (2H, m, ArH) 7.90 (2H, d, J = 7.0 Hz, ArH) 8.10 (2H, d, J = 7.4 Hz, 
ArH) 8.45 (1H, d, J=8.1 Hz, CH=CH) 11.47 (1H, s, NH) 13C NMR(100 MHz DMSO) δ: 
24.4 (CH2S) 52.5 (C19) (C(OCH2) 55.8 (SCHN) 62.4 (OCH2) 66.0 (OCH2) 101.3 
(CH=CH) 128.8 (ArC) 129.4 (ArC) 134.2 (ArC) 142.0 (CH=CH) 151.1 (NC=O) 162.7 
(HCC=O) 165.5 (CH2OC=O) IR (υmax = cm
-1) 3050, 2952, 2540, 2303, 1705, 1667, 
1650, 1418, 1457, 1240, 1173, 1060 HRSM EI calc: [C23H20N2O6SH
+] 453.1115 obs: 
[C23H19N2O6SH
+] 453.1118 
Synthesis of 3,3-bis(benzoylmethoxy)-thietan-2-yl-(N4-
benzoyl)cytosine 102 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure A to give the title compound as a white powder after 
purification by column chromatography 2:1 Ethyl acetate:hexane. Yield 47%, 366 mg. 
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MP 208 – 211 °C. 1H NMR (400 MHz CDCl3) δ: 2.96 (1H, d, J = 10.0 Hz, CH2S) 3.34 
(1H, d, J = 10.0 Hz, CH2S) 4.44 (1H, d, J = 12.0 Hz, OCH2) 4.59 (1H, d, J = 12.0 Hz, 
OCH2) 4.76 (1H, d, J = 11.5 Hz, OCH2) 4.95 (1H, d, J=11.5 Hz, OCH2) 6.49 (1H, s, 
SCHN) 7.35-7.63 (12H, m, ArH) 7.75 – 7.85 (3H, m, ArH) 7.94 (1H, d, J = 7.5 Hz, 
CH=CH) 8.12 (1H, d, J = 7.5 Hz, CH=CH) 8.12 (1H, d, J = 7.5 Hz, NH) 13C NMR (100 
MHz CDCl3) δ: 24.8 (C(OCH2)2 53.2 (CH2S) 58.4 (SCHN) 63.1 (OCH2) 66.7 (OCH2) 
128.6 (ArC) 129.8 (ArC) 133.4 (ArC) 166.1 (NC=O) 165.9 (CH2OC=O) 166.2 (NC=O) 
IR (υmax = cm
-1) 3326, 1708, 1693, 1617, 1547, 1428, 1293, 1114, HRSM EI calc: 
[C30H25N3O6SH
+] 556.1537 obs: [C30H25N3O6SH
+] 556.1539 
Synthesis of 3,3-bis(benzoylmethoxy)-thietane-2-yl-(5,6-dimethyl)-
uracil 103 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure A to give the title compound as a white powder after 
purification by column chromatography. Yield: 53%, 283mg. MP: 208-209° C. 1H 
NMR (400 MHz CDCl3) δ: 1.76 (3H, s, CH3) 2.04 (3H, s, CH3) 2.85 (1H, d, J = 9.0 Hz, 
SCH2) 3.94 (1H, d, J = 9.0 Hz, SCH2) 4.37 (1H, d, J = 11.5 Hz, OCH2) 4.92 (2H, s, 
OCH2) 5.01 (1H, d, J = 11.5 Hz, OCH2) 5.44 (1H, s, SCHN) 7.37 – 7.47 (4H, m, ArH) 
7.55 – 7.62 (2H, m, ArH) 7.83 (2H, d, J = 8.0 Hz, ArH) 8.03 (2H, d, J = 8.0 Hz, ArH) 
8.22 (1H, s, NH) 13C NMR (100 MHz CDCl3) δ: 11.4 (CH3) 17.4 (CH3) 29.5 (SCH2) 
53.2 (C(OCH2)2 59.5 (SCHN) 63.8 (OCH2) 66.7 (OCH2) 110.0 (C=C) 128.5 (ArC) 
129.4 (ArC) 133.6 (ArC) 162.7 (CH2OC=O) IR (υmax = cm
-1) 2924, 1711, 1651, 1600, 
1474, 1464, 1268, 1266, 1192, 1049 HRSM EI calc: [C25H25SO6N2] 481.1427 obs: 
[C25H25SO6N2] 481.1428 
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Synthesis of 3,3-bis(benzoylmethoxy)-thietan-2-yl-(6-methyl)-uracil 
104 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure A to give the title compound as a white powder after 
purification by column chromatography. Yield: 49%, 320mg. MP: 222-223° C. 1H 
NMR (400 MHz CDCl3) δ: 2.07 (1H, d, J = 8.0 Hz, SCH2) 2.10 (3H, s, CH3) 2.83 (1H, 
d, J = 8.0 Hz, SCH2) 3.95 (1H, d, J = 11.5 Hz, OCH2) 4.44 (1H, d, J = 11.5 Hz, OCH2) 
5.41 (1H, s, SCHN) 5.48 (1H, s, CH3C=CH) 7.37 – 7.46 (4H, m, ArH) 7.60 (2H, m, 
ArH) 7.87 (2H, d, J = 7.0 Hz, ArH) 8.01 (2H, d, J = 7.0 Hz, ArH) 9.0 (1H, s, NH)  13C 
NMR (100 MHz CDCl3) δ: 21.2 (CH3) 29.3 (SCH2) 53.2 (C(OCH2)2 59.1 (SCHN) 63.6 
(OCH2) 66.7 (OCH2) 104.2 (CH3C=CH) 128.9 (ArC) 129.7 (ArC) 133.7 (ArC) 150.6 
(CH3C=CHC=O) 153.0 (NC=O) 166.4 (CH2OC=O) IR (υmax = cm
-1) 2970, 1711, 1667, 
1601, 1450, 1286, 1108, 1070 HRSM EI calc: [C24H22SO6N2]  466.1199 obs: 
[C24H22SO6N2] 467.1270 
Synthesis of 3,3-bis(benzyoylmethoxy)-thietan-2-yl-(5-chloro)-uracil 
105 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure B to give the title compound as a white powder after 
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purification by column chromatography. Yield: 48%, 258 mg. MP: 197-199° C. 1H 
NMR (400 MHz CDCl3) δ: 3.05 (1H, d, J = 10.0 Hz, SCH2) 3.26 (1H, d, J = 10.0 Hz, 
SCH2) 4.41 (1H, d, J = 11.5 Hz, OCH2) 4.57 (1H, d, J = 11.5 Hz, OCH2) 4.61 (1H, d, 
J = 11.5 Hz, OCH2) 4.81 (1H, d, J = 11.5 Hz, OCH2) 6.21 (1H, s, SCHN) 7.41 – 7.50 
(4H, m, ArH) 7.57 - 7.62 (2H, m, ArH) 7.94 – 7.95 (2H, d, J = 7.0 Hz, ArH) 8.1 (2H, d, 
J = 7.0 Hz, ArH) 8.46 (1H, s, CH=CCl) 13C NMR (100 MHz CDCl3) δ: 25.0 (SCH2) 
53.2 (C(OCH2)2 57.5 (SCHN) 62.8 (OCH2) 66.2 (OCH2) 109.0 (CH=CCl) 128.6 (ArC) 
129.8 (ArC) 133.9 (ArC) 149.6 (CH=CCl) 165.7 (CH2OC=O)  IR (υmax = cm
-1) 3024, 
2844, 1720, 1702, 1615, 1450, 1428, 1286, 1255, 1113, 1059 HRSM EI calc: 
[C23H19SO6N2
35ClH+]  487.0652 obs: [C23H19SO6N2
35ClH+] 487.0725 
[C23H19SO6N2
37ClH+]  489.0693 obs: [C23H19SO6N2
37ClH+] 489.0696 
Synthesis of 3,3-bis(benzyoylmethoxy)-thietan-2-yl-(5-bromo)-uracil 
106 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure B to give the title compound as a white powder after 
purification by column chromatography. Yield: 66%, 491 mg. MP: 216-217° C. 1H 
NMR (400 MHz CDCl3) δ: 3.06 (1H, d, J = 10.0 Hz, SCH2) 3.26 (1H, d, J = 10.0 Hz, 
SCH2) 4.40 (1H, d, J = 12.5 Hz, OCH2) 4.58 (1H, d, J = 12.5 Hz, OCH2) 4.63 (1H, d, 
J = 12.5 Hz, OCH2) 4.83 (1H, d, J = 12.5 Hz, OCH2) 6.21 (1H, s, SCHN) 7.42 – 7.49 
(4H, m, ArH) 7.56 - 7.62 (2H, m, ArH) 7.96 (2H, d, J = 7.0 Hz, ArH) 8.1 (2H, d, J = 7.0 
Hz, ArH) 8.54 (1H, s, CH=CBr) 13C NMR (100 MHz CDCl3) δ: 25.0 (SCH2) 53.2 
(C(OCH2)2 57.5 (SCHN) 62.8 (OCH2) 66.2 (OCH2) 96.7 (CH=CBr) 128.6 (ArC) 129.8 
(ArC) 133.9 (ArC) 149.9 (CH=CBr) 166.1 (CH2OC=O)  IR (υmax = cm
-1) 3009, 2835, 
1704, 1683, 1651, 1450, 1317, 1259, 1087 HRSM EI calc: [C23H19SO6N2
79BrNa+] 
553.0039 obs: [C23H19SO6N2
79BrNa+] 553.0044 [C23H19SO6N2
81BrNa+] 555.0019 obs: 
[C23H19SO6N2
81BrNa+] 555.0022 
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Synthesis of 3,3-bis(benzyoylmethoxy)-thietan-2-yl-(5-iodo)-uracil 
107 
 
This procedure was modified from Nishizono et al.1 Synthesis of the title compound 
followed general procedure B to give the title compound as a white powder after 
purification by column chromatography. Yield: 66%, 491 mg. MP: 199-201° C. 1H 
NMR (400 MHz CDCl3) δ: 3.04 (1H, d, J = 10.0 Hz, SCH2) 3.27 (1H, d, J = 10.0 Hz, 
SCH2) 4.38 (1H, d, J = 12.5 Hz, OCH2) 4.57 (1H, d, J = 12.5 Hz, OCH2) 4.62 (1H, d, 
J = 12.5 Hz, OCH2) 4.80 (1H, d, J = 12.5 Hz, OCH2) 6.21 (1H, s, SCHN) 7.44 – 7.50 
(4H, m, ArH) 7.60 - 7.61 (2H, m, ArH) 7.96 (2H, d, J = 7.0 Hz, ArH) 8.1 (2H, d, J = 7.0 
Hz, ArH) 8.61 (1H, s, CH=CI) 13C NMR (100 MHz CDCl3) δ: 25.0 (SCH2) 53.3 
(C(OCH2)2 57.3 (SCHN) 62.8 (OCH2) 66.2 (OCH2) 128.6 (ArC) 129.8 (ArC) 133.9 
(ArC) 145.7 (CH=CI) 150.4 (CH=CI) 159.2 (NC=O) 166.0 (CH2OC=O)  IR (υmax = cm
-
1) 3001, 2828, 1702, 1644, 1597, 1450, 1317, 1257, 1085 HRSM EI calc: 
[C23H19SO6N2INa
+] 553.0039 obs: [C23H19SO6N2INa
+] 553.0044  
Synthesis of N6-Di(t-Boc)-Adenine 114 
 
This procedure followed Michel et al.2 To an oven dried round bottom flask under 
argon, adenine (2.5 g, 18.5 mmol, 1 equiv) was suspended in dry THF (125 mL). Di-
Tert-butyl-dicarbonate (8.73 g, 40 mmol, 4 equiv) was then added, followed by DMAP 
(226 mg, 1.85 mmol, 1 equiv) and the reaction was stirred at room temperature for 24 
hours. The solvent was evaporated in vacuo and the oily residue was redissolved in 
EtOAc (250 mL) and the organic phase was washed once with cold 1N HCl (40 mL) 
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and then brine (3 x 60 mL). The organic phase was then dried using sodium sulfate, 
and the solvent was filtered and removed in vacuo. The crude residue was 
redissolved in methanol (140 mL) and saturated sodium bicarbonate (60 mL) was 
added. The reaction was heated to 50 ° C for 1 hour under argon. The crude reaction 
mixture was cooled to room temperature and the product was extracted with 
chloroform (3 x 120 mL). The organic phase was dried over sodium sulfate and the 
solvent was removed in vacuo. The crude product was then purified by column 
chromatography using gradient elution using ethyl acetate:hexane (7:3 – 100% 
EtOAc) to give the title product as a beige solid. Yield: 85%. 1H NMR (400 MHz 
CDCl3) δ: 1.40 (18H, s, C(CH3)3) 8.55 (1H, s, CH) 8.92 (1H, s, CH) 
13C NMR (100 
MHz CDCl3) δ: 27.8 (C(CH3)3) 84.9 (C(CH3)3 145.0 (CH) 151.1 (C=O) 153.3 (CH) IR 
(υmax = cm
-1) 3239, 2988, 2360, 1780, 1737, 1584, 1453, 1330, 1254, 1129   
Synthesis of 2-phenyl-1,3-dioxan-5-ol 147 
 
This procedure was modified from Kim et al.3 To an oven dried round bottom flask 
under nitrogen, benzaldehyde dimethyl acetal (9.12 g, 60 mmol, 1 equiv) was 
dissolved in toluene (30 ml), and p-toluene sulfonic acid (1 g, 6 mmol, 0.1 equiv) was 
added. Glycerol (5.52 g, 60 mmol, 1 equiv) was added slowly and the reaction 
heated to 40° C in vacuo (200 mbar) for 6 hours. The crude reaction mixture was 
washed with sat. NaHCO3 (150 ml) and the organic phase separated. The aqeous 
phase was then washed with choloroform (3 x 50 ml) and the combined organic 
phases were dried over MgSO4. The organic phase was then filtered and the 
solvents evaporated in vacuo to give an off white residue. The crude residue was 
then dissolved in minimal chloroform and recrystallized from petroleum ether 60-40 to 
give the title compound as white crystals. Yield: 62%, 6.5 g. MP: 69 - 70° C Lit: 70 -
71 ° C. 1H NMR (400 MHz CDCl3) δ: 1.75 (1H, d, J = 6.0 Hz, OCH2 cis) 3.05 (1H, d, J 
= 6.0 Hz, OCH2 cis) 3.5 (1H, d, J = 10.0 Hz, CHOH trans) 3.99 (1H, o, J = 5.0 Hz, 
CHOH cis) 4.12 (2H, d, J = 11.0 Hz, OCH2 trans) 4.18 (2H, d, J = 11.0 Hz, OCH2 
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trans) 4.31 (2H, dd, J = 5.0 Hz, OCH2 cis) 5.43 (1H, s, PhCHO2 trans) 5.59 (1H, s, 
PhCHO2 cis) 7.33 – 7.41 (6H, m, ArH) 7.46 – 7.51 (4H, m, ArH) 
13C NMR (100 MHz 
CDCl3) δ: 61.2 (CHOH cis) 64.0 (CHOH trans) 71.7 (OCH2 cis) 72.3 (OCH2 trans) 
101.0 (PhCHO2 trans) 101.6 (PhCHO2 cis) 126.1 (ArC) 129.2 (ArC) 137.8 (ArC) IR 
(υmax = cm
-1) 3348, 2972, 2865, 1452, 1386, 1235, 1220, 1147, 1079, 1029) HRMS EI 
calc: [C10H11O3] 180.0786 obs [C10H11O3] 180.0859   
Synthesis of 2-phenyl-1,3-dioxan-5-one 148 
 
This procedure was modified from Tewes et al.4 To an oven dried round bottom flask 
under nitrogen, 2-phenyl-1,3-dioxan-5-ol 147 (2 g, 11 mmol, 1 equiv) was dissolved 
in DCM (440 ml) and cooled to 0° C. Dess Martin Periodinane (6.93 g, 16 mmol, 1.5 
equiv) was then added and the reaction was warmed to room temperature and stirred 
for three hours. The crude reaction mixture was washed with sat. NaHCO3 solution 
(200 ml) and the organic phase was separated. The aqueous phase was then 
extracted with DCM (3 x 120 ml) and the combined organic phases were then 
washed with sat. NaCl solution (3 x 120 ml). The combinded organic phase were 
dried over MgSO4, filtered and removed in vacuo. The crude residue was purified by 
flash column chromatography using hexane: ethyl acetate (8:2) to afford the title 
compound as a clear yellow oil. Yield: 80%, 1.57 g. 1H NMR (400 MHz CDCl3) δ: 
4.47 (2H, d, J = 17.5 Hz, OCH2) 4.48 (2H, d, J = 17.5 Hz, OCH2) 5.87 (1H, s, 
PhCHO2) 7.38 – 7.43 (3H, m, ArH) 7.51 – 7.55 (2H, m, ArH) 
13C NMR (100 MHz 
CDCl3) δ: 51.6 (OCH3) 66.5 (OCH2) 70.1 (OCH2) 100.8 (CH) 114.9 (C=CH) 126.1 
(ArC) 128.4 (ArC) 129.1 (ArC) 137.7 (ArC) 150.0 (C=CH) 165.8 (C=O) IR (υmax = cm
-
1) 3067, 3038, 2978, 1740, 1454, 1221 HRMS EI cal: [C10H10O3] 178.0630 obs: 
[C10H10O3] 178.0444 
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Synthesis of 3-(benzylthio)-3-methyl-butanoic acid 155 
 
This procedure followed Pattenden et al.5 To an oven dried round bottom flask under 
argon, 3-methyl but-2-enoic acid (5 g, 0.05 mol, 1 equiv) was added and dissolved in 
10 mL piperidine. Benzyl mercaptan (5.87 mL, 0.05 mol, 1 equiv) was added 
dropwise. The reaction was heated to reflux overnight and was then cooled to room 
temperature. Cold concentrated HCl (50 mL) was then added and extracted with 
diethyl ether (2 x 50 mL). The ether phase was then washed with saturated sodium 
carbonate (3 x 50 mL) and the extracted aqueous phase was re-acidified with 
concentrated HCl (3 x 50 mL). The aqueous phase was then re-extracted with fresh 
diethyl ether (3 x 50 mL). The organic phase was then dried with sodium carbonate 
and the solvent removed in vacuo to give a colourless oil. Yield: 75%. 1H NMR (400 
MHz CDCl3) δ: 1.51 (6H, s, CH3) 2.55 (2H, s, CCH2) 3.83 (2H, s, SCH2) 7.5 (5H, m, 
ArH) 13C NMR (100 MHz CDCl3) δ: 28.6 (CH3) 33.3 ((C(CH3)2) 43.6 (SCH2) 46.9 
(CCH2) 126.9 (ArC) 128.5 (ArC) 129.1 (ArC) 137.5 (ArC) 177.8 (CO2H). Data 
matched literature values. 
Synthesis of 3-thio-3-methyl-butanoic acid 156 
 
This procedure followed Pattenden et al.5 To an oven dried round bottom flask under 
argon, 3-(benzylthio)-3-methylbutanoic acid 155 (2.5 g, 11 mmol, 1 equiv) was 
dissolved in dry THF (9 mL). The reaction was cooled to -78 °C and 9mL of freshly 
distilled liquid ammonia was allowed to condense in the reaction vessel. Sodium 
metal (282 mg, 12 mmol, 1.1 equiv) was added portionwise until a steady royal blue 
colour was obtained. The reaction was stirred for 4 hours and was then allowed to 
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reach room temperature and a stream of nitrogen was used to remove any remaining 
ammonia. The reaction was quenched with IPA (50 mL) and dilute 1N HCl was 
added (50 mL) and the crude reaction mixture was extracted with diethyl ether (50 
mL). The organic phase was then  extracted with saturated sodium carbonate 
solution (50 mL), and the aqueous phase was re-acidified with concentrated 1N HCl 
(50 mL). The aqueous phase was extracted with chloroform (3 x 50 mL) to give the 
title compound as a colourless oil. Yield: quant. 1H NMR (400 MHz CDCl3) δ:  1.83 
(6H, s, CH3) 2.86 (1H, s, SH) 3.80 (2H, s, CH2) 
13C NMR (100 MHz CDCl3) δ: 21.6 
(CH3) 22.3 ((C(CH3)2) 49.1 (SCH2) 65.3 (CH2) 201.6 (CO2H). Data matched literature 
values. 
Synthesis of 1,3-di-O-(t-butyldimethylsilyloxy)-propanone 166 
 
This procedure was modified from Beaulieu et al.6 To an oven dried round bottom 
flask under nitrogen, 1,3-dihydroxy acetone dimer 165  (5.66 g, 0.031 mol, 1 equiv) 
was added to dry DCM (56 ml) followed by imidazole (18.8 g, 0.125 mol, 3 equiv) and 
t-butyl dimethyl silyl chloride (6.39 g, 0.094 mol, 4 equiv) and the reaction was stirred 
at room temperature overnight. The crude mixture was washed with water (100 ml) 
and extracted with chloroform (3 × 30 ml). The combined organic layers were dried 
over MgSO4, the solvents filtered and removed in vacuo. The crude oil was purified 
by column chromatography using gradient elution (100% petroleum ether to 8:2 
petroleum ether: ethyl acetate) on a pre-packed 100g biotage column to give a 
golden oil, yield: 9.07 g, 92%. 1H NMR (400 MHz CDCl3) δ: 0.1 (12H, s, SiCH3), 0.8 
(18H, s, C(CH3)3), 4.3 (4H, s, OCH2) 
13C NMR (100 MHz CDCl3) δ: 0.00 (SiCH3) 26.9 
(C(CH3) 68.1 (OCH2) 78.8 (C(CH3)3) 210.1 (C=O) IR (νmax cm
-1) 3011, 2936, 2856, 
1738, 1365, 1217 HRSM EI calc: [C35H42Si2O3Na
+] 341.1944 obs: [C35H42Si2O3 Na
+] 
341.2000 
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Synthesis of methyl-4-(tert-butyldimethyl silyloxy)-3-(tert-
butyldimethylsilyl methoxy)-but-2-enoate 167 
 
This procedure was modified from Takahashi et al.7 To an oven dried round bottom 
flask under argon NaH (377 mg, 9.43 mmol, 1.5 equiv) was added followed by 
dropwise addition of dry THF (50 ml). Methyl diethylphosphonoacetate (1.14 ml, 6.29 
mmol) was added slowly and the mixture was stirred for one hour at room 
temperature. After effervescence had ceased 1,3-di-O-(t-butyldimethylsilyloxy)-
propanone 166 (2 g, 6.29 mmol, 1 equiv) was added to the reaction mixture. The 
reaction was stirred overnight and completion was determined by TLC analysis 
(petroleum ether: ethyl acetate 9:1). The reaction was cooled to 0° C  by dropwise 
addition of ice cold water (100 ml) and the aqueous phase extracted with DCM (3 × 
200 ml). The combined organic phases were dried over MgSO4, the solvents filtered 
and evaporated in vacuo. The crude oil was purified by gradient elution (100% 
petroleum ether to 95:5 petroleum ether: ethyl acetate) on a biotage system with a 
100 g pre packed column. The title compound was obtained as a clear, golden oil; 
yield: 1.01 g, 70%. 1H NMR (400 MHz CDCl3) δ: 0.00 (6H, s, SiCH3) 0.02 (6H, s, 
SiCH3), 0.83 (9H, s, C(CH3)3), 0.86 (9H, s, C(CH3)3), 3.6 (3H, s, OCH3), 4.40 (2H, d, J 
= 1.1 Hz, CH2), 4.8 (2H, d, J = 1.1 Hz, CH2), 5.9 (1H, t, J = 2.0 Hz, C=CH) 
13C NMR 
(100 MHz CDCl3) δ: 0.00 (SiCH3), 20.4 (C(CH3)3) 25.6 (C(CH3)3), 51.4 (OCH3), 77.0 
(CH2), 78.2 (CH2), 111.0 (C=CH), 161.6 (C=CH), 166.8 (C=O), IR (νmax cm
-1) 2954, 
2886, 1718, 1655, 1453 HRSM EI calc: [C18H38Si2O4H
+] 375.2384 obs: 
[C18H38Si2O4H
+] 375.2381 
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Synthesis of methyl-[3-(benzylthio-)-4-(t-butyldimethylsilyloxy)-3-(t-
butyldimethy silylmethoxy)]-butanoic acid 178 
 
This procedure was modified from Nicolaou et al.8 To an oven dried round bottom 
flask under argon, methyl-[3-(benzylthio-)-4-(t-butyldimethylsilyloxy)-3-(t-butyldimethy 
silylmethoxy)]-butanoate 182 (1 g, 2 mmol, 1 equiv) was dissolved in dry 1,2-
dichloroethane (20 ml) and trimethyltin hydroxide (2.16 g, 12 mmol, 6 equiv) was 
added and the reaction heated to 80° C for 96 hours. The solvent was removed in 
vacuo and the residue dissolved in ethyl acetate (50 ml). The organic phase was 
washed with 0.01N KHSO4 (3 x 20 ml) and then the organic phase was washed with 
brine. The organic phase was then dried over Na2SO4, the solvent filtered and then 
removed in vacuo. The product was further dried under high vacuum to give the title 
compound as a clear oil. Yield 87%, 854 mg. 1H NMR (400 MHz CDCl3) δ: 0.00 (12H, 
s, SiCH3) 0.83 (18H, s, C(CH3)3) 2.73 (2H, s, CH2) 3.65 (2H, d, J = 10.0 Hz, OCH2) 
3.76 (2H, d, J = 10.0 Hz, OCH2) 3.86 (2H, s, SCH2) 7.15 - 7.27 (5H, m, ArH) 
13C 
NMR (100 MHz CDCl3) δ: 0.00 (SiCH3) 18.3 (C(CH3)3) 25.8 (C(CH3)3) 32.8 (SCH2) 
39.4 (CH2) 57.7 (CCH2) 66.2 (OCH2) 127.1 (ArC) 128.6 (ArC) 129.1 (ArC) 137.8 
(ArC) 174.2 (CO2H) IR (νmax cm
-1) 2953, 2929, 2855, 1707, 1495, 1472, 1462, 1388, 
1360, 1337, 1282, 1250, 1208, 1137, 1096, 1065, 1028, 1007 HRSM EI calc: 
[C24H44Si2SO4Na
+] 507.2397 obs: [C25H46Si2O4Na
+]  
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Synthesis of methyl-[3-(thio)-4-(t-butyldimethylsilyloxy)-3-(t-
butyldimethy silylmethoxy)]-butanoic acid 179 
 
This procedure was modified from Pattenden et al.5 To an oven dried round bottom 
flask under nitrogen, methyl-[3-(benzylthio-)-4-(t-butyldimethylsilyloxy)-3-(t-
butyldimethy silylmethoxy)]-butanoic acid 178 (1.1 g, 2.29 mmol, 1 equiv) was 
dissolved in dry THF (1.8 ml). The mixture was cooled to -78° C and 1.8 ml of freshly 
distilled liquid ammonia was allowed to condense in the reaction vessel. Sodium 
metal (58 mg, 2.52 mmol, 1.1 equiv) was added portionwise and the reaction was 
stirred for 4 hours. The reaction was allowed to warm to room temperature and a 
stream of nitrogen was used to remove any remaining ammonia. The reaction was 
then quenched with IPA (5 ml) and acidified to pH 4 with 0.01N HCl. The crude 
reaction mixture was then extracted with chloroform (3 x 10 ml) and the combined 
organic phases were dried with MgSO4. The organic phase was then filtered and 
removed in vacuo to yield the title compound as a colourless oil. Yield: 77%, 700 mg. 
1H NMR (400 MHz CDCl3) δ: 0.00 (12H, s, SiCH3) 0.84 (18H, s, C(CH3)3) 2.25 (1H, s, 
SH), 2.61 (2H, s, CH2CO2H) 3.58 (2H, d, J = 10.0 Hz, OCH2) 3.66 (2H, d, J = 10.0 
Hz, OCH2) 
13C NMR (100 MHz CDCl3) δ: 0.00 (SiCH3) 18.6 (C(CH3)3) 25.7 (C(CH3)3) 
39.3 (CH2CO2H) 50.5 (CCH2) 66.3 (OCH2) 176.0 (CO2H) IR (νmax cm
-1) 3345, 2930, 
2857, 1732, 1687, 1645, 1530, 1516, 1463, 1450, 1387, 1352, 1286, 1211, 1168, 
1102, 1059, 1007 HRSM EI calc: [C17H38Si2SO4H
+] 395.2102 obs: [C17H38Si2SO4H
+] 
395.3103      
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Synthesis of 4,4-bis(t-butyldimethylsilylmethoxy)-thietan-2-one 180 
 
 
This procedure was modified from Pattenden et al.5 To an oven dried round bottom 
flask under nitrogen, methyl-[3-(thio)-4-(t-butyldimethylsilyloxy)-3-(t-butyldimethy 
silylmethoxy)]-butanoic acid 179 (150 mg, 0.38 mmol, 1 equiv) was dissolved in dry 
DCM (0.61 ml) and triethylamine (0.11 ml, 0.76 mmol, 2 equiv) was added and the 
reaction was cooled to -10° C. Isobutylchloroformate (57 mg, 0.42 mmol, 1.1 equiv) 
was added dropwise and the reaction was stirred for 1 hour. The reaction was 
allowed to warm to room temperature and was quenched with water (5 ml) and the 
aqueous phase was extracted with DCM (5 x 10 ml). The combined organic phases 
were dried with MgSO4, filtered and the solvent removed in vacuo. The crude 
material was purified by gradient flash column chromatography using hexane: ethyl 
acetate (1:0, 19:1) to give the title compound as a colourless oil. Yield: 37%, 52 mg. 
1H NMR (400 MHz CDCl3) δ: 0.00 (12H, s, SiCH3) 0.81 (18H,s, C(CH3)3) 3.40 (2H, s, 
CH2C=O) 3.82 (2H, d, J = 10.0 Hz, OCH2) 3.85 82 (2H, d, J = 10.0 Hz, OCH2) 
13C 
NMR (100 MHz CDCl3) δ: 0.00 (SiCH3) 18.3 (C(CH3)3) 25.8 (C(CH3)3) 47.7 (C(CH2)2) 
57.8 (CH2C=O) 66.0 (OCH2) 190.4 (C=O) IR (νmax cm
-1) 2954, 2928, 2857, 1767, 
1471, 1463, 1253, 1088, 1005 HRSM EI calc: [C17H36Si2SO3Na
+] 399.1816 obs: 
[C17H36Si2SO3Na
+] 399.1817 
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Synthesis of 4-(tert-butyldimethyl silyloxy)-3-(tert-
butyldimethylsilylmethoxy)-but-2-ene-1-ol 181 
 
 
This procedure was modified from Patwardhan et al.9 To an oven dried round bottom 
flask under argon, methyl-4-(t-butyldimethyl silyloxy)-3-(t-butyldimethylsilyl methoxy)-
but-2-enoate 167 (1 g, 2.67 mmol, 1 equiv) was dissolved in THF (5 ml) and cooled 
to -78° C. Diisobutyl aluminium hydride (1.5 M in toluene, 5.3 ml. 8.02 mmol, 3 equiv) 
was added dropwise and the reaction was stirred for three hours. The reaction was 
then warmed to room temperature and quenched with water (20 ml), 2M NaOH (10 
ml) and water (10 ml). Rochelle’s salt was added until no precipitate remained. The 
aqueous phase was extracted with chloroform (3 x 30 ml) and the combined organic 
phases were dried over MgSO4. The solvent was filtered and then removed in vacuo. 
The crude residue was purified by gradient elution column chromatography (100% 
hexane, 8:2 hexane : ethyl acetate) to give the title compound as a colourless oil. 
Yield: 740 mg, 80%. 1H NMR (400 MHz CDCl3) δ: 0.00 (12H, s, SiCH3) 0.8 (18H, s, 
SiC(CH3)3 2.1 (1H, s, OH) 4.1 (2H, m, CH2OH) 4.13 (4H, m, SiOCH2) 5.72 (1H, m, 
C=CH) 13C NMR (100 MHz CDCl3) δ: 0.00 (SiCH3) 18.2 (Si(C(CH3)3) 25.8 
(Si(C(CH3)3) 59.1 (SiOCH2) 59.3 (SiOCH2) 64.4 (CH2OH) 125.5 (C=CH) 141.0 
(C=CH) IR (νmax cm
-1) 3354, 2954, 2885, 1252, 1067 HRMS EI calc: [C12H14O3H
+] 
347.2432 obs: [C12H14O3H
+] 347.2433 
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Synthesis of methyl-[3-(benzylthio-)-4-(t-butyldimethylsilyloxy)-3-(t-
butyldimethy silylmethoxy)]-butanoate 182 
 
This procedure was modified from Pattenden et al.5 To an oven dried round bottom 
flask under argon, methyl-4-(t-butyldimethyl silyloxy)-3-(t-butyldimethylsilyl methoxy)-
but-2-enoate 167 (2 g, 5.34 mmol, 1 equiv) was added followed by piperidine (1.07 
ml) and toluene thiol (0.63 ml, 1 equiv). The reaction was heated to reflux for 96 
hours. The reaction was allowed to cool to room temperature and was quenched with 
water (10 ml) and partitioned with chloroform (10 ml). The aqueous phase was 
extracted with chloroform (3 x 10 ml) and the combined organic phase was dried with 
MgSO4, the solvent filtered and removed in vacuo. The residue was purified by flash 
column chromatography hexane: ethyl acetate 8:2 to give the title compound as a 
golden brown oil. Yield: 88%, 2.34 g.  1H NMR (400 MHz CDCl3) δ: 0.01 (3H, s, 
SiCH3) 0.85 (3H, s, C(CH3)3) 2.60 (2H, s, CH2) 3.62 (3H, s, OCH3) 3.70 (2H, d, J = 
10.0 Hz, OCH2) 3.78 (2H, d, J = 10.0 Hz, OCH2) 3.89 (2H, s, SCH2) 7.11 – 7.27 (5H, 
m, ArH) 13C NMR (100 MHz CDCl3) δ: 0.00 (SiCH3) 22.7 (C(CH3)3) 25.9 (C(CH3)3) 
32.8 (CH2) 37.7 (SCH2) 42.3 (CCH2) 51.4 (OCH3) 53.3 (CCH2) 65.3 (OCH2) 127.4 
(ArC) 128.7 (ArC) 138.3 (ArC) 171.2 (C=O)  IR (νmax cm
-1) 2952.1, 2928.3, 2855.9, 
1738.4, 1470.8, 1251.2, 1198.2, 1096.2 HRSM EI calc: [C25H46Si2O4Na
+] 521.2542 
obs: [C25H46Si2SO4Na
+] 521.2548  
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Synthesis of 2,3-isopropylidene-D-ribose 200 
 
This procedure was modified from Jin et al.10 To an oven dried round bottom flask 
under argon D-ribose (150 g, 1 mole, 1 equiv) was suspended in acetone (1.25 L) 
and concentrated sulfuric acid (4.5 ml, 30 µL/g) was added dropwise over 2 hours 
and was stirred under argon for 4 hours. The reaction was quenched with solid 
sodium bicarbonate (168 g) until neutral. The reaction mixture was filtered and the 
solvent removed in vacuo to give the title compound as a colourless oil. Yield: 100%, 
202 g. αD
20 (C= 0.1, chloroform): -19.82° α:β ratio 1:1 1H NMR (400 MHz DMSO) δ: 
1.32 (3H, s, CH3) 1.49 (3H, s, CH3) 3.45 (1H, s, OH) 3.77 (2H, m, CH2OH) 4.49 (1H, 
d, J = 5.0 Hz, CHβOH) 4.59 (1H, d, J = 6.0 Hz, CH) 4.85 (1H, d, J = 6.0 Hz, CH) 5.44 
(1H, d, J = 5.0 Hz, CHαOH) 
13C NMR (100 MHz DMSO) δ: 24.7 (CH3) 26.4 (CH3) 
63.7 (CH2OH) 81.4 (CH) 86.9 (CH) 87.8 (CHβOH) 103.1 (CHαOH) 112.0 (C(CH3)2) IR 
(υmax = cm
-1) 3400, 2942, 1373, 1209, 1158, 1033 HRSM EI calc: [C8H14O5Na
+] 
213.0740 obs: [C8H14O5Na
+] 213.0744 
Synthesis of 2,3-isopropylidene-5-O-trityl-D-ribose 201 
 
This procedure was modified from Beigelman et al.11 To an oven dried round bottom 
under argon flask 2,3-isopropylidene-D-ribose 200 (5g, 0.026 mol, 1 equiv) was 
dissolved in pyridine (104 ml). DMAP (32 mg, 0.26 mmol) 0.01 equiv) was added 
followed by trityl chloride (10.9 g, 0.039 mol, 1.5 equiv) and the mixture was stirred 
overnight at room temperature. The pyridine was removed in vacuo and the crude 
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residue was dissolved in ethyl acetate (150 ml) and partitioned with saturated brine 
(50 ml) and then extracted ethyl acetate (3 x 150 ml). The organic extracts were 
combined and dried over MgSO4, and the solvent was filtered and removed in vacuo. 
The residue was purified by gradient flash column chromatography hexane : ethyl 
acetate (9:1 to 8:2) to give the title compound as a white solid. Yield: 82% 6.9 g. αD
20 
(C= 0.17, chloroform): -14.68° MP: 50-52 °C α:β 1:5 1H NMR (400 MHz DMSO) δ: 
1.34 (3H, s, CH3) 1.48 (3H, s, CH3) 3.40 (1H, d, J= 3.5 Hz, CH2) 3.42 (1H, d, J= 3.0 
Hz, CH2) 3.89 (1H, d, J = 9.0 Hz, CHβ) 4.35 (1H, t, J = 3.0 Hz, CH)  4.67 (1H, d, J = 
9.0 Hz, CHβ) 5.32 (1H, d, J = 9.0 Hz, CHβOH) 5.75 (1H, dd, J = 3.0 Hz, 9.0 Hz, 
CHαOH) 7.22 - 7.26 (6H, m, ArH) 7.26 - 7.33 (6H, m, ArH) 7.38 - 7.41 (3H, m, ArH) 
13C NMR (100 MHz DMSO) δ: 25.1 (CH3) 26.2 (CH3) 65.1(CH2) 79.5 (C(Ph)3) 81.9 
(CH) 87.1 (CH) 98.0 (CHαOH) 103.6 (CHβOH) 113.1 (CH) 125.0 (ArC) 127.2 (ArC) 
127.5 (ArC) 128.0 (ArC) 128.1 (ArC) 128.6 (ArC) 128.7 (ArC) IR (υmax = cm
-1) 3426, 
2938, 1596, 1490, 1448, 1373, 1319, 1210, 1158, 1067, 1001 HRSM EI 
calc:[C27H28O5Na
+] 455.1826 obs:[C27H28O5Na
+] 455.1829 
Synthesis of 2,3-isopropylidene-5-O-trityl-D-hamamelose 202 
 
This procedure was modified from Beigelman et al.11 To an oven dried round bottom 
flask under argon, 2,3-isopropylidene-5-O-trityl-D-ribose 201 (4.54 g, 1 equiv, 0.01 
mol) was dissolved in methanol (42 ml) and potassium carbonate (1.66 g, 1.1 equiv, 
0.012 mol) was added. 39% formaldehyde in water (25 ml) was added dropwise over 
an hour and the mixture was heated at 65° C for 24 hours. The reaction was cooled 
to room temperature and quenched with chloroform (150 ml) and partitioned with 
water (150 ml), then the aqueous phase was extracted with chloroform (3 x 150 ml). 
The organic phase was dried over Na2SO4, the solvent was filtered and then 
removed in vacuo. The residue was used crude in the next step. Crude yield: 82%, 
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4.5 g. (υmax = cm
-1) 3308, 2937, 1597, 1490, 1448, 1371, 1216, 1153, 1065 HRSM EI 
calc:[C28H30O6Na
+]  485.1931 obs: [C28H30O6Na
+] 485.1935 
Synthesis of 2,3-isopropylidene-5-O-trityl-D-hamamelolactone 203 
 
This procedure was modified from Stewart et al.12 To an oven dried round bottom 
flask under argon, 2,3-isopropylidene-5-O-trityl-D-hamamelose 202 (1 g, 2.16 mmol, 
1 equiv) was dissolved in dry DCM (3 ml). K2CO3 (447 mg, 1.5 equiv, 3.24 mmol) 
was added and the reaction was cooled to 0° C and bromine (1.21 ml, 1.1 equiv) was 
added dropwise over 1 hour. The reaction was allowed to warm to room temperature 
and was reacted for a further 24 hours. The crude reaction mixture was quenched 
with saturated sodium thiosulfate solution (10 ml) and the aqueous phase was 
extracted with DCM (5 x 10 ml). The combined organic phases were dried over 
Na2SO4, the solvent filtered and removed in vacuo. The residue was crude in the 
next step. Crude yield: 11%, 111 mg. HRSM EI calc:[C28H29O6Na
+]  483.1784 obs: 
[C28H29O6Na
+] 483.1791 
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Synthesis of 2-(tert-butyldiphenyl silylmethoxy)-2,3-isopropylidene-
5-O-trityl-D-hamamelolactone 204 
 
This procedure was modified from Beaulieu et al.6 To a dry round bottom flask 2,3-
isopropylidene-5-O-trityl-D-hamamelose 203 (187 mg, 0.14 mmol, 1 equiv) was 
dissolved in dry DCM (0.82 ml) and imidazole (42 mg, 0.61 mmol, 1.5 equiv) was 
added followed by t-butyldiphenylsilyl chloride (113 mg, 0.41 mmol, 1 equiv). The 
reaction was stirred overnight at room temperature under argon and then quenched 
with water (5 ml). The aqueous phase was extracted with 5x5 ml chloroform, the 
combined organic phases were dried with MgSO4, the solvent filtered and then 
removed in vacuo. The residue was purified by gradient flash column 
chromatography hexane: ethyl acetate (19:1, 9:1, 17:2, 8:2) to give the title 
compound as a colourless oil. Yield: 44%, 127 mg. 1H NMR (400 MHz DMSO) δ: 0.9 
(9H, s, C(CH3) 1.35 (3H, s, CH3) 1.41 (3H, s, CH3) 3.40 (2H, s, J = 6.0 Hz, CH2OSi) 
3.88 (1H, d, J = 11.0 Hz, CH2OTr) 3.91 (1H, d, J = 11.0 Hz, CH2OTr) 4.47 (1H, t, J = 
1 Hz, CH) 4.66 (1H, d, J = 1 Hz, CH) 7.2 – 7.7 (25H, m, ArH) 13C NMR (100 MHz 
DMSO) δ: 19.2 (C(CH3)3) 26.9 (C(CH3)3) 27.0 (CH3) 63.2 (CH2OSi) 63.7 (CH2OTr) 
80.0 (CH) 83.1 (CH) 127.8 (ArC) 128.1 (ArC) 135.2 (ArC) IR (υmax = cm
-1)  HRSM EI 
calc:[C44H46O6Na
+] 721.2961  obs:[C44H46O6Na
+] 723.3115 
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Synthesis of 2,3-isopropylidene-ribolactone 215 
 
This procedure was modified from Stewart et al.12 To a round bottom flask D-ribose 
(5 g, 26.2 mmol, 1 equiv) was dissolved in water (21 mL). Potassium carbonate (5.44 
g, 1.5 equiv, 39.4 mmol) and the reaction was cooled to 0 ° C. Bromine (4.64 g, 1.1 
equiv, 29.0 mmol) was added dropwise and the reaction was stirred for 1 hour. The 
reaction was allowed to warm to room temperature and left to react further overnight. 
The reaction was quenched with saturated sodium thiosulfate (21 mL), and then the 
aqueous phase was extracted with DCM (4 x 40 mL). The organic phase was 
washed with brine before being dried over the solvent was removed in vacuo. The 
residue was boiled in EtOAc (50 mL) for 10 minutes and then cooled to 0 ° C. The 
product was crystallised using petroleoum ether 40-60 and the resulting white 
crystals were dried under high vacuum. Yield: quant. 1H NMR (400 MHz CDCl3) δ: 
1.39 (3H, s, CH3) 1.48 (3H, s, CH3) 2.80 (1H, s, OH), 3.80 (1H, d, J = 11.0 Hz, CH) 
3.99 (1H, d, J = 11 Hz, CH) 4.64 (1H, m, CH), 4.79 (1H, d, J = 5.0 Hz, CH2OH) 4.84 
(1H, d, J = 5.0 Hz, CH2OH) 
13C NMR (100 MHz CDCl3) δ: 25.1 (CH3) 26.8 (CH3) 61.8 
(2xCH) 76.7 (CH) 82.9 (CH2OH) 113.1 (C(CH3)2) 175.2 (C=O). Data matches 
literature. 
Synthesis of 2,3-isopropylidene-5-O-trityl-ribolactone 216 
 
This procedure was modified from Stewart et al.12 To an oven dried round bottom 
flask, 2,3-isopropylidene-5-O-trityl-D-ribose (1 g, 2.4 mmol, 1 equiv) was dissolved in 
dry DCM (3 mL). Potassium carbonate (470 mg, 3.4 mmol, 1.5 equiv) was added and 
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the reaction was cooled to 0 °C. Bromine (0.14 mL, 2.6 mmol. 1.1 equiv) was added 
dropwise. The reaction was stirred overnight under argon. The reaction was warmed 
to room temperature slowly and quenched with saturated sodium thiosulfate (15 mL) 
and extracted with DCM (3 x 15 mL). The organic was dried over sodium sulfate and 
the solvents were removed in vacuo. The residue was purified by gradient flash 
column chromatography hexane: ethyl acetate (9:1, 8:2) to give the title compound 
as a gel. Yield: 43%, 432 mg. 1H NMR (400 MHz DMSO) δ: 1.34 (3H, s, CH3) 1.47 
(3H, s, CH3) 
13C NMR (100 MHz DMSO) δ: 25.9 (CH3) 27.0 (CH3) 63.0 (2xCH) 77.8 
(CH2OTr) 81.6 (CH) 113.1 (C(CH3)2) 126.2 (ArC) 127.3 (ArC) 129.2 (ArC) 130.3 
(ArC) 143.8 (OC(Ph)3) 174.5 (C=O) IR (υmax = cm
-1) HRSM EI calc:[C44H46O6Na
+] 
430.1780  obs:[C44H46O6Na
+] 430.1782   
Cell Viability Assay: SHS-Y5Y cells were cultured using standard methods and 
plated out into 96 well plates (100 μL) for experiments.13 Each compound (serially 
diluted from 100 μM) was added to SHS-Y5Y cells and allowed to incubate for 24 
hours at 37° C and 5% CO2. A solution of XTT (2,3-bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide) was prepared by mixing 1 mg/ml XTT in 
cell culture media (no serum) with 1.6 mg/ ml phenazine methasulfate and was 
added to each well. The plate was incubated for an additional 4 hours at 37° C and 
5% CO2. Cell viability was measured by comparing the optical density (Spectramax 
Spectrophotometer, Molecular Devices) in wells containing cells and test compounds 
to the vehicle control wells. A positive control of 10 μM of H2O2 was used to 
determine that the assay was measuring a decrease in cell viability.  
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Appendix 
Below is the raw data for the cell viability assays performed on thymine 79 uracil 80, 
5FU 84 and 5,6-DMU 89. 
Table A.1.1: Raw data for thymine 79 
1 μM 1 μM 10 μM 10 μM 100 μM 100 μM DMSO H2O2 
1.0656 1.1861 1.0152 0.9992 0.9287 0.9446 0.9771 0.2599 
1.0674 1.0858 0.9907 1.0958 0.936 1.004 1.0725 0.2631 
1.1749 1.0656 0.8364 1.1281 0.9528 1.0571 0.9227 0.2472 
1.1465 1.1352 1.2281 1.1588 1.0241 1.0339 0.932 0.2473 
1.2792 1.0173 1.0737 1.368 1.029 0.9925 0.9675 0.2743 
0.9334 1.1286 1.3661 1.1742 1.0674 0.8744 0.9994 0.2679 
0.7035 1.3037 0.4966 0.8438 0.7331 0.4835 0.9538 0.2515 
0.876 1.4938 0.7179 1.3565 0.701 0.7564 1.0041 0.2611 
0.9459 1.1679 0.6827 1.2532 0.9376 1.3003 0.9242 0.2704 
0.9226 0.9695 1.0201 1.2467 1.1835 1.1789 0.9481 0.3058 
1.0621 0.9852 1.1748 1.1349 1.1723 1.0779 1.1347 0.3866 
0.986 0.9918 1.1663 1.034 1.0722 1.0322 1.0684 0.2856 
1.3058 1.5584 1.376 1.4697 1.6986 1.1363 1.1886 0.2632 
1.3191 1.4394 1.1937 1.4033 1.5953 1.3317 1.3275 0.2663 
1.3191 1.403 1.3803 1.5497 1.6512 1.5608 1.4072 0.2451 
1.3822 1.0543 1.4063 1.7165 1.5878 1.5428 1.3809 0.2618 
1.3425 1.4339 1.3299 1.4011 1.5073 1.3782 1.3663 0.2584 
1.2853 1.3665 1.4049 1.3804 1.2576 1.169 1.4337 0.2499 
 
Table A.1.2: Raw data for uracil 80 
1 μM 1 μM 10 μM 10 μM 100 μM 100 μM DMSO H2O2 
0.9176 0.9033 0.9171 0.9087 0.9118 0.8662 0.889 0.3412 
0.9902 0.9718 0.8777 0.805 0.8361 0.8467 0.9349 0.3395 
1.0047 0.9741 0.9337 0.8701 0.9107 0.8531 0.9156 0.3459 
0.9565 0.9595 0.9291 0.85 0.8917 0.9108 0.8737 0.3562 
0.9649 0.9325 0.8682 0.8798 0.8757 0.8491 0.9016 0.3676 
0.8583 0.9642 0.8723 0.8572 0.8712 0.8555 0.8872 0.3676 
0.8549 0.8535 0.773 0.7367 0.8374 0.8087 0.9818 0.2459 
0.9736 0.9701 0.9053 0.9106 0.7745 0.926 0.9713 0.2382 
1.007 0.9647 0.9682 0.9033 0.7754 0.873 0.9654 0.2328 
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0.9845 0.9711 1.0188 0.8239 0.776 0.8663 0.9524 0.2295 
0.9857 0.926 0.9124 0.7842 0.8179 0.8668 0.9524 0.2266 
0.7387 0.7581 0.7638 0.8914 0.8139 0.79 0.8005 0.228 
0.9419 0.7629 0.8513 0.8608 0.9333 0.6809 0.8037 0.2519 
0.8068 0.8756 0.9546 1.157 1.1378 0.9747 1.0789 0.2313 
0.8197 0.7964 1.1232 1.157 1.239 1.0262 1.0538 0.2312 
0.7937 0.8036 1.0797 1.0985 1.0713 1.0833 0.9851 0.2487 
0.9065 0.9302 1.0423 0.877 1.0788 0.9839 1.0083 0.232 
0.9143 0.9253 0.7431 0.7547 0.9737 0.7696 0.9377 0.2219 
 
Table A.1.3: Raw data for 5FU 84 
1 μM 1 μM 10 μM 10 μM 100 μM 100 μM DMSO H2O2 
0.9015 0.9291 0.9422 0.9677 0.9184 0.9589 0.9016 0.4145 
0.9861 0.9109 0.8552 0.9394 0.8251 0.8035 0.8846 0.3597 
1.0705 0.9423 1.0249 0.9985 0.7547 0.7933 0.9442 0.3468 
1.0022 0.7672 1.0533 0.9819 0.7566 0.7874 1.0767 0.4073 
1.0194 0.9918 1.0607 1.0095 0.7845 0.7957 1.0189 0.4097 
0.9514 0.9529 0.9724 1.0085 0.7561 0.8558 0.949 0.3706 
0.8537 0.8988 0.8813 0.9034 0.9297 0.925 0.9344 0.2614 
0.9578 0.8439 0.8901 0.9986 0.8855 0.8144 1.063 0.2567 
1.0099 0.9871 0.9523 0.9483 0.8372 0.8288 1.0334 0.2504 
0.9296 0.9013 0.8407 1.0105 0.8404 0.8254 1.03 0.2519 
0.9882 1.0073 0.8922 0.9684 0.8126 0.9231 1.0274 0.2487 
0.8928 1.0425 0.8876 0.84 0.8257 0.8908 0.7834 0.2466 
0.6342 0.9923 0.4832 0.9667 0.5007 1.2152 0.9729 0.245 
0.9212 1.1115 0.7101 1.1128 0.5331 0.9622 1.011 0.2432 
1.0286 1.1299 0.9053 0.8008 0.5766 1.5858 0.9685 0.2144 
0.9507 1.0352 1.2361 1.226 0.9539 2.269 1.079 0.2385 
0.9301 0.8811 0.6312 0.5993 0.8768 2.0582 0.9495 0.2267 
0.9269 1.0259 0.9057 1.0095 0.9569 2.0045 0.95 0.2855 
 
Table A.1.4: Raw data for 5,6-DMU 89 
1 μM 1 μM 10 μM 10 μM 100 μM 100 μM DMSO H2O2 
0.8856 0.924 0.9315 0.8812 0.838 0.8732 0.8964 0.3722 
0.9151 0.973 0.9217 0.8834 0.8526 0.8236 0.9292 0.392 
0.8696 0.956 0.9429 0.9179 0.9763 0.8772 0.9305 0.3498 
0.9828 0.8974 0.9401 0.9954 0.9702 0.9303 0.9938 0.363 
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1.0372 0.9283 0.9671 1.0269 1.0192 0.9306 0.9575 0.3516 
0.98 0.9973 0.9534 1.0478 0.9942 0.8939 0.9303 0.3497 
0.895 0.8322 0.8934 0.8299 1.0139 0.8276 0.8475 0.2583 
1.1019 0.9848 1.0635 1.0901 0.9228 0.9658 1.0797 0.2689 
1.0133 1.009 1.0975 0.967 0.8659 0.9397 1.0523 0.2727 
1.0589 1.0021 1.0366 0.9534 0.8587 0.9851 1.0721 0.2636 
1.0677 1.0803 1.0775 1.0396 0.8156 0.9529 1.0207 0.2642 
0.9089 0.842 0.8827 0.8106 0.7437 0.6898 0.8067 0.2655 
0.5453 0.7694 0.5745 0.7872 0.3387 0.4342 0.8332 0.279 
0.582 0.7949 0.6703 1.0176 0.3227 0.6477 0.9354 0.2534 
0.5941 0.7606 0.8583 0.995 0.3487 0.7368 1.0425 0.2289 
0.6239 0.8133 1.0067 1.0013 0.3573 0.8698 1.0233 0.2183 
0.7093 0.7559 1.0238 0.8938 0.504 1.0092 1.0143 0.2443 
0.7222 0.8487 0.7701 0.8209 0.5439 0.9831 0.9762 0.2028 
 
 
Figure A1.1: Thymine 79 replicate 1 
 
Figure A.1.2: Thymine 79 replicate 2 
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Figure A.1.3: Thymine 79 replicate 3 
 
Figure A.1.4: Uracil 80 replicate 1 
 
Figure A.1.5: Uracil 80 replicate 2 
 
Figure A.1.6: Uracil 80 replicate 3 
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Figure A.1.7: 5FU 84 replicate 1 
 
Figure A.1.8: 5FU 84 replicate 2 
 
Figure A.1.9: 5FU 84 replicate 3 
 
Figure A.1.10: 5,6-DMU 89 replicate 1 
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Figure A.1.11: 5,6-DMU 89 replicate 2 
 
Figure A.1.12: 5,6-DMU 89 replicate 3 
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